ࡱ> !q` RvbjbjqPqPp::#%<'<'<'<'''' (XXX8  (4ėė"0l82222222$9h<2'}ʙ"}}2<'<'4^}<''2}22P'6' t&X|2BTk4`4<F <\<'lZ@Z422U^4}}}} ( (.ę ( (. ( ( (<'<'<'<'<'<' Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limiteda joint stock company established in the People s Republic of China with limited liability Stock Code: 0719 2012 ANNUAL RESULTS ANNOUNCEMENTThe board of directors (the  Board ) and directors (Directors) of Shandong Xinhua Pharmaceutical Company Limited (the Company) hereby announces the audited consolidated results of the Company and its subsidiaries (the Group) for the year ended 31 December 2012. The following financial information has been prepared in accordance with Hong Kong Generally Accepted Accounting Principles (HKGAAP) and the Peoples Republic of China (PRC) accounting standards. This results announcement (the Announcement) is summarised from the annual report (the Annual Report) and investors are advised to read the full text of the Annual Report to understand the full details. The Announcement is published in Chinese and English. If there are any discrepancies between the Chinese version and the English version, the Chinese version shall prevail. I. Financial summary(i) Prepared in accordance with HKGAAP (Audited)Consolidated Income StatementItem2012 RMB0002011 RMB000 2010RMB000Revenue2,932,1162,917,8602,589,447 Profit before tax33,51591,272128,967 Income tax expense (8,499)(13,302)(22,159)Profit for the year25,01677,970106,808 Non-controlling interests2,5993,5955,509 Profit attributable to owners of the Company22,41774,375101,299 Consolidated Statement of Financial PositionItem2012RMB0002011 RMB0002010 RMB000Total assets3,639,4903,017,4122,772,599 Total liabilities(1,855,699)(1,259,624)(1,048,367)Non-controlling interests(39,701)(39,807)(38,010)Equity attributable to owners of the Company1,744,0901,717,9811,686,222 Prepared in accordance with PRC accounting standards (Audited) Principal Financial DataItem2012 RMB 2011RMBChange as compared to the last year (%)2010RMBTotal operating income2,971,519,619.90 2,937,528,055.33 1.162,614,233,634.62Operating profit(18,705,181.33)71,927,673.11(126.01)131,701,950.29Profit before taxation34,981,068.9893,211,526.67(62.47)125,128,440.97Profit attributable to the equity holders of the Company23,663,577.9676,023,665.57(68.87)97,256,602.75Profit attributable to the equity holders of the Company after extraordinary loss(20,394,764.53)54,823,601.21(137.20)102,314,847.16Net cash flow from operating activities37,817,990.3997,083,018.85(61.05)173,000,248.75ItemAs at 31 December 2012RMBAs at 31 December 2011RMBChange as compared to the end of last year (%)As at 31 December 2010RMBTotal assets 3,628,270,364.033,004,190,190.6820.772,739,564,533.49Total liabilities1,851,281,249.011,254,451,169.3747.581,025,030,560.11Total equity attributable to equity holders of the Company1,737,287,914.321,709,932,330.071.601,676,523,546.19Capital (share)457,312,830.00457,312,830.00-457,312,830.00Principal Financial IndicatorsItem2012RMB2011RMBChange as compared to the last year (%)2010RMBBasic earnings per share0.050.17(70.59)0.21Diluted earnings per share0.050.17(70.59)0.21Basic earnings per share after extraordinary loss(0.04)0.12(133.33)0.22Return on equity of weighted average% 1.384.46Decreased by 3.08 points5.81Return on equity of weighted average after extraordinary loss% (1.19)3.22Decreased by 4.41 points6.11Net cash flow from operating activities per share0.080.21(61.90)0.38ItemAs at 31 December 2012RMBAs at 31 December2011RMBChange as compared to the end of last year (%)As at 31 December 2010RMBNet assets per share attributable to equity holders of the Company3.803.741.603.67Asset-liability ratio (%)51.0241.76Increased by 9.26 points37.42(iii) Reconciliation of accounts prepared in accordance with PRC accounting standards and HKGAAPProfit attributable to owners of the CompanyRMBNet assetsRMB20122011As at 31 December 2012As at 1 January 2012Prepared under HKGAAP22,417,000.0074,375,000.001,744,090,000.001,717,981,000.00Prepared under PRC accounting standards23,663,577.9676,023,665.571,737,287,914.321,709,932,330.07HKGAAP adjustments:Deferred taxation221,422.04292,334.43(1,199,914.32)(1,420,330.07)Provision for education fund(1,468,000.00)(1,941,000.00)8,002,000.009,469,000.00Others----HKGAAP adjustments total(1,246,577.96)(1,648,665.57)6,802,085.688,048,669.93 Note: Explanation of the difference between the PRC accounting standards and HKGAAP:1. Education expenses are regarded as actual expenditure without the need of provision under HKGAAP. As at 31 December 2012, the balance of education expenses was RMB8,002,000.00 under the PRC accounting standards, and the education expenses were RMB1,468,000.00 for 2012;2. The aforesaid difference also led to the difference in the Companys deferred income tax, with the difference in accumulated deferred income tax being RMB1,199,914.32 and the deferred income tax of the current period being RMB221,422.04.II. DIVIDENDSThe Board has announced and proposed a final dividend for the year ended 31 December 2012 of RMB0.01 per share in the Company (the Share) (approximately HK$0.0125 per Share, including income tax) on 307,312,830 A Shares and 150,000,000 H Shares in issue. The proposed dividend is subject to approval by the shareholders of the Company at the Companys annual general meeting for the year 2012. In respect of the book closure period of the proposed dividend, please see the announcement dated 22 March 2013 headed 2012 Final Dividend Distribution and Enterprise Income Tax Withholding of Overseas Non-resident Enterprises for details. III. MAIN BUSINESS AND FINANCIAL SITUATIONThe Group is mainly engaged in the development, production and sale of bulk pharmaceuticals, preparations, chemical products and other products. The profit of the Group is mainly attributable to its principal operations.Analysis of financial situation and operating results in accordance with PRC accounting standardsTotal assets of the Group as at 31 December 2012 was approximately RMB3,628,270,000, increased by approximately RMB624,080,000 or 20.77%, as compared with the figure of approximately RMB3,004,190,000 at the beginning of the year. The increase in total assets was mainly due to the increase of loans.Cash of the Group as at 31 December 2012 was approximately RMB422,144,000, increased by approximately RMB122,915,000, as compared with the figure of approximately RMB299,229,000 at the beginning of the year. The increase in cash was mainly due to the increase of loans.Total equity attributable to the shareholders of the Company as at 31 December 2012 was approximately RMB1,737,288,000, increased by approximately RMB27,356,000 or 1.60%, as compared with the figure of approximately RMB1,709,932,000 at the beginning of the year. This increase was mainly attributable to the increase of profits this year.The total liabilities of the Group as at 31 December 2012 were approximately RMB1,851,281,000, representing an increase of approximately RMB596,830,000 or 47.58%, as compared with the figure of approximately RMB1,254,451,000 at the beginning of the year. The increase was mainly attributable to objective of the Group to ensure sufficient supply of funds for production, operation and projects, leading to an increase in loans.Operating loss of the Group for the year of 2012 and net profit attributable to the Companys shareholders for 2012 amounted to approximately RMB18,705,000 and approximately RMB23,664,000 respectively, representing relatively large decreases as compared with those of the previous year. The decreases were mainly attributable to a downturn in both the domestic and foreign demand for the leading products of the Company's bulk drugs, the sale of preparation products has been under the impact of, among other things, the medical reform, the tendering result and the limitation imposed on the use of antibiotic. The chemical product market in which the Companys subsidiary operates is highly competitive and has experienced decline in both demand and prices. The amount of interest expenses increased due to increased borrowings by the Company for the purposes of ensuring usual production and operation of the Company and funding the relocation of the Company.The Groups net increase in cash and cash equivalents for the year of 2012 was approximately RMB107,579,000. The increase was mainly attributable to the increase of loans. Analysis under HKGAAPAs at 31 December 2012, the current ratio and the quick ratio of the Group was 130.41% and 83.22% respectively, and the rate of accounts receivable turnover (rate of accounts receivable turnover = revenue/average trade and bill receivables100%) and the rate of stock turnover (rate of stock turnover = cost of sales/average inventories100%) were 861.57% and 528.16% respectively.The Groups demand for working capital did not show significant seasonal fluctuation throughout the year.The Groups main source of funds was loans. As at 31 December 2012, the total amount of outstanding loans was approximately RMB1,211,017,000. As at 31 December 2012, cash on hand and in bank of the Group amounted to approximately RMB422,144,000 (including bank acceptance drafts deposits of approximately RMB37,500,000). As at 31 December 2012, the Group charged the land use rights in Hutianzhen, Zhangdian, to a bank for loans. The total original value of the land use rights is RMB73,109,000, net value is RMB68,113,000. The Group pledged accounts receivable US$10,123,000 to a bank for a loan of US$10,000,000. There was no other charge on the Groups assets except the above charged assets. The Group has stringent internal control systems for cash and fund management to strengthen its financial management. The Group maintained a good level of liquidity and had strong debt repayment ability.In 2012, the Group acquired 100% equity interest of Shandong Tianda Biological Pharmaceutical Company Limited held by its original shareholders at a consideration of approximately RMB22,000,000. After the acquisition, it was renamed as the Xinhua Pharmaceutical (Gaomi) Company Limited and was added into the 2012 scope of consolidated financial statements of the Company.Apart from the above transactions, the Group did not have material acquisitions and sales of assets, nor any material mergers and acquisitions during the reporting period.As at 31 December 2012, the number of staff employed by the Group was 6,066, and the total amount of salaries and wages for 2012 was approximately RMB228,698,000.The debt-to-capital ratio of the Group was 69.44% (debt-to-capital ratio = total borrowings / equity attributable to owners of the Company 100%).The bank balance of the Company will mainly be used as working capital for project construction and relocation of the Company.The assets and liabilities of the Group were mainly recorded in Renminbi. For the year ended 31 December 2012, the revenue from the Groups exports was approximately US$175,179,000, which exposed the Group to certain risks associated with the fluctuation of exchange rates. Therefore, the Group has taken the following measures to lower the risks from the fluctuation of exchange rates: (1) the Group has increased the price of its export products to decrease the risks from the fluctuation of exchange rates; (2) the Group has made arrangements with overseas customers when entering into significant export contracts that the risks associated with the fluctuation in exchange rates shall be borne by both parties if the fluctuation exceeds the range of exchange rate fluctuation agreed by both parties.IV. business reviewIn 2012, the Group encountered great difficulties in its development. In response, the Group took proactive measures against adverse factors such as weak demand for pharmaceutical products both at home and abroad, and a dampened chemical industry market, and successfully ensured a healthy production and operation through focusing on technological progress, vigorously developing new markets, endeavoring to reduce purchase costs, strengthening risk management and accelerating project construction. 1. Emphasis on marketing with focus on market development for key and strategic productsActive efforts were made in development of pharmaceutical market both at home and abroad. Through strengthening the strategic partnership with world renowned pharmaceutical companies, we saw a rapid growth in the export of major bulk pharmaceuticals including caffeine and ibuprofen. As such, we maintained as one of the top five players in China in terms of bulk pharmaceuticals export. Upon passing the on-site audit of the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, the amount of preparation products exported to the European Union grew substantially. Accordingly, we became one of the first batch of fifteen Chinese entities being Pioneers in Preparation Products Internationalization Among Chinas Pharmaceutical Companies (-N WOmiR WSHQ\Omi), and was honored as one of the top ten players in terms of preparations export in China. Meanwhile, we took advantage of our in-house production of bulk pharmaceuticals to expand the sales of preparation products in China. Through adopting the  differentiated focusing strategy, we achieved rapid growth in sales of new products such as ShuTaiDe(l_) and JieNing(N[). We grasped market opportunities to reduce purchase costs, with a decrease in purchase cost of RMB51.14 million in 2012. 2. Emphasis on technological renovation with focus on industrialization of research and development outcomes We devoted more resources in research and development and actively established strategic partnerships with scientific research academies and institutions at home and abroad to build research and development platforms, thus forming multi-layer and multi-pattern research and development approaches for new medicines. Currently, we have 10 new products which had been reported to the pharmaceutical product assessment center of the State Food and Drug Administration. We are in the process of submitting relevant registration materials for 6 new products. In addition, we have 15 items at the mid-scale trial production stage, and 31 items having completed the laboratory research work. We have 8 new products including the DC pellet Ibuprofen (DCF|^m) actively engaged in the production implementation whereas 15 new products including Ibuprofen Capsules (^m}ˑV) have completed trial production or production on-site inspection. We successfully implemented 21 scientific and technological outcomes which enabled us to save raw material cost of RMB8.85 million. During the year, we were granted 7 invention patents and 3 new utility model patents. The Company was upgraded by the Patent Bureau of Shangdong Province to have the highest three-star rating with the tile of China Patent Shandong Star Enterprise(-N W\)Rq\qgffOmi). 3. Emphasis on park construction with focus on scientific project planning The new headquarter building in the High Technology Industrial Development Zone was put into formal use and the new research center is about to be put into use. The salicylic acid and aspirin projects in Hutian Park were successfully put into production at the first attempt, and passed the GMP certification. Meanwhile, the aspirin project was granted the EU COS certificate. In addition, we have completed construction for the multi-functional industrialization center, which are receiving the presences of a batch of new products. Plant construction has been completed for the 5A(N[ |R"uT) series products (i.e. Analgin, Aminopyrine, Isopropylantipyrine, Antipyrine and Analgin magnesium), for which equipment installations are under progress. The production capacity expansion projects at Shouguang park have been completed one after another and are put into production in succession. Relocations of Calcium Polycarbophil, Trimethoprim and Barbitone have been completed in tandem, and they have passed GMP certification smoothly. 4. Emphasis on corporate management to tamp the growth foundations We increased efforts in risk management and control and revised a number of risk management rules. We kept enhancing quality management. The workshop for solid preparations smoothly passed the review of MHRA, while the liquid preparations workshop (4lݑRʎ) and various relocated products passed the new GMP certification. Analgin and Trimethoprim products were granted new CEP certificates. Amlodipine besylate received the DMF registration number from FDA of the USA. In addition, the Company smoothly passed over 100 cases of quality audits made by customers and completed 12 quality breakthroughs. During the year, we devoted more resources in environmental protection, which made emissions of COD and ammonia nitrogen drop respectively by 6.96% and 3.01% year on year. We implemented over 20 energy conservation projects, leading to a year on year drop of 4.09% in the energy consumption per RMB10,000 production value. V. ProspectsThere is no significant improvement in the market demand in 2013 so far, and the market competition remains intense for bulk pharmaceuticals. As affected by the bidding system and price cuts for essential drugs, the marketing of preparation products will experience great difficulties. As our relocation and reconstruction project reaches its critical stage, a large amount of capital is required for construction. We also face great pressure in respect of environmental protection. 2013 is a critical year for the Groups implementation of the 12th Five-Year plan. It is also the 70th anniversary of the Company. The Group will focus on the following tasks: 1. Grasp opportunities for marketing We will aggressively push ahead with the internationalization strategy to ensure continuing growth in export of major bulk pharmaceuticals. Taking the opportunity that the solid preparation workshop has successfully completed its capacity expansion and reconstruction and obtained the recognition by the MHRA of Britain, we will strive for a rapid growth in export of preparation products. We will strengthen direct communication with international clients through our subsidiaries in the US and Europe to maintain our international markets and further increase our international market share. By fully leveraging on the multi-function industrialization center, we will increase efforts in developing the domestic market for featured bulk pharmaceuticals, with an aim to fostering new profit drivers. We will proceed with our marketing strategy of extensive preparation products, and formulate proper marketing strategy through the one strategy for one product approach for key products. We will increase efforts in marketing of new products and work practically on drugs bidding, so as to further enlarge our market share. The Group will strengthen the hierarchy management of and cooperation with suppliers and further reduce the number of exclusive suppliers. We seek to further reduce procurement costs through improving and standardizing the procurement management measures. 2. Broaden thoughts for scientific progress We will speed up the development of new products. The Company is about to obtain the production approval for the calcium polycarbophil (ZaSl#), a specific medicine for constipation, and is striving for the approval for another four new medicines this year. We will further increase investment in research and development, and make full use of existing research and development platform to strengthen cooperation with both local and overseas research and development institutions. In specific, we will strive for registration of eight new products, obtaining of eight patent pending numbers, completion of mid-scale trial productions for nine projects, completion of laboratory research for eight projects, and prepare for another 16 new projects At the same time, we will actively conduct biopharmacy research , so as to cater for the long term development of the Company . 3. Strengthen execution with focus on fundamental management Great efforts will be put in improvement and optimization of production process, and strengthening of quality control. We will continue to promote the application of the four new technologies, and strictly control various expenses in overhaul, environmental protection, energy and power as well as period expense to continuously reduce production cost and enhance competitiveness. We will enhance the management and control over significant matters of our subsidiaries and provide more resources support to them, so as to improve the management standard and growth momentum of our subsidiaries. 4. Push ahead with scientific development with focus on industrial park construction We will ensure the production relocation of the aspirin production line be completed as scheduled, and the technological renovation for the 5A products series to be completed smoothly, for which we will strive for a successful commissioning at the first attempt. The Group will further improve the bidding system for equipment purchase and project construction, and duly carry out subsequent audit and assessment to guarantee the project quality and lower construction costs. 5. Exercise strict control over expenses with focus on risk control Centralized capital management will be implemented and strict restrictions on capital approval authority and process for capital approval will be put in place. With strengthened budget management, we will ensure various non-production expenditures be controlled within the budget. We will enhance risk management to properly control account receivables. Meanwhile, we will determine the quotas for various funds occupation to reduce funds occupation. Through taking active measures against the operating difficulties, the Group managed to ensure a healthy production and operation in 2012. 2013 is a critical year for the Group to proceed with the 12th Five-Year plan, the Group will as always carry forward the reform and renovation spirit, and strive to achieve various production and operation tasks, thus giving a salute to the 70th anniversary of the Company. VI. Important IssuesStaff and RemunerationThe Groups staff remuneration was determined in accordance with State policies, the Companys profit in the corresponding period and the average income of local residents.As at 31 December 2012, the number of staff employed by the Group was 6,066 , and the total amount of their salaries and wages for the year 2012 was approximately RMB228,698,000.Purchase, Sale or Redemption of the Companys Listed SecuritiesDuring the year ended 31 December 2012, the Company did not redeem the Companys listed securities. Neither the Company nor its subsidiaries, purchased, sold or redeemed any of the Companys listed securities.Connected TransactionsSignificant connected transactions carried out in the normal course of the Groups business are summarised as follows:Item2012 RMB0002011 RMB000With holding company and its subsidiariesSale of water, electricity, steam and waste materials11,97310,667Sale of bulk pharmaceuticals and chemical raw materials63,14129,057 Purchase of raw materials 72,74452,696 Payment of annual trademark licence fee7,5001,100Acquisition of land use rights8,399-0Total of transactions approved in general meeting 163,757 93,520 Design fees income66116 Rental expenses500500Others total566616With ultimate holding company  Interest expenses of loan29,150- Underwriting expenses of loan1,500-Total30,650-With associatesPurchase of raw materials1,076276Sale of water, electricity and steam377447Total1,453723With minority shareholders Sale of bulk pharmaceuticals and chemical raw materials137,816157,367 Purchase of chemical raw materials and water, electricity, steam-0447Total137,816157,814Grand total 334,242252,673 In the opinion of the Directors (including the independent non-executive Directors), the above transactions were carried out in the ordinary and usual course of the Groups business and on normal commercial terms. The aggregate amount of the above transactions for each of the years 2011 and 2012 did not exceed the annual cap approved in the general meeting of the Company.AuditorsThe accounts of the Company and the Group for this year prepared in accordance with HKGAAP and PRC accounting standards have been audited by SHINEWING (HK) CPA Limited (practicing certified public accountants in Hong Kong) and ShineWing Certified Public Accountants (certified public accountants in the PRC) respectively.The Company intends to re-appoint SHINEWING (HK) CPA Limited and ShineWing Certified Public Accountants as international auditors and PRC auditors of the Company respectively for the year 2013 at the annual general meeting for the year 2012 to be held in 2013.Corporate Governance Code The Directors (including the independent non-executive Directors) are of the opinion that for the year ended 31 December 2012, the Company complied with all code provisions set out in the Corporate Governance Code contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The Company has always strived to comply with the best practices of the Corporate Governance Code. Material Litigation and ArbitrationThe Group was not involved in any material litigation or arbitration and no material litigation or arbitration is pending or threatened or was made against the Group during the reporting period.Sale of AssetsIn 2012, the Group acquired 100% equity interest of Shandong Tianda Biological Pharmaceutical Company Limited held by its original shareholders at a consideration of approximately RMB22,000,000. After the acquisition, it was renamed as the Xinhua Pharmaceutical (Gaomi) Company Limited and was added into the 2012 scope of consolidated financial statements of the Company.Apart from the above transactions, the Group did not have material acquisitions and sales of assets, nor any material mergers and acquisitions during this reporting period.Amendments to the ArticlesA special resolution in respect of the amendments to Article 147 of the Articles of Association was passed at the Extraordinary General Meeting of the Company held on 28 December 2012.Audit CommitteeThe audit committee has, together with the management, reviewed the accounting principles, practices and methods adopted by the Group and has reviewed the auditing, internal control and financial reporting of the Group. The audit committee has convened four meetings to review the audited financial statements for 2011, the unaudited 1st quarterly financial statements for 2012, the unaudited interim statements for 2012 and the unaudited 3rd quarterly financial statements for 2012.The audit committee convened a meeting on 21 March 2013 to review the 2012 audited accounts and annual results announcement.VII. FINANCIAL REPORTSThe financial reports of the Company and the Group for the financial year ended 31 December 2012 have been audited by SHINEWING (HK) CPA Limited (practicing certified public accountants in Hong Kong) and ShineWing Certified Public Accountants (certified public accountants in the PRC) in accordance with HKGAAP and PRC accounting standards respectively. In their respective auditors reports there was no qualified opinion.1. financial statement and notes Prepared Under PRC Accounting StandardsConsolidated and the Companys Income Statement for the year 2012 (AUDITED) Unit: RMBItem20122011Consolidated The CompanyConsolidatedThe Company1.Total operating income2,971,519,619.901,752,796,478.562,937,528,055.331,805,458,124.22 Includes: Operating income2,971,519,619.901,752,796,478.562,937,528,055.331,805,458,124.222.Total operating costs2,996,016,283.801,725,454,400.942,874,617,794.851,749,515,071.83 Includes: Operating cost2,447,201,083.031,453,204,111.042,391,580,913.171,533,694,893.06 Taxes and surcharges15,429,035.699,305,384.5213,158,975.169,000,247.70 Selling expenses239,897,943.2929,066,464.92199,663,018.5722,897,050.70 Administrative expenses215,688,194.67171,459,300.11176,046,032.51145,042,121.62 Financial expenses60,254,240.0059,629,956.9237,268,918.2336,971,658.53 Assets Impairment loss17,545,787.122,789,183.4356,899,937.211,909,100.22 Add: Gain or loss from changes in fair value---- Investment gain or loss5,791,482.579,254,512.719,017,412.6310,509,738.64 Includes: Investment gain or loss from related ventures and joint ventures3,202,592.713,202,592.715,140,685.085,140,685.083. Operating profit(18,705,181.33)36,596,590.3371,927,673.1166,452,791.03 Add: Non-operating income66,954,709.0637,760,293.4432,370,741.3126,378,632.29 Less: Non-operating cost13,268,458.7510,231,507.9211,086,887.757,352,654.85 Includes: Loss from the disposal of non-current assets6,807,412.806,714,600.833,910,059.763,858,833.734. Profit before taxation34,981,068.9864,125,375.8593,211,526.6785,478,768.47 Less: Income tax expense8,718,849.878,237,041.9313,592,585.9211,247,672.855. Profit after taxation26,262,219.1155,888,333.9279,618,940.7574,231,095.62 Includes: Profit attributable to the equity holders of the Company23,663,577.96-76,023,665.57- Minority interest2,598,641.15-3,595,275.18-6. Earnings per share 1) Basic earnings per share0.050.120.170.16 2) Diluted earnings per share0.050.120.170.167.Other comprehensive income17,527,259.5017,196,207.20(20,051,251.32)(19,188,362.40)8. Total comprehensive income43,789,478.6173,084,541.1259,567,689.4355,042,733.22 Includes: Total comprehensive income attributable to the equity holders of the Company41,074,969.15-56,274,425.38- Total comprehensive income attributable to minority interest2,714,509.46-3,293,264.05-Financial Notes:1. During this reporting period, Xinhua Pharmaceutical (Gaomi) Company Limited was included in the scope of consolidated financial statements of the Company.2. financial statements AND NOTES PREPARED UNDER HKGAAPCONSOLIDATED INCOME STATEMENTNOTES20122011RMB000RMB000Revenue32,932,1162,917,860Cost of sales(2,427,711)(2,369,697)Gross profit504,405548,163Investment income5,5924,105Other income66,46546,335Other expenses(15,341)(34,658)Distribution and selling expenses(239,897)(214,103)Administrative expenses(231,907)(235,613)Finance costs4(59,004)(28,098)Share of profit of an associate3,2025,141Profit before tax33,51591,272Income tax expense5(8,499)(13,302)Profit for the year625,01677,970Profit for the year attributable to:Owners of the Company22,41774,375Non-controlling interests2,5993,59525,01677,970Earnings per share basic and diluted8RMB0.049RMB0.163CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME20122011RMB000RMB000Profit for the year25,01677,970Other comprehensive income (expense):Exchange differences arising on translation of a foreign operation330(864)Fair value gain (loss) arising on available-for-sale investments 20,231(22,574)Income tax relating to components of other comprehensive income(3,035)3,386Other comprehensive income (expense) for the year, net of tax17,526(20,052)Total comprehensive income for the year42,54257,918Total comprehensive income attributable to:Owners of the Company39,82854,625Non-controlling interests2,7143,29342,54257,918CONSOLIDATED STATEMENT OF FINANCIAL POSITIONNOTES20122011RMB000RMB000Non-current assetsTechnical knowhow14,686-Property, plant and equipment1,426,1871,065,521Construction in progress273,977363,330Prepaid lease payments on land use rights235,658217,022Investment properties68,90637,142Interest in an associate24,96321,761Available-for-sale investments156,303136,072Deferred tax assets19,16816,588Goodwill2,716-Prepayments for acquisition of land use rights63,55531,7872,286,1191,889,223Current assetsInventories 489,673423,789Trade and other receivables9428,468389,356Prepaid lease payments on land use rights5,8405,711Amounts due from fellow subsidiaries3,9716,600Tax recoverable3,2753,504Restricted bank balances46,60031,263Bank balances and cash375,544267,9661,353,3711,128,189Current liabilitiesTrade and other payables10522,747485,119Dividend payables5,31115,111Amounts due to fellow subsidiaries1,484 2,835Amount due to an associate51461Amount due to ultimate holding company13,500-Tax payable883608Borrowings 493,370475,1471,037,809978,881Net current assets315,562149,308Total assets less current liabilities2,601,6812,038,53120122011RMB000RMB000Capital and reservesShare capital457,313457,313Reserves1,282,2041,246,949Proposed final dividend4,57313,719Equity attributable to owners of the Company1,744,0901,717,981Non-controlling interests39,70139,807Total equity1,783,7911,757,788Non-current liabilitiesDeferred tax liabilities12,3315,570Loan from ultimate holding company496,500-Borrowings221,147213,321Deferred income87,91261,852817,890280,7432,601,6812,038,531NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNDER HKGAAP1. BASIS OF PREPARATIONThe audited consolidated financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs), Hong Kong Accounting Standards (HKASs) issued by Hong Kong Institute of Certified Public Accountants (HKICPA) and the disclosure requirements of Appendix 16 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.2. APPLICATION OF NEW AND REVISED HONG KONG FINANCIAL REPORTING STANDARDS (HKFRSs) / CHANGES IN ACCOUNTING POLICIESIn the current year, the Group has applied the following new and revised HKFRSs issued by the Hong Kong Institute of Certified Public Accountants (the HKICPA). Amendments to HKFRS 1 First-time Adoption of Hong Kong Financial Reporting Standards Severe Hyperinflation and Removal of Fixed Dates for First-time Adopters Amendments to Hong Kong Accounting Standard (HKAS) 12 Deferred Tax: Recovery of Underlying AssetsAmendments to HKFRS 7 Financial Instruments: Disclosures Transfers of Financial AssetsThe application of the above amendments to HKFRSs has had no material impact on the Groups financial performance and position for the current and prior years and/or the disclosures set out in these consolidated financial statements.Changes in accounting policiesDuring the year, the Group has changed its accounting policy relating to its property, plant and equipment as follow.Prior to the change, the Group used to measure its property, plant and equipment using the revaluation model. The management of the Group considers that measuring property, plant and equipment at cost model provides more relevant information about the Groups financial performance and is consistent with the Groups accounting policies under the General Acceptable Accounting Policies. As a result, the Group has decided to state it at cost, less any accumulated depreciation and accumulated impairment losses. There is no effect of this voluntary change in accounting policy on the amounts reported in the consolidated financial statements for the current and prior years as there had been no material difference between the fair value and carrying value under cost model of the property, plant and equipment at each date of revaluations made after recognition of the assets.The Group has not early applied the following new and revised standards, amendments and interpretations that have been issued but are not yet effective.HKFRSs (Amendments)Annual Improvements 2009-2011 Cycle1HKFRS 1 (Amendments)Government loans1Amendments to HKFRS 7 Disclosures Offsetting Financial Assets and Financial Liabilities1Amendments to HKFRS 9 and HKFRS 7Mandatory Effective Date of HKFRS 9 and Transition Disclosures2Amendments to HKFRS 10, HKFRS 11 and HKFRS 12Consolidated Financial Statements, Joint Arrangements and Disclosure of Interests in Other Entities: Transition Guidance1Amendments to HKFRS 10, HKFRS 12 and HKAS 27Investment Entities4HKFRS 9Financial Instruments2HKFRS 10Consolidated Financial Statements1HKFRS 11Joint Arrangement1HKFRS 12Disclosures of Interests in Other Entities1HKFRS 13Fair Value Measurement1HKAS 19 (as revised in 2011)Employee Benefits1 HKAS 27 (as revised in 2011)Separate Financial Statements1HKAS 28 (as revised in 2011)Investments in Associate and Joint Ventures1Amendments to HKAS 1 Presentation of Items of Other Comprehensive Income3Amendments to HKAS 32 Offsetting Financial Assets and Financial Liabilities4HK(IFRIC) Int 20Stripping Costs in the Production Phase of a Surface Mine11 Effective for annual periods beginning on or after 1 January 2013.2 Effective for annual periods beginning on or after 1 January 2015.3 Effective for annual periods beginning on or after 1 July 2012.4 Effective for annual periods beginning on or after 1 January 2014.Annul improvements to HKFRSs 2009-2011 Cycle issued in June 2012The Annual Improvements to HKFRSs 2009 2011 Cycle include a number of amendments to various HKFRSs. The amendments are effective for annual periods beginning on or after 1 January 2013. Amendments to HKFRSs include the amendments to HKAS 16 Property, Plant and Equipment and the amendments to HKAS 32 Financial Instruments: Presentation.The amendments to HKAS 16 clarify that spare parts, stand-by equipment and servicing equipment should be classified as property, plant and equipment when they meet the definition of property, plant and equipment in HKAS 16 and as inventory otherwise. The directors do not anticipate that the application of the amendments will have a material effect on the Groups consolidated financial statementsThe amendments to HKAS 32 clarify that income tax on distributions to holders of an equity instrument and transaction costs of an equity transaction should be accounted for in accordance with HKAS 12 Income Taxes. The directors anticipate that the amendments to HKAS 32 will have no effect on the Groups consolidated financial statements.Amendments to HKAS 32 Offsetting Financial Assets and Financial Liabilitiesand amendments to HKFRS 7 Disclosures Offsetting Financial Assets and Financial LiabilitiesThe amendments to HKAS 32 clarify existing application issues relating to the offset of financial assets and financial liabilities requirements. Specifically, the amendments clarify the meaning of currently has a legally enforceable right of set-off and simultaneous realisation and settlement.The amendments to HKFRS 7 require entities to disclose information about rights of offset and related arrangements (such as collateral posting requirements) for financial instruments under an enforceable master netting agreement or similar arrangement.The amendments to HKFRS 7 are effective for annual periods beginning on or after 1 January 2013 and interim periods within those annual periods. The disclosures should also be provided retrospectively for all comparative periods. However, the amendments to HKAS 32 are not effective until annual periods beginning on or after 1 January 2014, with retrospective application required. The directors anticipate that the application of these amendments to HKAS 32 and HKFRS 7 may result in more disclosures being made with regard to offsetting financial assets and financial liabilities in the future.HKFRS 9 Financial InstrumentsHKFRS 9 Financial Instruments issued in November 2009 and amended in October 2011 introduces new requirements for the classification and measurement of financial assets and financial liabilities and for derecognition.HKFRS 9 requires all recognised financial assets that are within the scope of HKAS 39 Financial Instruments: Recognition and Measurement to be subsequently measured at amortised cost or fair value. Specifically, debt investments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortised cost at the end of subsequent accounting periods. All other debt investments and equity investments are measured at their fair values at the end of subsequent accounting periods. In addition, under HKFRS 9, entities may make an irrevocable election to present subsequent changes in the fair value of an equity investment (that is not held for trading) in other comprehensive income, with only dividend income generally recognised in profit or loss.The most significant effect of HKFRS 9 regarding the classification and measurement of financial liabilities relates to the presentation of changes in fair value of a financial liability (designated as at fair value through profit or loss) attributable to changes in the credit risk of that liability. Specifically, under HKFRS 9, for financial liabilities that are designated as at fair value through profit or loss, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is presented in other comprehensive income, unless the recognition of the effects of changes in the liabilitys credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. Changes in fair value attributable to a financial liabilitys credit risk are not subsequently reclassified to profit or loss. Previously, under HKAS 39, the entire amount of the change in the fair value of the financial liability designated as at fair value through profit or loss was recognised in profit or loss.HKFRS 9 is effective for annual periods beginning on or after 1 January 2015, with earlier application permitted.The directors of the Company anticipate that HKFRS 9 that will be adopted in the Groups consolidated financial statements for the annual period beginning 1 January 2015 and that the application of the new standard will have no significant impact on amounts reported in respect of the Groups financial assets and financial liabilities.New and revised standards on consolidation, joint arrangements, associates and disclosuresIn June 2011, a package of five standards on consolidation, joint arrangements, associates and disclosures was issued, including HKFRS 10, HKFRS 11, HKFRS 12, HKAS 27 (as revised in 2011) and HKAS 28 (as revised in 2011). Key requirements of these five standards are described below.HKFRS 10 replaces the parts of HKAS 27 Consolidated and Separate Financial Statements that deal with consolidated financial statements and HK(SIC)-Int 12 Consolidation Special Purpose Entities. HKFRS 10 includes a new definition of control that contains three elements: (a) power over an investee, (b) exposure, or rights, to variable returns from its involvement with the investee, and (c) the ability to use its power over the investee to affect the amount of the investors returns. Extensive guidance has been added in HKFRS 10 to deal with complex scenarios.HKFRS 11 replaces HKAS 31 Interests in Joint Ventures and HK (SIC)-Int 13 Jointly Controlled Entities Non-Monetary Contributions by Venturers. HKFRS 11 deals with how a joint arrangement of which two or more parties have joint control should be classified. Under HKFRS 11, joint arrangements are classified as joint operations or joint ventures, depending on the rights and obligations of the parties to the arrangements. In contrast, under HKAS 31, there are three types of joint arrangements: jointly controlled entities, jointly controlled assets and jointly controlled operations. In addition, joint ventures under HKFRS 11 are required to be accounted for using the equity method of accounting, whereas jointly controlled entities under HKAS 31 can be accounted for using the equity method of accounting or proportionate accounting. HKFRS 12 is a disclosure standard and is applicable to entities that have interests in subsidiaries, joint arrangements, associates and/or unconsolidated structured entities. In general, the disclosure requirements in HKFRS 12 are more extensive than those in the current standards.In July 2012, the amendments to HKFRS 10, HKFRS 11 and HKFRS 12 were issued to clarify certain transitional guidance on the application of these five HKFRSs for the first time.These five standards, together with the amendments relating to the transitional guidance, are effective for annual periods beginning on or after 1 January 2013 with earlier application permitted provided that all of these standards are applied at the same time. The directors of the Company do not anticipate that the application of these five standards will have significant impact on the amounts reported in the consolidated financial statements under the current group structure. The directors of the Company will reassess the impact on 1 January 2013.Amendments to HKFRS 10, HKFRS 12 and HKAS 27 Investment EntitiesThe amendments to HKFRS 10 introduce an exception to consolidating subsidiaries for an investment entity, except where the subsidiaries provide services that relate to the investment entitys investment activities. Under the amendments to HKFRS 10, an investment entity is required to measure its interests in subsidiaries at fair value through profit or loss.To qualify as an investment entity, certain criteria have to be met. Specifically, an entity is required to:obtain funds from one or more investors for the purpose of providing them with professional investment management services;commit to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; andmeasure and evaluate performance of substantially all of its investments on a fair value basis.Consequential amendments to HKFRS 12 and HKAS 27 have been made to introduce new disclosure requirements for investment entities.The amendments to HKFRS 10, HKFRS 12 and HKAS 27 are effective for annual periods beginning on or after 1 January 2014, with early application permitted. The directors anticipate that the application of the amendments will have no effect on the Group as the Company is not an investment entity.HKFRS 13 Fair Value MeasurementHKFRS 13 establishes a single source of guidance for fair value measurements and disclosures about fair value measurements. The Standard defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. The scope of HKFRS 13 is broad; it applies to both financial instrument items and non-financial instrument items for which other HKFRSs require or permit fair value measurements and disclosures about fair value measurements, except in specified circumstances. In general, the disclosure requirements in HKFRS 13 are more extensive than those in the current standards. For example, quantitative and qualitative disclosures based on the three-level fair value hierarchy currently required for financial instruments only under HKFRS 7 Financial Instruments: Disclosures will be extended by HKFRS 13 to cover all assets and liabilities within its scope.HKFRS 13 is effective for annual periods beginning on or after 1 January 2013, with earlier application permitted.The directors anticipate that the application of the new Standard may affect the amounts reported in the consolidated financial statements and result in more extensive disclosures in the consolidated financial statements.Amendments to HKAS 1 Presentation of Items of Other Comprehensive IncomeThe amendments to HKAS 1 Presentation of Items of Other Comprehensive Income introduce new terminology for the statement of comprehensive income and income statement. Under the amendments to HKAS 1, a statement of comprehensive income is renamed as a statement of profit or loss and other comprehensive income and an income statement is renamed as a statement of profit or loss. The amendments to HKAS 1 retain the option to present profit or loss and other comprehensive income in either a single statement or in two separate but consecutive statements. However, the amendments to HKAS 1 require items of other comprehensive income to be grouped into two categories: (a) items that will not be reclassified subsequently to profit or loss; and (b) items that may be reclassified subsequently to profit or loss when specific conditions are met. Income tax on items of other comprehensive income is required to be allocated on the same basis the amendments do not change the option to present items of other comprehensive income either before tax or net of tax.The amendments to HKAS 1 are effective for annual periods beginning on or after 1 July 2012. The presentation of items of other comprehensive income will be modified accordingly when the amendments are applied in future accounting periods.3. SEGMENTAL INFORMATIONThe Groups operating segments, based on information reported to the board of directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment of segment performance focuses on the types of goods supplied. The principal types of goods supplied are bulk pharmaceuticals, preparations, chemical and other products and commerce circulations. The Groups reportable segments under HKFRS 8 are as follows:Bulk pharmaceuticals:Development, production and sales of bulk pharmaceuticalsPreparations:Development, production and sales of preparations (e.g. tablets and injections)Chemical and other products:Production and sales of chemical and other products Commerce circulations:Trading of pharmaceutical products (including retail and wholesale)Information regarding the above segments is reported below. Segment revenues and resultsThe following is an analysis of the Groups revenue and results by reportable segment.For the year ended 31 December 2012Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,422,469586,292718,835204,520-2,932,116Inter-segment sales6,822357,55711,852277,524(653,755)-Total 1,429,291943,849730,687482,044(653,755)2,932,116Segment profit (loss) 108,804  9,967  (17,964) (20,797)80,010Unallocated income28,954Unallocated expenses(19,647)Finance costs(59,004)Share of profit of an associate3,202Profit before tax 33,515For the year ended 31 December 2011Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsEliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales1,491,589553,395734,364138,512-2,917,860Inter-segment sales11,077346,34458,129275,781(691,331)-Total 1,502,666899,739792,493414,293(691,331)2,917,860Segment profit 136,02322,841(39,034)11,133 130,963Unallocated income21,181Unallocated expenses(37,915)Finance costs(28,098)Share of profit of an associate5,141Profit before tax 91,272The accounting policies of the reportable segments are the same as the Groups accounting policies described. Segment profit represents the profit earned by each segment without allocation of investment and other income (excluding government grants), other expenses, depreciation for investment properties, finance costs and share of profit of an associate. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment. Inter-segment sales are charged at prevailing market rates.Segment assets and liabilitiesThe following is an analysis of the Groups assets and liabilities by reportable segment:At 31 December 2012Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,600,335569,590135,428639,3782,944,731Unallocated corporate assets694,759Consolidated assets3,639,490Segment liabilities230,70393,82551,620162,097538,245Unallocated corporate liabilities 1,317,454Consolidated liabilities1,855,699At 31 December 2011Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Segment assets1,300,312483,372182,817536,6152,503,116Unallocated corporate assets514,296Consolidated assets3,017,412Segment liabilities239,10391,33271,11386,467488,015Unallocated corporate liabilities 771,609Consolidated liabilities1,259,624For the purposes of monitoring segment performances and allocating resources among segments:all assets are allocated to reportable segments other than deferred tax assets, interest in an associate, available-for-sale investments, investment properties, tax recoverable, restricted bank balances, bank balances and cash. Assets used jointly by reportable segments are allocated on the basis of revenues earned by individual reportable segments; andall liabilities are allocated to reportable segments other than liabilities associated with dividend payable, deferred tax liabilities, loan from ultimate holding company, borrowings, deferred income and tax payable. Liabilities for which reportable segments are jointly liable are allocated on the basis of revenues earned by individual reportable segments. Other segment informationFor the year ended 31 December 2012Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 284,23284,1051,093173,417542,847Depreciation and amortisation (excluded depreciation for investment properties)90,83028,7632,17441,061162,828Impairment losses recognised in respect of property, plant and equipment---9898Impairment losses recognised in respect of trade and other receivables 124379,721469,928Reversal of impairment loss on trade and other receivables(156)(47)(361)(21)(585)Reversal of allowance for inventories(884)(263)(864)(2,796)(4,807)Write-down of inventories2,2326631,8523,2127,959Note: Non-current assets excluded financial instruments, investment properties, deferred tax assets and interest in an associate. For the year ended 31 December 2012Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-24,963--24,963Interest income2,0085541503083,020Gain on disposal of property, plant and equipment and prepaid lease payment on land use rights9,7882,841-28512,914Finance costs(44,716)(13,291)(413)(584)(59,004)Income tax expense(6,805)(1,200)(40)(454)(8,499)For the year ended 31 December 2011Amounts included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Addition to non-current assets (Note) 219,50159,3021,221182,177462,201Depreciation and amortisation (excluded depreciation for investment properties)83,97522,4901,28023,725131,470Impairment losses recognised in respect of trade and other receivables 41920,55530,6297851,681Reversal of impairment loss on trade and other receivables--(216)-(216)Reversal of allowance for inventories(6,789)(1,973)(126)(2)(8,890)Write-down of inventories1,0727677022,8995,440Note: Non-current assets excluded financial instruments, investment properties, deferred tax assets and interest in an associate. For the year ended 31 December 2011Amounts regularly provided to the chief operating decision maker but not included in the measure of segment profit or segment assets:Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other productsTotalRMB000RMB000RMB000RMB000RMB000Interest in an associate-21,761--21,761Interest income1,592401941192,206Loss on disposal of property, plant and equipment(5,706)(1,598)(25)(4,016)(11,345)Finance costs(21,779)(6,133)(181)(5)(28,098)Income tax (expense) credit(9,819)6053,820(7,908)(13,302)Geographical informationThe Groups customers are mainly located in the PRC, Europe, America and other countries. Revenues from external customers20122011RMB000RMB000PRC1,772,7791,838,173Europe496,242410,081America470,377507,721Others192,718161,8852,932,1162,917,860Over 99% of the Groups non-current assets are located in the PRC and therefore the analysis of non-current assets by geographical location of the assets is not presented.Information about major customersThe Groups customer base includes a wide range of different customers. During the year ended 31 December 2012 and 2011, the Group had no single customer that contributed 10% or more of the Groups revenue. Therefore, there was no significant concentration of source of income from a particular customer.4. FINANCE COSTS20122011RMB000RMB000Interest on:- Bank loans wholly repayable within 5 years28,50526,714 Government loans wholly repayable within 5 years1,2651,205 Loan from ultimate holding company30,650-60,42027,919Less: interest capitalised at a rate of 5.90 6.90% per annum(2,818)-57,60227,919Discount charges on bank acceptance notes1,40217959,00428,0985. INCOME TAX EXPENSE20122011RMB000RMB000PRC enterprise income tax - Current9,77919,719 - Under-provision in prior years1,56766811,34620,387 Deferred tax (2,847)(7,085)8,49913,302Under the Law of the PRC on Enterprise Income Tax (the EIT Law) and Implementation Regulation of the EIT Law, the tax rate of the PRC companies is 25% for both years. Pursuant to the relevant laws and regulations in the PRC, the Company was accredited as a high-tech enterprise. The accreditation is valid for three years. The Company is entitled to the preferential tax rate of 15% for a period of three years from 1 January 2011 to 31 December 2013. Pursuant to the relevant laws and regulations in the PRC, the Groups subsidiary, SINO-USA Zibo Xinhua - Perrigo Pharmaceutical Company Limited, operating in the PRC is entitled to exemption from the PRC income tax for the two years ended 31 December 2009, followed by a 50% reduction of the PRC income tax for the three years ended 31 December 2012. No extension on this tax reduction was granted after 31 December 2012. Pursuant to the relevant laws and regulations in the PRC, the Groups subsidiary, Zibo Xinhua-Eastwest Pharmaceutical Company Limited, operating in the PRC is entitled to exemption from the PRC income tax for the two years ended 31 December 2008, followed by a 50% reduction of the PRC income tax for the three years ended 31 December 2011. No extension on this tax reduction was granted after 31 December 2011.The tax charge for the year can be reconciled to the profit before tax per the consolidated income statement as follows: 20122011RMB000RMB000Profit before tax 33,51591,272Tax at the domestic income tax rate of 25% (2011: 25%)8,37922,818Effect of preferential tax rate in the PRC(6,005)(8,354)Effect of tax exemption granted to PRC subsidiaries(1,062)(827)Tax effect of share of profits of an associate(480)(771)Tax effect of income not taxable for tax purpose(1,903)(285)Tax effect of expenses not deductible for tax purpose4,706805Tax effect of additional allowance (Note)(1,045)(1,272)Tax effect of tax losses not recognised1,03643Tax effect of deductible temporary differences not recognised3,306492Utilisation of tax losses previously not recognised -(15)Under-provision in prior years1,567668Tax charge for the year8,49913,302Note: The amount represents the tax effect of additional tax allowance granted to the Group in respect of research and development expenditure as stipulated in the relevant tax rules in the PRC. 6. PROFIT FOR THE YEARProfit for the year has been arrived at after charging (crediting):20122011RMB000RMB000Depreciation for property, plant and equipment154,728125,759Depreciation for investment properties4,3063,257Amortisation of prepaid lease payments on land use rights5,8405,711Amortisation of technical know-how (included in administrative expenses)2,260-Total depreciation and amortisation167,134134,727Auditors remuneration1,6491,199Research and development costs recognised as an expense30,10734,492Operating lease rentals on land and buildings1,235936Impairment losses recognised in property, plant and equipment98-Impairment losses recognised in respect of financial assets-trade and other receivables (Note 9)9,92851,681Reversal of allowance for inventories (included in cost of sales)(4,807)(8,890)Write-down of inventories (included in cost of sales)7,9595,440Staff costs (excluding directors and supervisors emoluments) 301,013252,157Cost of inventories recognised as an expense2,427,7112,369,6977. DIVIDENDS20122011RMB000RMB000Dividends recognised as distribution during the year- 2011 final dividend: RMB0.03 (2011 : 2010 final dividend RMB0.05) per share 13,71922,866For the year ended 31 December 2012, final dividend of RMB0.01 (2011: RMB0.03) per share (approximately HK$0.0125 (2011: HK$0.0368) per share, including income tax of A shares) on 307,312,830 A shares and 150,000,000 H shares has been proposed by the directors of the Company and is subject to approval by shareholders at the annual general meeting and has been included as a dividend reserve in the consolidated financial statements.8. EARNINGS PER SHAREThe calculation of the basic earnings per share is based on the Groups profit for the year attributable to the owners of the Company of approximately RMB22,417,000 (2011: RMB74,375,000) and based on the weighted average number of 457,312,830 (2011: 457,312,830) shares in issue during the year.Basic earnings per share and diluted earnings per share for two years ended 31 December 2012 and 2011 are the same as there were no dilutive events existed during both years.9. TRADE AND OTHER RECEIVABLES20122011RMB000RMB000Trade and bills receivables403,563393,531Less : Allowance for doubtful debts of trade receivables(63,125)(53,328)340,438340,203Other receivables, deposits and prepayments53,09645,127VAT recoverable14,73713,270Consideration receivable on disposal of land28,987-Less : Allowance for doubtful debts of other receivables(8,790)(9,244)88,03049,153Total trade and other receivables428,468389,356As at 31 December 2012, included in the trade receivables of approximately RMB127,346,000 (2011: RMB107,959,000) and approximately RMB2,071,000 (2011: RMB1,826,000) is denominated in United States Dollars (USD) and Great Britain Pounds (GBP) respectively.The Groups revenue from export sales is on letter of credit or documents against payment. The credit period is agreed upon and stipulated in the sales contract. Except for some particular customers where payment in advance is normally required, the Group allows an average credit period of 30 days to its local trade customers and 90 days for local hospital customers. The following is an aged analysis of the trade and bills receivables net of allowance for doubtful debts presented based on the invoice date which approximated to the revenue recognition dates at the end of the reporting period.20122011RMB000RMB000Within one year333,317335,408More than one year but within two years6,9043,212More than two years but within three years2171,583340,438340,203Included in the Groups trade and bills receivable balance are debtors with aggregate carrying amount of approximately RMB42,551,000 (2011: RMB39,684,000) which are past due as at the reporting date for which the Group has not provided for impairment loss. In respect of trade and bill receivables, individual credit evaluations are performed on all customers requiring credit over a certain amount. These evaluations focus on the customers past history of making payments when due and current liability to pay, and take into account information specific to the customer as well as pertaining to the economic environment in which the customers operate. 86% (2011: 76%) of the trade and bill receivables that are neither past due nor impaired have good settlement history under the Groups individual credit evaluations. The Group does not hold any collateral over these balances.Ageing of trade receivables which are past due but not impaired20122011RMB000RMB000Within one year37,80238,193More than one year but within than two years4,5321,343More than two years but within than three years217148Total42,55139,684Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, management believes that no impairment allowance is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of trade receivables20122011RMB000RMB000At 1 January53,3281,979Impairment losses reversed(111)-Impairment losses recognised9,90851,349At 31 December63,12553,328In determining the recoverability of trade receivables, the Group considers any change in the credit quality of the trade receivables from the date credit was initially granted up to the end of the reporting period. The concentration of credit risk is limited due to the customer base being large and unrelated.Included in the allowance for doubtful debts are individually impaired trade receivables with an aggregate balance of approximately RMB63,125,000 (2011: RMB53,328,000) which were found to be under severe financial difficulties. The Group does not hold any collateral over these balances.Movements in the allowance for doubtful debts of other receivables20122011RMB000RMB000At 1 January9,2449,128Impairment losses reversed(474)(216)Impairment loss recognised20332At 31 December8,7909,244Included in the allowance for doubtful debts are individually impaired other receivables with an aggregate balance of approximately RMB8,790,000 (2011: RMB9,244,000) which were found to be under severe financial difficulties. The Group does not hold any collateral over these balances.During the year ended 31 December 2011, the Group recorded compensation income of approximately RMB7,907,000. At 31 December 2011, the balance is yet to be settled and is included in other receivables in the consolidated statement of financial position. The balance has been settled during the year ended 31 December 2012. As at 31 December 2012, certain secured bank loans were secured by trade and bills receivables of the Group with an aggregate carrying values of approximately RMB62,855,000 (2011: RMB58,837,000).10. TRADE AND OTHER PAYABLES20122011RMB000RMB000Trade payables394,431355,211Other payables and accrued charges52,41154,686Accrued construction expenses75,90575,222522,747485,119The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period. 20122011RMB000RMB000Within one year382,711346,815More than one year but less than two years6,2943,986More than two years but less than three years1,707601Over three years 3,7193,809394,431355,211The average credit period on purchases of goods is approximately 30 days. The Group has financial risk management policies in place to ensure that all payables are settled within the credit timeframe.11. RELATED PARTY TRANSACTIONS(a) Except as disclosed elsewhere in the consolidated financial statements, the other significant related party transactions, which were carried out in the normal course of the Groups business are detailed as follows:20122011RMB000RMB000Immediate holding company:SXPGC:- Payment of annual trademark licence fee (Note1)7,5001,100- Rental expense500500- Acquisition of land use rights8,399-Ultimate holq r s   x z . 0 2 4 T V ٿ٧vgvgT;T1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*CJOJQJaJphh:7hmCJOJQJaJh:7hmCJOJQJaJh:7hm5CJOJQJaJ"h:7hm5CJOJQJaJo(.h:7h45CJOJPJQJaJnHo(tH2jhgh~,5CJOJQJUmHnHo(uhghm5CJOJQJo(+hghm6KHOJPJQJaJnHtHq r t u v  x 2 X rs!"78ij^T^`^ $dT^a$ $UDb]a$$a$KpuV X \ ^ ` b  ͯ͂oVoVo;4h:7hfyB*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*CJOJQJaJphh:7hmB*OJQJph:h:7h5B*CJOJPJQJ\aJnHo(phtH:h:7hfy5B*CJOJPJQJ\aJnHo(phtH+h:7hm5B*CJOJQJ\aJph7h:7hm5B*CJOJPJQJ\aJnHphtH eopQprsҷҞ҅҅҅jjO@h:7hmCJOJQJaJ4h:7h=NhB*CJOJPJQJaJnHo(phtH4h:7hB*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH1h:7htB*CJOJPJQJaJnHphtH4h:7htB*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph4h:7hB*CJOJPJQJaJnHo(phtH !"8<FijҿmQ57h:7hm5B*CJOJPJQJ\aJnHphtH7h:7hm5B*CJOJPJQJ\aJnHphtH:h:7h>H5B*CJOJPJQJ\aJnHo(phtH+h:7hm5B*CJOJQJ\aJphh:7hmCJOJQJaJh:7hmCJOJQJaJ%h:7hmB*CJOJQJaJph%h:7hmB*CJOJQJaJph4h:7h>HB*CJOJPJQJaJnHo(phtH ѼѓweSA-&h:7hm6CJPJ]aJnHtH#h:7hmCJPJaJnHo(tH#h:7hCJPJaJnHo(tH#h:7h.mNCJPJaJnHo(tHh:7hmCJaJ h:7hm56CJ\]aJ&h:7hm5CJPJ\aJnHtH)h:7h5CJPJ\aJnHo(tH)h:7h5CJPJ\aJnHo(tHh:7hm5CJ\aJh:7hmCJKHaJ&h:7hm5CJPJ]aJnHtHmb $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$1$IfWDd` $$1$Ifa$   ȶ夗nZnOnZnO>O h:7hyxVCJPJaJnHtHh:7hyxVCJaJ'h:7hyxVCJKHOJQJ^JaJo($h:7hyxVCJKHOJQJ^JaJ*h:7hyxV5CJKHOJQJ^JaJo(h:7hyxVCJKHaJ#h:7hyxVCJPJaJnHo(tH#h:7hmCJPJaJnHo(tH#h:7hCJPJaJnHo(tHh:7hmCJaJh:7hmCJKHaJh:7hm6CJ]aJ xm $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la$$1$Ifa$gd   (1:{mmm$$1$Ifa$gd $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 la &'(01:;NOV\]fgƪ{g{ZO{g{ZOZ{g{ZOCOh:7hyxVCJaJo(h:7hyxVCJaJh:7hyxVCJKHaJ'h:7hyxVCJKHOJQJ^JaJo($h:7hyxVCJKHOJQJ^JaJ6h:7hyxV5CJKHOJPJQJ^JaJnHo(tH6h:7h=C5CJKHOJPJQJ^JaJnHo(tH*h:7hyxV5CJKHOJQJ^JaJo($h:7hyxVCJKHPJaJnHtH h:7hyxVCJPJaJnHtH:;OV]f{mmm$$1$Ifa$gd $$1$Ifa$xkd$$Ifl,\3 EW! p9!644 lafg{mmm$$1$Ifa$gd $$1$Ifa$xkd*$$Ifl,\3 EW! p9!644 laqccc$$1$Ifa$gdv$ $Ifa$xkd$$Ifl,\3 EW! p9!644 la׶oY;%+h:7hm5B*CJOJQJ\aJph:h:7hi5B*CJOJPJQJ\aJnHo(phtH+h:7h]4fCJOJPJQJaJnHo(tH+h:7hmCJOJPJQJaJnHo(tH(h:7hmCJOJPJQJaJnHtH7h:7hm5B*CJOJPJQJ\aJnHphtHh:7hyxVCJKHaJ'h:7hyxVCJKHOJQJ^JaJo($h:7hyxVCJKHOJQJ^JaJ*h:7hyxV5CJKHOJQJ^JaJo( ooooJ%<TPL HD@< ^TQ ^xkdB$$Ifl,\3 EW! p9!644 la Ħyn`K6/h:7hm56CJPJ\]aJnHo(tH)h:7h5CJPJ\aJnHo(tH)h:7hi5CJPJ\aJnHo(tHh:7hm5CJ\aJh:7hmCJaJ&h:7hm5CJPJ]aJnHtH1h:7hmB*CJOJPJQJaJnHphtH:h:7hm5B*CJOJPJQJ\aJnHo(phtH:h:7h*O5B*CJOJPJQJ\aJnHo(phtH:h:7hs5B*CJOJPJQJ\aJnHo(phtH  &.5=;$1$IfWD`; $$1$Ifa$%<TPL HD@< ^.<TPL HD@< WD^`gd`)F  "#$%&-.0245<>JKU^ǵٵqf[E2$h:7hPCJKHOJQJ^JaJ*h:7hP5CJKHOJQJ^JaJo(h:7hPCJaJh:7hPCJaJ&h:7hm6CJPJ]aJnHtHh:7hm6CJ]aJ&h:7hm5CJPJ\aJnHtHh:7hm5CJ\aJ#h:7hCJPJaJnHo(tH#h:7hgICJPJaJnHo(tHh:7hmCJaJh:7hmCJaJ h:7hm56CJ\]aJ=>KU_j~ppp$$1$Ifa$gd$1$Ifxkd$$Ifl,\S "b :::"644 la]^_jk|}Ϯϐo\H7 h:7h CJKHOJQJaJ'h:7h CJKHOJQJ^JaJo($h:7h CJKHOJQJ^JaJ*h:7h 5CJKHOJQJ^JaJo(h:7h CJaJh:7h CJaJ$h:7hPCJKHOJQJ^JaJ*h:7hP5CJKHOJQJ^JaJo(h:7hPCJaJh:7hPCJaJ h:7hPCJKHOJQJaJ'h:7hPCJKHOJQJ^JaJo(jk}~ppp$$1$Ifa$gd$1$IfxkdF$$Ifl,\S "b :::"644 la]~ppp$$1$Ifa$gd$1$Ifxkd$$Ifl,\S "b :::"644 la]$~ppp$$1$Ifa$gd$1$IfxkdB$$Ifl,\S "b :::"644 la]$%&0d¯qS=+h:7hm5B*CJOJQJ\aJph:h:7h>H5B*CJOJPJQJ\aJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH h:7h CJKHOJQJaJ'h:7h CJKHOJQJ^JaJo($h:7h CJKHOJQJ^JaJ*h:7h 5CJKHOJQJ^JaJo(h:7h CJaJ#h:7h CJPJaJnHo(tHh:7h CJaJ $%&efaYPP^gd`)F & Fgds%<TPL HD@< ^xkd$$Ifl,\S "b :::"644 la]defgĦuaQ:#:-h:7h5CJKHPJ\aJnHo(tH-h:7h=5CJKHPJ\aJnHo(tHh:7h=5CJKH\aJ'h:7h=5CJKHPJaJnHtH1h:7hmB*CJOJPJQJaJnHphtH.h:7hO(p5B*CJOJQJ\aJo(ph:h:7hT5B*CJOJPJQJ\aJnHo(phtH:h:7h`)F5B*CJOJPJQJ\aJnHo(phtH:h:7hm5B*CJOJPJQJ\aJnHo(phtH  $$Ifa$gd*$$1$Ifa$gd=$$1$Ifa$gd* $$1$Ifa$%<TPL HD@< ^ ˷ˏmˣ`L9$h:7hspCJKHPJaJnHtH'h:7hspCJKHPJaJnHo(tHh:7h=CJKHaJ'h:7h(:CJKHPJaJnHo(tHh:7h=6CJ]aJ'h:7h=CJKHPJaJnHo(tH'h:7hCJKHPJaJnHo(tH'h:7h'CJKHPJaJnHo(tHh:7h=CJKHaJ h:7h=56CJ\]aJ,h:7h=56CJPJ\]aJnHtH#pbVVHH$$1$Ifa$gd $$Ifa$gd$$1$Ifa$gdykd>$$Ifl4r&*p#tG?644 laf4 #$5DS\kl "#PUouv̸̥̥̥w$h:7h=CCJKHPJaJnHtHh:7hspCJKHaJh:7hspCJKHaJo($h:7hspCJKHPJaJnHtH'h:7hspCJKHPJaJnHo(tHh:7hspCJKHaJ'h:7hspCJKHOJQJ^JaJo($h:7hspCJKHOJQJ^JaJ+#$5ES\kseYYYY $$Ifa$gd$$1$Ifa$gdykd$$Iflr&*p#tG?644 laklseYYKK$$1$Ifa$gd $$Ifa$gd$$1$Ifa$gdykd$$Iflr&*p#tG?644 la "seYYYK$$1$Ifa$gd $$Ifa$gd$$1$Ifa$gdVkd]$$Iflr&*p#tG?644 la"#useYYYK$$1$Ifa$gd $$Ifa$gd$$1$Ifa$gdVkd $$Iflr&*p#tG?644 laseWWKW $$Ifa$gd$$1$Ifa$gd$$1$Ifa$gdykd $$Iflvr&*p#tG?644 la(BC˷mm`M@h:7hspCJKHaJ$h:7hspCJKHPJaJnHtHh:7h CJKHaJ$h:7h CJKHPJaJnHtHh:7h CJKHaJ'h:7h CJKHPJaJnHo(tH*h:7h 5CJKHPJaJnHo(tH'h:7h 5CJKHPJaJnHtHh:7h=CCJKHaJ$h:7h=CCJKHOJQJ^JaJ'h:7h=CCJKHOJQJ^JaJo($(?CseWKW=$$1$Ifa$gd(: $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3kdv $$Iflvr&*p#tG?644 laCrK=$$1$Ifa$gdykd) $$Iflvr&*p#tG?644 la $$Ifa$gd(:$$4$Ifa$gd(:$$1$Ifa$gd3 YK$$1$Ifa$gdykd $$Iflr&*p#tG?644 la$$1$Ifa$gd!W $$Ifa$gd!W "#@GRW^̸̥p\pOp\pOh:7h CJKHaJ'h:7h CJKHOJQJ^JaJo($h:7h CJKHOJQJ^JaJh:7h CJKHaJo('h:7h CJKHPJaJnHo(tH$h:7h CJKHPJaJnHtH'h:7hspCJKHPJaJnHo(tHh:7hspCJKHaJ'h:7hspCJKHOJQJ^JaJo($h:7hspCJKHOJQJ^JaJ "#^ogYMMM $$Ifa$gd0$$1$Ifa$gdykd $$Iflr&*p#tG?644 la $$Ifa$gd!WeWK $$Ifa$gd0$$1$Ifa$gdykdB$$Iflr&*p#tG?644 la$$1$Ifa$gd0sj]P]B$$1$Ifa$gd=!w ^`gd{kA ^`gdU9^gdU9kd$$Iflr&*p#tG?644 la Ĭ☄t]F]5(h:7h44CJKHaJ h:7h4456CJ\]aJ-h:7h`)5CJKHPJ\aJnHo(tH-h:7h445CJKHPJ\aJnHo(tHh:7h445CJKH\aJ'h:7h44CJKHOJQJ^JaJo('h:7h!f05CJKHPJaJnHtH.h:7h{kA5B*CJOJQJ\aJo(ph:h:7hC5B*CJOJPJQJ\aJnHo(phtH:h:7hU95B*CJOJPJQJ\aJnHo(phtH  8=ABGkd$$Ifr$<$4 ap2 $$Ifa$gd44$$1$Ifa$gd44    8:<=@AB[dmsõèõo[oo[oG'h:7hYCJKHPJaJnHo(tH'h:7hYCJKHOJQJ^JaJo($h:7hYCJKHOJQJ^JaJ$h:7hYCJKHPJaJnHtH$h:7h44CJKHOJQJ^JaJh:7h44CJKHaJh:7h446CJ]aJ'h:7h44CJKHPJaJnHo(tH'h:7h`)CJKHPJaJnHo(tH'h:7hoCJKHPJaJnHo(tHB[`emrs<kd$$Ifr$<$4 ap2 $$Ifa$gd0$$1$Ifa$gd0 $1$Ifgd=!wsHkd$$Ifr$<$4 ap2$$1$Ifa$gd0 $1$Ifgd=!w.0246@HJZblnz|  ʷ݅uuaʷM'h:7hYCJKHPJaJnHo(tH'h:7hYCJKHPJaJnHo(tHh:7hYCJKHQJaJo(+h:7hYCJKHPJQJaJnHo(tHh:7hYCJKHaJh:7hYCJKHQJaJ$h:7hYCJKHPJaJnHtH$h:7hYCJKHOJQJ^JaJ'h:7hYCJKHOJQJ^JaJo(h:7hYCJKHaJo(6@JSH $1$Ifgd=!wkdr$$Ifr$<$4 ap2$$1$Ifa$gd0J| "E: $1$Ifgd=!wkdb$$Ifr$<$4 ap2$$1$Ifa$gd0$$4$Ifa$gda "2:RT\^`ո륒kXD*3h:7h44CJKHOJPJQJ^JaJnHo(tH'h:7h!f05CJKHPJaJnHtH$h:7h}CJKHOJQJ^JaJ'h:7h}CJKHOJQJ^JaJo($h:7h}CJKHOJQJ^JaJ$h:7h}CJKHPJaJnHtH$h:7hYCJKHOJQJ^JaJh:7hYCJKHaJh:7hYCJKHQJaJo(+h:7hYCJKHPJQJaJnHo(tH'h:7hYCJKHOJQJ^JaJo("T^`E: $1$Ifgd=!wkdR$$Ifr$<$4 ap2$$1$Ifa$gd0$$4$Ifa$gdaSE$$1$Ifa$gd=!wkdB$$Ifr$<$4 ap2$$1$Ifa$gd!W-26e|$$1$Ifa$gd44 $$Ifa$gd44$$4$Ifa$gd44 !+,/01256y{|տ묙q]I<]I<h:7h44CJKHaJ'h:7h44CJKHPJaJnHo(tH'h:7h`)CJKHPJaJnHo(tH'h:7hVMCJKHPJaJnHo(tH'h:7hCCJKHPJaJnHo(tH$h:7hCCJKHPJaJnHtH$h:7h44CJKHPJaJnHtH*h:7h445CJKHPJaJnHo(tH*h:7h`)5CJKHPJaJnHo(tH'h:7h445CJKHPJaJnHtHaVHH::$$1$Ifa$gd0$$1$Ifa$gd!W $1$Ifgd=!wkd2$$Ifr$<$4 ap2  ƸƤww٤dVdBd'h:7h}CJKHPJaJnHo(tHh:7h}CJKHaJo($h:7h}CJKHPJaJnHtH3h:7h}CJKHOJPJQJ^JaJnHo(tH$h:7h}CJKHOJQJ^JaJ'h:7h}CJKHOJQJ^JaJo(h:7h}CJKHaJo($h:7h}CJKHPJaJnHtH'h:7h}CJKHPJaJnHo(tH$h:7h44CJKHOJQJ^JaJaVHH9$$1$4$Ifa$gd-(M$$1$Ifa$gd!W $1$Ifgd=!wkd$$Ifr$<$4 ap2!ʽjSJ;+h:7hmCJPJnHo(tHh:7hmCJPJnHtHh:7hmCJ,h:7hmB*OJPJQJnHo(phtH+h:7hm5B*CJOJQJ\aJph+h:7hB\CJOJPJQJaJnHo(tH$h:7h}CJKHOJQJ^JaJ'h:7h}CJKHPJaJnHo(tHh:7h}CJKHaJ$h:7h}CJKHPJaJnHtHh:7h}CJKHaJo('h:7hszCJKHPJaJnHo(tH !SQQDT^`kd $$Ifr$<$4 ap2$$1$Ifa$gdAs`kd$$If4FLt%u<d&    4 ahf4 $$Ifa$"6TPL HD@<%^ İvdR߰>>v&h:7h5CJPJQJnHo(tH#h:7h`)CJPJQJnHo(tH#h:7h0{CJPJQJnHo(tH"h:7hm5CJPJnHo(tH&h:7h`)5CJPJQJnHo(tH&h:7hd5CJPJQJnHo(tH&h:7hm5CJPJQJnHo(tHh:7hmCJ#h:7hmCJPJQJnHo(tHh:7hmCJPJnHo(tHh:7haoCJPJnHo(tH /?QRyz ɷ|iUiUL|iLۧ|iUiUih:7hYCJ'h:7hYCJKHOJQJ^JaJo($h:7hYCJKHOJQJ^JaJh:7hYCJPJnHo(tH#h:7hYCJPJQJnHo(tHh:7hmCJh:7hmCJPJnHo(tH#h:7h`)CJPJQJnHo(tH#h:7hdCJPJQJnHo(tH#h:7hmCJPJQJnHo(tH#h:7hCJPJQJnHo(tH!/@QxrffXX$$1$Ifa$gd $$Ifa$gd$Ifkd$$If4rLt%ud&4 ahf4QRz{uii[[$$1$Ifa$gd $$Ifa$gd$Ifkd:$$IfrLt%ud&4 ah{u=u1 $$Ifa$gd7kdx$$IfL%d&d&4 ah$Ifkd$$IfrLt%ud&4 ah2AP]ja[$Ifkd$$IfrLt%ud&4 ah$$1$Ifa$gd $$Ifa$gd 123?BFGNPjkqrstuvwz{뭦y`1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*OJQJnHphtH3h:7hYCJKHOJPJQJ^JaJnHo(tH h:7hY$h:7hYCJKHOJQJ^JaJh:7hYCJPJnHo(tH#h:7hYCJPJQJnHo(tHh:7hYCJ'h:7hYCJKHOJQJ^JaJo(jkrtvxz{uii[[$$1$Ifa$gd $$Ifa$gd$Ifkdt$$IfrLt%ud&4 ahz{{ugggg$$1$Ifa$gd$Ifkd$$IfrLt%ud&4 ah45FG8 9 {WUUPPPUgd{kA#9TPL HD@<%^kd$$IfrLt%ud&4 ah345BJOmvz ,/;CӽӧrbrLL+h:7h~`dCJOJPJQJaJnHo(tHh:7hYCJOJQJaJo(h:7hYCJOJQJaJ+h:7hq#jCJOJPJQJaJnHo(tHh:7h{kACJOJQJaJo(+h:7h{kACJOJPJQJaJnHo(tH+h:7hmCJOJPJQJaJnHo(tH+h:7ha.CJOJPJQJaJnHo(tH+h:7hu6CJOJPJQJaJnHo(tHCDJO, 6 8 9 H V d ӮӟÏp]B]4h:7hdG;B*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJphh:7hmCJOJQJaJh:7h^"CJOJQJaJo(h:7hYCJOJQJaJo(h:7hYCJOJQJaJ(h:7h{kACJOJPJQJaJnHtHh:7h{kACJOJQJaJo(+h:7h{kACJOJPJQJaJnHo(tH+h:7hq#jCJOJPJQJaJnHo(tH9 G H """"##2$3$_%`%n&o&''o)p)^gdB#*TPL HD@<^gd-/^gd-/$^`a$gdEN2^^gdi >!G!!!!!ʯhM2hhʜ4h:7h=CB*CJOJPJQJaJnHo(phtH4h:7h ]B*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH4h:7h8FB*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph4h:7h0<B*CJOJPJQJaJnHo(phtH4h:7hq#jB*CJOJPJQJaJnHo(phtH4h:7hdB*CJOJPJQJaJnHo(phtH!!!!!!!""""/"0"J"K"""""""#ҽҏ|fWD%h:7hmB*CJOJQJaJphh:7hmCJOJQJaJ+h:7hmCJOJPJQJaJnHo(tH$h:7hiB*PJnHo(phtH4h:7hiB*CJOJPJQJaJnHo(phtH%h:7hiB*CJOJQJaJph(h:7hiB*CJOJQJaJo(ph1h:7hiB*CJOJPJQJaJnHphtH(h:7h?.B*CJOJQJaJo(ph#######$$$3$a$b$c$d$h$y$nS>(h:7h-/B*CJOJQJaJo(ph4h:7h7nB*CJOJPJQJaJnHo(phtH4h:7h-/B*CJOJPJQJaJnHo(phtH%h:7h-/B*CJOJQJaJph+h:7hEN2CJOJPJQJaJnHo(tHh:7hEN2CJOJQJaJh:7hmCJOJQJaJ+h:7ho*CJOJPJQJaJnHo(tH1h:7hmB*CJOJPJQJaJnHphtHy$z${$~$$$$$$$$$$$$$$$$$$$$$$$$$$$%%L%N%X%巢巢墷t4h:7h-/B*CJOJPJQJaJnHo(phtH%h:7hB#B*CJOJQJaJph(h:7h-/B*CJOJQJaJo(ph%h:7h-/B*CJOJQJaJph4h:7h@B*CJOJPJQJaJnHo(phtH4h:7h8hB*CJOJPJQJaJnHo(phtH"X%]%_%d%%%%%%%%%%%%%%%%%%%%%%%%%& & &&ҷҷlQlQll҇lQlQl҇lQl4h:7h@B*CJOJPJQJaJnHo(phtH4h:7h(EB*CJOJPJQJaJnHo(phtH(h:7h-/B*CJOJQJaJo(ph4h:7h7nB*CJOJPJQJaJnHo(phtH4h:7h-/B*CJOJPJQJaJnHo(phtH%h:7h-/B*CJOJQJaJph4h:7h?jB*CJOJPJQJaJnHo(phtH&&&0&4&6&W&g&l&m&o&&ʷʜlQ64h:7h-/B*CJOJPJQJaJnHo(phtH4h:7h*B*CJOJPJQJaJnHo(phtH4h:7hB*CJOJPJQJaJnHo(phtH(h:7h*B*CJOJQJaJo(ph4h:7h`B*CJOJPJQJaJnHo(phtH%h:7h-/B*CJOJQJaJph4h:7h(EB*CJOJPJQJaJnHo(phtH4h:7h@B*CJOJPJQJaJnHo(phtH &&&&&&&&&&&&&&&&&&&&''' ' ''''''9'J'K'ӸӈmRmRmRmmRmRmӈmӈm4h:7h@B*CJOJPJQJaJnHo(phtH4h:7hB*CJOJPJQJaJnHo(phtH(h:7h-/B*CJOJQJaJo(ph4h:7h[9B*CJOJPJQJaJnHo(phtH4h:7h-/B*CJOJPJQJaJnHo(phtH%h:7h-/B*CJOJQJaJph1h:7h-/B*CJOJPJQJaJnHphtH K'L'O'P'S'T'W'v'z'{'}'''''''ʷnS@%h:7hB#B*CJOJQJaJph4h:7h*B*CJOJPJQJaJnHo(phtH(h:7h*B*CJOJQJaJo(ph4h:7h-/B*CJOJPJQJaJnHo(phtH1h:7h-/B*CJOJPJQJaJnHphtH%h:7h-/B*CJOJQJaJph4h:7hB*CJOJPJQJaJnHo(phtH4h:7h@B*CJOJPJQJaJnHo(phtH''( (0(1(O(Z(](c(r(((((%)&)?)L)N)\)d)g)h)m)o)p)y)~)))))))))))* *!*ҹҤҹ幤Ҥҹvvvivivivih:7h'PJnHtHh:7h'PJnHo(tH h:7h'1h:7hmB*CJOJPJQJaJnHphtH(h:7hB#B*CJOJQJaJo(ph1h:7hB#B*CJOJPJQJaJnHphtH%h:7hB#B*CJOJQJaJph4h:7hB#B*CJOJPJQJaJnHo(phtH)!*,*:*e*s*x*|*********.+/+9+:+C+K+U+\+++++++,,2-3-C-E-v-y-{-|-}--꺧q4h:7h[9B*CJOJPJQJaJnHo(phtH4h:7h#)5B*CJOJPJQJaJnHo(phtH%h:7h*B*CJOJQJaJph4h:7h*B*CJOJPJQJaJnHo(phtHh:7h'PJnHtHh:7h'o( h:7h'h:7h'PJnHo(tH(p)2-3-----v/w///$1%122k3l3445526366^gd ^ ^`gd-}^gd*$7$8$G$H$a$gd'----------------ееlSD/(h:7hmCJOJPJQJaJnHtHh:7hmCJOJQJaJ1h:7h*B*CJOJPJQJaJnHphtH4h:7hgB*CJOJPJQJaJnHo(phtH%h:7h#)5B*CJOJQJaJph4h:7h#)5B*CJOJPJQJaJnHo(phtH4h:7h*B*CJOJPJQJaJnHo(phtH(h:7h*B*CJOJQJaJo(ph4h:7h=CB*CJOJPJQJaJnHo(phtH--- ...F.G.M.S.X...//4/S/Z/`/f////Ūv[[@@[[v4h:7hT%B*CJOJPJQJaJnHo(phtH4h:7h B*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH4h:7h[9B*CJOJPJQJaJnHo(phtH4h:7h^@B*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph+h:7hmCJOJPJQJaJnHo(tH"h:7hm5CJOJQJ\aJ///0"0#0$0a0b0c0f0g0j0k0n0o0ҿҤnSnSnSn84h:7hmB*CJOJPJQJaJnHo(phtH4h:7h'B*CJOJPJQJaJnHo(phtH4h:7hApB*CJOJPJQJaJnHo(phtH4h:7hFWB*CJOJPJQJaJnHo(phtH4h:7h^@B*CJOJPJQJaJnHo(phtH%h:7h-/B*CJOJQJaJph%h:7hmB*CJOJQJaJph4h:7h'B*CJOJPJQJaJnHo(phtHo0p0000000000001111111 1#1ӸӂgLgLggLgLg4h:7h'B*CJOJPJQJaJnHo(phtH4h:7hApB*CJOJPJQJaJnHo(phtH4h:7h(B*CJOJPJQJaJnHo(phtH4h:7hFWB*CJOJPJQJaJnHo(phtH4h:7h^@B*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph1h:7hmB*CJOJPJQJaJnHphtH#1$1%1:1;1=1G111111ʯy^C(C(4h:7hpHB*CJOJPJQJaJnHo(phtH4h:7h:R@B*CJOJPJQJaJnHo(phtH4h:7h-%B*CJOJPJQJaJnHo(phtH4h:7h+B*CJOJPJQJaJnHo(phtH4h:7hFWB*CJOJPJQJaJnHo(phtH4h:7h0B*CJOJPJQJaJnHo(phtH4h:7hyBB*CJOJPJQJaJnHo(phtH4h:7hmB*CJOJPJQJaJnHo(phtH 1111111111222#222寔y^C(C4h:7h`B*CJOJPJQJaJnHo(phtH4h:7hla4B*CJOJPJQJaJnHo(phtH4h:7h}uPB*CJOJPJQJaJnHo(phtH4h:7hQs_B*CJOJPJQJaJnHo(phtH4h:7hbhUB*CJOJPJQJaJnHo(phtH4h:7hpHB*CJOJPJQJaJnHo(phtH4h:7hYB*CJOJPJQJaJnHo(phtH4h:7h'B*CJOJPJQJaJnHo(phtH224292<2?2I2X2^2q2r22222寔{`E*4h:7hyBB*CJOJPJQJaJnHo(phtH4h:7hcKB*CJOJPJQJaJnHo(phtH4h:7h}uPB*CJOJPJQJaJnHo(phtH1h:7h]LXB*CJOJPJQJaJnHphtH4h:7hYB*CJOJPJQJaJnHo(phtH4h:7h]LXB*CJOJPJQJaJnHo(phtH4h:7hla4B*CJOJPJQJaJnHo(phtH4h:7hCOB*CJOJPJQJaJnHo(phtH2L3i3j3k3l3s3u33333333츝oTATAT%h:7h~q]B*CJOJQJaJph4h:7h~q]B*CJOJPJQJaJnHo(phtH4h:7hh,?B*CJOJPJQJaJnHo(phtH%h:7he_4B*CJOJQJaJph4h:7h>_B*CJOJPJQJaJnHo(phtH4h:7hmB*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*CJOJQJaJph3-444D4E4F4L4s4x4z44444444444ʷʷʷʷʜttY>4h:7hmB*CJOJPJQJaJnHo(phtH4h:7h>_B*CJOJPJQJaJnHo(phtH%h:7h;B*CJOJQJaJph(h:7h;B*CJOJQJaJo(ph4h:7h;B*CJOJPJQJaJnHo(phtH%h:7he_4B*CJOJQJaJph4h:7hB*CJOJPJQJaJnHo(phtH4h:7h@B*CJOJPJQJaJnHo(phtH44555_5`5q55555555555̹jU:4h:7hq=B*CJOJPJQJaJnHo(phtH(h:7hmB*CJOJQJaJo(ph1h:7hmB*CJOJPJQJaJnHphtH4h:7hC!B*CJOJPJQJaJnHo(phtH4h:7h%ynB*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph1h:7h B*CJOJPJQJaJnHphtH4h:7h B*CJOJPJQJaJnHo(phtH556666%6062636^6c66666667ҷҁfҁK8K8K%h:7hL9!B*CJOJQJaJph4h:7hL9!B*CJOJPJQJaJnHo(phtH4h:7h;FB*CJOJPJQJaJnHo(phtH4h:7hB*CJOJPJQJaJnHo(phtH4h:7hC!B*CJOJPJQJaJnHo(phtH4h:7h%ynB*CJOJPJQJaJnHo(phtH%h:7hmB*CJOJQJaJph4h:7hafxf}fff$g%gzg{ghhhh]i_iiiiijjjjjkkmkkklll.lmmv[4h:7h]P&B*CJOJPJQJaJnHo(phtH/h:7hR5B*CJPJaJnHo(phtH h:7hR5B*CJaJph4h:7hRB*CJOJPJQJaJnHo(phtH8h:7hRB*CJKHOJPJQJaJnHo(phtH(h:7hRB*CJOJQJaJo(ph%h:7hRB*CJOJQJaJph!hh^i_iiijjlkmkmmmmm(m)m@mAmmmnnnn^ ^` +gdy^gd$^gdRmmmm(m)mAmEmMmnnnn&n4n:n}n~nnnnnڬڙgN;gN;%h:7h8FB*CJOJQJaJph1h:7hC!B*CJOJPJQJaJnHphtH1h:7hdB*CJOJPJQJaJnHphtH1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*CJOJQJaJph.h:7hm5CJOJPJQJ\aJnHtH+h:7hyCJOJPJQJaJnHo(tHh:7hmCJOJQJaJ+h:7h. CJOJPJQJaJnHo(tHnnnnno o o o+o2o3oFoӻӑv[@'@1h:7hvbB*CJOJPJQJaJnHphtH4h:7hvbB*CJOJPJQJaJnHo(phtH4h:7hx8B*CJOJPJQJaJnHo(phtH4h:7hC!B*CJOJPJQJaJnHo(phtH4h:7hdB*CJOJPJQJaJnHo(phtHh:7hmCJOJQJaJ.h:7hm5CJOJPJQJ\aJnHtH%h:7hmB*CJOJQJaJph1h:7h8FB*CJOJPJQJaJnHphtH FoIopoqo{o}ooooooooo5pҹҞҹsdK9"h:7hm5CJOJQJ\aJ1h:7hm5CJOJPJQJ\aJnHo(tHh:7hmCJOJQJaJ.h:7hm5CJOJPJQJ\aJnHtH%h:7h%B*CJOJQJaJph4h:7h%B*CJOJPJQJaJnHo(phtH1h:7hmB*CJOJPJQJaJnHphtH%h:7hmB*CJOJQJaJph4h:7hD B*CJOJPJQJaJnHo(phtHnooooFpGpHpMpRp[papip$V$If^V`a$$V$If^V`a$gd!I$T^T`a$gdC$ T^`a$gde1T^T` ^`^ 5p7pEpFpGpHpLpMpOpPpQpRpԻtfQ<')h:7hm5CJPJ\aJnHo(tH)h:7hW=5CJPJ\aJnHo(tH)h:7hd5CJPJ\aJnHo(tHh:7hm5CJ\aJh:7hmPJnHo(tHh:7h!IPJnHo(tH(h:7hmCJOJPJQJaJnHtH+h:7hCJOJPJQJaJnHo(tH1h:7hm5CJOJPJQJ\aJnHo(tH"h:7hm5CJOJQJ\aJ1h:7hL/5CJOJPJQJ\aJnHo(tH RpSpZp[p]p^p_p`paphpipjp~ppp°|k`J,J:h:7hI05B*CJOJPJQJ\aJnHo(phtH+h:7hm5B*CJOJQJ\aJphh:7hmnHtH h:7hmCJPJaJnHtH&h:7hm6CJPJ]aJnHtHh:7hm6CJ]aJ#h:7hW=CJPJaJnHo(tH#h:7hW8CJPJaJnHo(tHh:7hmCJaJh:7hm5nHtH h:7hm56CJ\]aJ)h:7hm56CJPJ]aJnHtHipjppppzee$V$If^V`a$&6TPL HD@<{$If^]kdQ$$IflF! $  !    4 la pppppppppppppqqq$q%qBqIqPqQqRqSq{qqqqqqqr粥Բr^'h:7hA)CJKHPJ\aJnHtHh:7hA)CJKHaJo('h:7hKCJKHPJaJnHo(tHh:7hA)aJo( h:7hA)h:7hA)CJKHaJh:7hA)5CJKHaJ'h:7hA)CJKHPJaJnHo(tH$h:7hA)CJKHPJaJnHtHh:7hA)aJ h:7hmh:7hm5ppppprr$$1$Ifa$gd;[ v${$IfVDFWDj^`a$gdM]kd$$IflF! $  !    4 la ppqq$qrr$$1$Ifa$gd;[ v${$IfVDFWDj^`a$gdM]kdE$$IflF! $  !    4 la $q%qBqIqPqzz$$1$Ifa$gd;[Vi$IfVD$WD2^V`igdM]kd$$IflF! $  !    4 la PqQq{qqqzz$$1$Ifa$gd;[%$IfVDOWDU^%`gdK]kdE$$IflF! $  !    4 la qqqqrzz$$1$Ifa$gd;[.$IfVDPWD^`.gdM]kd$$IflF! $  !    4 la rrrjrrrrrrrrrss s$s,s4s6s@sBspsrstsvsxszs|sssɻɻsdVKh:7h. CJaJh:7h. hCJaJh:7h. h5CJaJ*h:7h. 5CJKHPJaJnHo(tHh:7h. 5CJKHaJo(h:7h. 5CJKHaJh:7h. CJKHaJ h:7h. h:7h. CJKH\aJh:7h. 5CJKH\aJ!h:7h. 5CJKH\aJo( h:7hA)h:7hA)CJKH\aJrrjrrr$$1$Ifa$gd;[{$Ifgd4e]kdE $$IflF! $  !    4 la rrrrrzz$$1$Ifa$gd;[Vi$IfVD$WD2^V`igd4e]kd $$IflF! $  !    4 la rrrsszz$$1$Ifa$gd;[Vi$IfVD$WD2^V`igd4e]kdE!$$IflF! $  !    4 la s s$s,s4s$$1$Ifa$gd;[{$Ifgd4e]kd!$$IflF! $  !    4 la 4s6stsvsxsww$d$If]a$gd;[$d$If]^a$gd4e]kdE"$$IflF! $  !    4 la xszsssszk$d$Ifa$gd;[$$1$Ifa$gd;[.$IfVDPWD^`.gd4e]kd"$$IflF! $  !    4 la sssssssttt t ttttt*t+t,t-tGtHtNtRtSt|ll\M?h:7h. CJKHaJo(h:7h. CJOJQJaJh:7h. 5CJOJQJaJh:7h. 5CJKH\aJ.h:7h. 5B*CJOJQJ\aJo(ph(h:7h. CJOJPJQJaJnHtHh:7h. CJaJh:7h. CJaJo(h:7h. CJKHaJ h:7h. h:7h. hOJQJaJh:7h. OJQJaJh:7h. 5CJKHaJsstt tzk$d$Ifa$gd;[$$1$Ifa$gd;[.$IfVDPWD^`.gd4e]kdE#$$IflF! $  !    4 la  t ttttwiZ$d$Ifa$gd;[$$1$Ifa$gd;[)6TPL HD@<{$If^gd4e]kd#$$IflF! $  !    4 la tt*t+t,t}}$d$Ifa$gd;[V$If^V`gd4e]kdE$$$IflF! $  !    4 la ,t-tHtNtRtzz$$1$Ifa$gd;[Vi$IfVD$WD2^V`igd4e]kd$$$IflF! $  !    4 la RtStyt}tt||$$1$Ifa$gd;[Vi$IfVD$WD2^V`igd4e_kdE%$$IflF! $  !    4 la StTtntstxtyt}ttttttttttttttt彯ycM8(h:7h. CJOJPJQJaJnHtH+h:7h. 5CJOJPJQJaJnHtH*h:7h. 5CJKHPJ\aJnHtHh:7h. CJKH\aJh:7h. 5CJKH\aJ!h:7h. 5CJKH\aJo( h:7h. h:7h. 5CJKHaJ'h:7h. CJKHPJaJnHo(tH'h:7h[CJKHPJaJnHo(tHh:7h. CJKHaJo(h:7h. CJKHaJttttt$$1$Ifa$gd;[ $Ifgd4e]kd%$$IflF! $  !    4 la ttttt}}$d$Ifa$gd;[V$If^V`gd4e]kdI&$$IflF! $  !    4 la tttttzz$$1$Ifa$gd;[$IfVDIWDj^`gd4e]kd&$$IflF! $  !    4 la tttt u%u>u?uvvv vvvv&v*v:v0h:7hX5CJKHaJh:7h<_2CJKHh:7h<_2CJKH\aJo('h:7heCJKHPJaJnHo(tH*h:7h<_2CJKHPJ\aJnHo(tH'h:7hW=CJKHPJaJnHo(tH'h:7hXCJKHPJaJnHo(tH'h:7h<_2CJKHOJQJ\^JaJ&h:7h<_25CJKHOJQJaJo(+h:7hmCJOJPJQJaJnHo(tH+h:7h,CJOJPJQJaJnHo(tHՅօׅ |nnnn$$1$Ifa$gdT $1$IfgdTwkdI)$$Ifl4TF #& &J& #6    44 lagp ĮڍyfR?y4h:7h<_2CJKH$h:7hXCJKHPJaJnHtH'h:7hJ0CJKHPJaJnHo(tH$h:7hJ0CJKHPJaJnHtH'h:7h<_2CJKHPJ\aJnHtHh:7hXCJKHaJ'h:7hX5CJKHPJaJnHtH*h:7hJ05CJKHPJaJnHo(tH*h:7ha5CJKHPJaJnHo(tH*h:7h<_25CJKHPJ\aJnHtHh:7hX5CJKH\aJ $5FWWL@@2$$1$Ifa$gd! $$Ifa$gd! $1$IfgdTkd<*$$Ifl4Tr +# &&&&#644 lagp2 $Fhiʆˆ'(Ceهڇ-.OmÈ߈23bfjkɉʉ'ABVtɊ89BCr߬h:7h!CJKH\aJh:7h!CJKHaJh:7h!CJKHh:7h!CJKHaJh:7h!5CJKHaJ$h:7h!CJKHPJaJnHtHDWhiK6* $$Ifa$gd!L$1$IfWD^L`gdTkdE+$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!ʆˆ?4 $1$IfgdTkdL,$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!'(?kda-$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!(CTev$$1$Ifa$gd! $$Ifa$gd! $1$IfgdṪYNBB4$$1$Ifa$gd! $$Ifa$gd! $1$IfgdTkdv.$$IflTr +#& ''''#644 lagp2̇هڇK@44 $$Ifa$gd! $1$IfgdTkd/$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!-.FOK@/ $1$IfWD` gdT $1$IfgdTkd0$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!O^m|?kd1$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!Èш߈$$1$Ifa$gd! $$Ifa$gd! $1$IfWDp^ `gdT߈ %YNBB4$$1$Ifa$gd! $$Ifa$gd! $1$IfgdTkd2$$IflTr +#& ''''#644 lagp2%23bdK6* $$Ifa$gd! $1$IfWDp^ `gdTkd3$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!dfhjkK@ $1$IfgdTkd4$$IflXr +#& ''''#644 lagp2$$1$Ifa$gd!?kd 6$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!'4A$$1$Ifa$gd! $$Ifa$gd! $1$IfWDp^ `gdTABVftYNBB4$$1$Ifa$gd! $$Ifa$gd! $1$IfgdTkd7$$Iflr +# ''''#644 lagp2K6* $$Ifa$gd!D$1$IfWD^`DgdTkd38$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!Ɋ׊?kdH9$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!+8$$1$Ifa$gd! $$Ifa$gd! $1$IfWDp^ `gdT89rYD88 $$Ifa$gd! $1$IfWD^` gdTkd]:$$IflXr +#& ''''#644 lagp2ϋK@4 $$Ifa$gd! $1$IfgdTkdr;$$IflXr +#& ''''#644 lagp2$$1$Ifa$gd!݋0LMf܌݌.=>TVXYwލ9UqrÎĎˎێպզզ'h:7hZmCJKHPJaJnHo(tH'h:7h!CJKHPJaJnHo(tHh:7h!CJKHaJh:7h!5CJKHaJ$h:7h!CJKHPJaJnHtHh:7h!CJKHh:7h!CJKHaJ4ϋ݋?4 $1$IfgdTkd<$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!#0>LM?kd=$$IflXr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!Mft$$1$Ifa$gd! $$Ifa$gd! $1$IfgdTYD8*$$1$Ifa$gd! $$Ifa$gd!$1$IfWD ^`gdTkd>$$IflXr +#& ''''#644 lagp2,K@4 $$Ifa$gd! $1$IfgdTkd?$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!,.;=>TUVK@ $1$IfgdTkd@$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!VWXYwK6 $1$IfWD^` gdTkdA$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd!w|?kdC$$IflTr +#& ''''#644 lagp2$$1$Ifa$gd! $$Ifa$gd!$$1$Ifa$gd! $$Ifa$gd! $1$IfWD^` gdTލP;// $$Ifa$gd! $1$IfWD^` gdTkdD$$IflTr +#& ''''  #644 lagp2 9B- $1$IfWD^` gdTkdAE$$IflTr +#& ''''  #644 lagp2$$1$Ifa$gd!9GUcqr6kdhF$$IflXr +#& ''''  #644 lagp2$$1$Ifa$gd! $$Ifa$gd!rˎَێ$$1$Ifa$gd! $$Ifa$gd! $1$IfWD^` gdT.=JKLMNPQ[̹̫t^F3%h:7hm5CJOJQJ\]aJ/h:7hFo56OJPJQJ\]nHo(tH+h:7hFoCJOJPJQJaJnHo(tH+h:7h5CJOJPJQJaJnHo(tH'h:7hZmCJKHPJaJnHo(tHh:7h!CJKHaJh:7h!5CJKHaJ$h:7h!CJKHPJaJnHtH'h:7h!CJKHPJaJnHo(tHh:7h!CJKH'h:7h!CJKHPJaJnHo(tH.;P;/ $$Ifa$gd! $1$IfWD^` gdTkdG$$IflXr +#& ''''  #644 lagp2;=JLMNOB88 T^kd~H$$IflXr +#& ''''  #644 lagp2$$1$Ifa$gd!OPQbc:;YZzrdgdIA^(<TPL HD@<e C^gdrO%<TPL HD@<e C^"7TPL HD@<e C^ $da$gdX T^ [\_`abcdfr{ÏƏϏϴ衑xnxnd[QHHh:7hQ#CJh:7hQ#CJo(h:7hICJh:7hICJo(h:7hXCJo(h:7hXCJh:7hQ#CJPJnHo(tHh:7hXCJPJnHo(tH%h:7hm5CJOJQJ\]aJ4h:7h)G5CJOJPJQJ\]aJnHo(tH1h:7hm5CJOJPJQJ\]aJnHtH-h:7hm5CJOJQJ\]aJnHtH$9:;HOXϷz\I/'h:7hrO5B*CJOJQJo(ph3h:7hrO5B*CJOJPJQJnHo(phtH$h:7hrO5B*CJOJQJph:h:7hRv5B*CJOJPJQJ\aJnHo(phtH:h:7hm5B*CJOJPJQJ\aJnHo(phtH=h:7hqk5;B*CJOJPJQJ\aJnHo(phtH.h:7hm5;B*CJOJQJ\aJph+h:7hm5B*CJOJQJ\aJph4h:7hmB*CJOJPJQJaJnHo(phtH XYZ[efjkƶƔq_MAMMh:7hIA^CJaJo(#h:7hIA^CJPJaJnHo(tH#h:7h]RCJPJaJnHo(tH#h:7hIA^5CJPJaJnHtH h:7hIA^CJPJaJnHtH *h:7hIA^CJaJ*h:7hIA^>*CJOJQJaJnH o(tH h:7hIA^>*CJOJQJaJh:7hIA^CJaJ&h:7hIA^5CJPJaJnHo(tH3h:7hrO5B*CJOJPJQJnHo(phtHZ[afklmnv~fWWW$d$Ifa$gd'gpkdI$$Ifl\r#+vvv$4 a%$!d$Ifa$gd'gZd$If^Z`gd'g ~zk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdJ$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdJ$$Ifl\r#+vvv$4 aĐŐȐɐʐ͐ϐАݐސ"#)017@AJKQRSTfwijijijijֳijֳijֳֳijijijijh:7hIA^5CJaJ h:7hIA^CJPJaJnHtH#h:7hIA^CJPJaJnHo(tHh:7hIA^CJaJo(h:7hIA^CJaJ# *h:7hIA^CJPJaJnHtHBʐzkSS$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdK$$Ifl\r#+vvv$4 aʐː̐͐ΐϐzk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdK$$Ifl\r#+vvv$4 aϐАݐސzk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdL$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdL$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd M$$Ifl\r#+vvv$4 a!")0zk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdM$$Ifl\r#+vvv$4 a01@AJSzkXX$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdN$$Ifl\r#+vvv$4 aSTvwzk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdN$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdO$$Ifl\r#+vvv$4 aȑʑӑܑzk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdO$$Ifl\r#+vvv$4 aȑɑʑӑԑՑ֑בڑۑݑ "#01=EFGOPVWX\ѴѴŴŴtŴѴ&h:7hIA^hCJPJaJnHtHh:7hIA^5CJaJ# *h:7hIA^CJPJaJnHtH *h:7hIA^CJaJo( h:7hIA^CJPJaJnHtHh:7hIA^CJaJo(#h:7hIA^CJPJaJnHo(tH#h:7h]RCJPJaJnHo(tHh:7hIA^CJaJ+ܑݑ zkSS$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdO$$Ifl\r#+vvv$4 a zk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd{P$$Ifl\r#+vvv$4 a"#*1zk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdP$$Ifl\r#+vvv$4 a12EGOXzkSS$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdwQ$$Ifl\r#+vvv$4 aXYZ[\]zk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdQ$$Ifl\r#+vvv$4 a\]^rstȒՒ֒ג4ABCTUVWʸ܉講講謸܉ʸk:h:7hrO5B*CJOJPJQJ\aJnHo(phtH#h:7hIA^5CJPJaJnHtH h:7hIA^CJPJaJnHtHh:7hIA^CJaJo(#h:7hIA^CJPJaJnHo(tH#h:7h]RCJPJaJnHo(tHh:7hIA^5CJaJh:7hIA^CJaJ *h:7hIA^CJaJ']^rt{zkSS$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdsR$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdR$$Ifl\r#+vvv$4 azkXX$nd$If]na$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdoS$$Ifl\r#+vvv$4 aǒȒϒ֒|m^^$d$Ifa$gd'g$d$Ifa$gd'gd$IfVDG^gdIA^pkdS$$Ifl\r#+vvv$4 a֒ג|mUU$d$&dIfPa$gd'g$d$Ifa$gd'gd$IfVDG^gdIA^pkdkT$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdT$$Ifl\r#+vvv$4 azkSS$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdgU$$Ifl\r#+vvv$4 azk\\$d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdU$$Ifl\r#+vvv$4 aACLUzkSS#$d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdcV$$Ifl\r#+vvv$4 aUVWXYZ[\]^_`iaaaaaaaaadgdrO%<TPL HD@<e C^pkdV$$Ifl\r#+vvv$4 a `abcdefg%$!d$Ifa$gd'g$d$Ifa$gd'g d$Ifgd'gdgdGdgdrOWgtГՓ֓ߓsssgU?+h:7hGCJOJPJQJaJnHo(tH#h:7hG5CJPJaJnHtHh:7hG5CJaJh:7hGCJOJQJaJh:7hG>*CJaJo(*h:7hG>*CJOJQJaJnH o(tH h:7hG>*CJOJQJaJh:7hGCJaJ h:7hGCJPJaJnHtH"h:7hrO5CJPJnHo(tHh:7hrO5CJ"h:7hd 5CJPJnHo(tHs__%$!d$Ifa$gd'g$d$Ifa$gd'g d$Ifgd'gpkd_W$$If\r+p##4 axiUU%$!d$Ifa$gd'g$d$Ifa$gd'g$d$IfWD^`$gd'gpkdW$$If\r+p##4 axiUU%$!d$Ifa$gd'g$d$Ifa$gd'g$d$IfWD^`$gd'gpkdX$$If\r+p##4 aՓ֓ݓzkOO%$!d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdY$$If\r+p##4 aߓ?WX\abcntxyzӾr龳rbrbrrr龳rh:7hGCJaJnH o(tH h:7hGCJPJaJnHtHh:7hGCJaJo(h:7hGCJOJQJaJ(h:7hGCJOJPJQJaJnHtHh:7hGCJaJ(h:7hGCJOJPJQJaJnHtH+h:7hGCJOJPJQJaJnHo(tH+h:7hGCJOJPJQJaJnHo(tH$zkWW%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdY$$If\r+p##4 azkWW%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkdIZ$$If\r+p##4 aWX\bzkWW%$!d$Ifa$gd'g$d$Ifa$gd'gd$If^`gd'gpkdZ$$If\r+p##4 abcxiUU%$!d$Ifa$gd'g$d$Ifa$gd'g4d$IfWDt^4`gd'gpkd}[$$If\r+p##4 axiiMM%$!d$&dIfPa$gd'g$d$Ifa$gd'g4d$IfWDt^4`gd'gpkd\$$If\r+p##4 a !()2;?LMT\кo`TFTFT4T#h:7hG5CJPJaJnHtHh:7hG5CJaJo(h:7hG5CJaJh:7hGCJOJQJaJ(h:7hGCJOJPJQJaJnHtHh:7hGCJaJ(h:7hGCJOJPJQJaJnHtH+h:7hGCJOJPJQJaJnHo(tH+h:7hGCJOJPJQJaJnHo(tHh:7hGCJaJo( h:7hGCJPJaJnHtH#h:7hGCJPJaJnHo(tH zkWW%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd\$$If\r+p##4 aLMT]xiMM%$!d$&dIfPa$gd'g$d$Ifa$gd'g:d$IfWD^`:gd'gpkdK]$$If\r+p##4 a\]`abc͕̕"/01˼ఞrbrr˼h:7hG5CJOJQJaJ+h:7hGCJOJPJQJaJnHo(tH+h:7hGCJOJPJQJaJnHo(tH#h:7hG5CJPJaJnHtHh:7hG5CJaJh:7hGCJOJQJaJ(h:7hGCJOJPJQJaJnHtHh:7hGCJaJ(h:7hGCJOJPJQJaJnHtH"]^_`abzkWW%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd]$$If\r+p##4 abczkOO%$!d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd^$$If\r+p##4 azkWW%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd_$$If\r+p##4 a͕̕}E3nd$IfWD2`ngd'g7kdG`$$Ifrp###4 a%!d$Ifgd'gpkd_$$If\r+p##4 akYnd$IfWD2`ngd'gpkd`$$If\r+p##4 a%$!d$Ifa$gd'g$d$Ifa$gd'gr^O;%$!d$Ifa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkd3a$$If\r+p##4 a%$!d$&dIfPa$gd'g !")0zfW;;%$!d$&dIfPa$gd'g$d$Ifa$gd'gZd$If^Z`gd'gpkda$$If\r+p##4 a%$!d$Ifa$gd'g0123456789:^^^^^^^^(<TPL HD@<e C^gdrOdgdDpkdgb$$If\r+p##4 a 12KXxyz{нЕteNtNteC6h:7hd 0JCJaJh:7hd CJaJ-h:7hd 0J5>*CJPJaJnHo(tHh:7hd 5>*CJaJo(!h:7hd 0J5>*CJaJo(h:7hd 0J5>*CJaJh:7hd 5CJ\aJ3h:7hrO5B*CJOJPJQJnHo(phtH$h:7hrO5B*CJOJQJph3h:7hd 5B*CJOJPJQJnHo(phtH)h:7hG5CJPJ\aJnHo(tH:;<=>?@ABCDEFGHIJKxy(<TPL HD@<e C^gdd (<TPL HD@<e C^gdrOyzJkdc$$Ifl\ g"04 la$d$$Ifa$gd]> d$$Ifgd]>̖֖ז $567`apqrsܾɾzlzlYzl$h:7hd h6*0J5CJaJo(h:7hd CJ\aJo(h:7hd CJ\aJh:7hd CJaJo( h:7hd CJPJaJnHtHh:7hd 0JCJaJh:7hd 5CJ\aJh:7hd CJaJ$h:7hd 0JCJPJaJnHtH'h:7hd 0J5CJPJaJnHtHh:7hd 0J5CJaJo("VJJJJ d$$Ifgd]>kdc$$Ifl\ g"04 la$d$$Ifa$gd]>eYYJY$d$$Ifa$gd]> d$$Ifgd]>kdd$$Ifl\ g"04 la̖͖Ԗ֖eSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdYe$$Ifl\ g"04 la֖ז eSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kd!f$$Ifl\ g"04 la $%-5eSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdf$$Ifl\ g"04 la56`aiqeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdg$$Ifl\ g"04 laqreN:+$d$$Ifa$gd]>$d$$Ifa$gd]>o 'd$$IfWDd`gd]>o 'kdyh$$Ifl\ g"04 laVD5$d$$Ifa$gd]>d$$IfWDd`gd]>kdAi$$Ifl\ g"04 la$d$$Ifa$gd]>— &()*XYghijlmnȼȼȼ☆pcRc h:7hd CJPJaJnHtHh:7hd 0JCJaJ*h:7hd 0J5CJPJaJnHo(tH#h:7hd CJPJaJnHo(tH&h:7hd CJPJ\aJnHo(tHh:7hd 0J5CJaJo(h:7hd CJaJo(h:7hd CJ\aJo(h:7hd CJ\aJh:7hd CJaJ$h:7hd h6*0J5CJaJo( eS?00$d$$Ifa$gd]>$d$$Ifa$gd]>o 'd$$IfWDd`gd]>kd j$$Ifl\ g"04 laeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdj$$Ifl\ g"04 la &(eSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdk$$Ifl\ g"04 la()XY`eSD,$d$$&dIfPa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdol$$Ifl\ g"04 la`ghijMA2$d$$Ifa$gd]> d$$Ifgd]>kdEm$$Ifl\ g"04 la$d$$&dIfPa$gd]>jklmnoVJ;$d$$Ifa$gd]> d$$Ifgd]>kdn$$Ifl\ g"04 la$d$$Ifa$gd]>noҘԘBCHIOPQ`afgmn™ęřƙǙ鑽鑽#h:7hd CJPJaJnHo(tHh:7hd CJ\aJo(h:7hd CJ\aJ h:7hd CJPJaJnHtHh:7hd 0JCJaJo(h:7hd 0JCJaJh:7hd CJaJo(h:7hd CJaJ9oyMA2$d$$Ifa$gd]> d$$Ifgd]>kdn$$Ifl\ g"04 la$d$$&dIfPa$gd]>VD5$d$$Ifa$gd]>d$$IfWDd`gd]>kdo$$Ifl\ g"04 la$d$$Ifa$gd]>ҘԘܘVD5$d$$Ifa$gd]>d$$IfWDd`gd]>kdp$$Ifl\ g"04 la$d$$Ifa$gd]>eSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdsq$$Ifl\ g"04 laBCIOeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdIr$$Ifl\ g"04 laOP`agmeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kds$$Ifl\ g"04 lamneSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kds$$Ifl\ g"04 laeSD,$d$$&dIfPa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdt$$Ifl\ g"04 la™M;,$d$$Ifa$gd]>d$$IfWDd`gd]>kdu$$Ifl\ g"04 la$d$$&dIfPa$gd]>™ÙęřƙǙVD5$d$$Ifa$gd]>d$$IfWDd`gd]>kdwv$$Ifl\ g"04 la$d$$Ifa$gd]>ǙљۙܙMA2$d$$Ifa$gd]> d$$Ifgd]>kd[w$$Ifl\ g"04 la$d$$&dIfPa$gd]>Ǚڙۙܙݙ !"34ABeklstɚʚ˚֚ךߚɺ׮׮נננ׮׮׮׮׮h:7hd hCJaJo(#h:7hd CJPJaJnHo(tHh:7hd CJ\aJo(h:7hd CJ\aJh:7hd 5CJ\aJo(h:7hd 5CJ\aJh:7hd CJaJ h:7hd CJPJaJnHtHh:7hd CJaJo(2VD5$d$$Ifa$gd]>d$$IfWDd`gd]>kd1x$$Ifl\ g"04 la$d$$Ifa$gd]> !34:AVD5$d$$Ifa$gd]>d$$IfWDd`gd]>kdy$$Ifl\ g"04 la$d$$Ifa$gd]>ABefmseSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdy$$Ifl\ g"04 lasteSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kdz$$Ifl\ g"04 laǚɚeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kd{$$Ifl\ g"04 laɚʚ֚ךۚߚeSD55$d$$Ifa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kd_|$$Ifl\ g"04 laߚeSD,$d$$&dIfPa$gd]>$d$$Ifa$gd]>d$$IfWDd`gd]>kd5}$$Ifl\ g"04 laM;,$d$$Ifa$gd]>d$$IfWDd`gd]>kd ~$$Ifl\ g"04 la$d$$&dIfPa$gd]>VD5$d$$Ifa$gd]>d$$IfWDd`gd]>kd~$$Ifl\ g"04 la$d$$Ifa$gd]>M;d$$IfWDd`gd]>kd$$Ifl\ g"04 la$d$$&dIfPa$gd]>01G; d$$Ifgd]>kd$$Ifl\ g"04 la$d$$Ifa$gd]>$d$$Ifa$gd]>01ABCDFGHmnدؙuiXiJuh:7hEF5>*CJaJ!h:7hEF0J5CJ\aJo(h:7hEFCJaJo(h:7hEF5CJ\aJ+h:7hEFCJOJPJQJaJnHo(tH+h:7h+CJOJPJQJaJnHo(tH h:7hd CJPJaJnHtHh:7hd CJ\aJh:7hd CJaJo(h:7hd CJaJh:7hd 5CJ\aJo(h:7hd 5CJ\aJ19ABCM;d$$IfWDd`gd]>kd$$Ifl\ g"04 la$d$$&dIfPa$gd]>CDEFGmG; d$$Ifgd]>kdU$$Ifl\ g"04 la$d$$Ifa$gd]>$d$$Ifa$gd]>mnx9kd+$$Ifl\ g"04 la$d$$&dIfPa$gd]>$d$$Ifa$gd]>o '$d$$Ifa$gd]>Zd$If^Z`gd]>'$ da$gdE `L===$d$$Ifa$gd]>Zd$If^Z`gd]>kd$$Ifl\4\ "04 lagÛ՛ޛ%+-IN`jklmops˽𪽟ppppppp#h:7hEFCJPJaJnHo(tH h:7hEFCJPJaJnHtHh:7hEFCJaJo(h:7hEFCJaJ$h:7hEF0JCJPJaJnHtHh:7hEF5CJ\aJ'h:7hEF0J5CJPJaJnHtH!h:7hEF0J5CJ\aJo(h:7hEF0J5CJ\aJ,`L=..$d$$Ifa$gd]>$d$$Ifa$gd]>Zd$If^Z`gd]>kd$$Ifl\4\ "04 lagÛěśƛ`L=..$d$$Ifa$gd]>$d$$Ifa$gd]>Zd$If^Z`gd]>kd$$Ifl\4\ "04 lagƛǛ՛֛ޛ`N?00$d$Ifa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>kd$$Ifl\4\ "04 lag`N?00$d$Ifa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>kd$$Ifl\4\ "04 lag%`N?'$d$&dIfPa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>kda$$Ifl\4\ "04 lag%,-./H4%$d$$Ifa$gd]>Zd$If^Z`gd]>kdA$$Ifl\4\ "04 lag$d$&dIfPa$gd]>/012_`Q=.$d$$Ifa$gd]>Zd$If^Z`gd]>kd/$$Ifl\4\ "04 lag$d$Ifa$gd]>`jtuQ=.$d$$Ifa$gd]>Zd$If^Z`gd]>kd$$Ifl\4\ "04 lag$d$Ifa$gd]>H4Zd$If^Z`gd]>kd$$Ifl\4\ "04 lag$d$&dIfPa$gd]>B.Zd$If^Z`gd]>kd$$Ifl\4\ "04 lag$d$Ifa$gd]>$d$$Ifa$gd]>œŜǜ̜ 24<=>?IJSVWZ[\lvwyz|}~ʸ۸ʸ۸ʸʸ۸۸۸۸h:7hEF5CJ\aJo(#h:7hEFCJPJaJnHo(tH h:7hEFCJPJaJnHtHh:7hEFCJaJo(h:7hEF5CJ\aJh:7hEFCJaJ>Ɯǜ9kdٍ$$Ifl\4\ "04 lag$d$&dIfPa$gd]>$d$$Ifa$gd]>ǜȜɜʜ˜̜.kdǎ$$Ifl\4\ "04 lag$d$Ifa$gd]>$d$$Ifa$gd]>Zd$If^Z`gd]>̜.kd$$Ifl\4\ "04 lag$d$Ifa$gd]>$d$$Ifa$gd]>Zd$If^Z`gd]> 0kd$$Ifl\4\ "04 lag$d$Ifa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>34<>$Hd$4$If]a$gd]>$d$Ifa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>>?JKS[`N?00$d$Ifa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>kdu$$Ifl\4\ "04 lag[\lmt`N?'$d$&dIfPa$gd]>$d$$Ifa$gd]>d$IfVDG^gd]>kdU$$Ifl\4\ "04 lagt{|}~H<-$d$$Ifa$gd]> d$$Ifgd]>kd5$$Ifl\4\ "04 lag$d$&dIfPa$gd]>~QE6$d$$Ifa$gd]> d$$Ifgd]>kd#$$Ifl\4\ "04 lag$d$Ifa$gd]>H<-$d$$Ifa$gd]> d$$Ifgd]>kd$$Ifl\4\ "04 lag$d$&dIfPa$gd]>QE6$d$$Ifa$gd]> d$$Ifgd]>kd$$Ifl\4\ "04 lag$d$Ifa$gd]>H88'$ da$gdEkd$$Ifl\4\ "04 lag$d$&dIfPa$gd]>Ýѝϴϖl]G0-h:7hrOB*CJOJQJaJnHphtH+h:7hrOCJOJPJQJaJnHo(tHh:7hrO5CJ\aJo(6h:7hrO5CJKHOJPJQJ\^JaJnHtHh:7hrO5CJ\aJ:h:7hrO5B*CJOJPJQJ\aJnHo(phtH5h:7hEF5CJOJPJQJ\^JaJnHo(tH2h:7hEF5CJOJPJQJ\^JaJnHtH+h:7hEFCJOJPJQJaJnHo(tH  ~r`$RdG$VDb^Ra$gdh d^gdh$;d^`;a$gdh#9TPL HD@<+{^ UVD^Ugdw~gdrOd^`gdrO%<TPL HD@<e C^gdEF  #˲q\PBP7h:7hhCJaJh:7hh5CJaJo(h:7hh5CJaJ)h:7hrO5CJPJ\aJnHo(tHh:7hrO5CJ\aJo(4h:7h[B*CJOJPJQJaJnHo(phtH-h:7hrOB*CJOJQJaJnHphtH0h:7hrOB*CJOJQJaJnHo(phtH4h:7hrOB*CJOJPJQJaJnHo(phtH1h:7hrOB*CJOJPJQJaJnHphtH#(5CSY01NOPQZ[_~0=>Ll晋o h:7hD]hv*5CJaJo(h:7hD]CJaJh:7hh5CJ\aJ#h:7hyVCJPJaJnHo(tH"h:7hhhZCJaJnH tH "h:7hhh,CJaJnH tH h:7hhh:7hhCJaJnH o(tH h:7hhCJaJh:7hhCJaJnH tH +ŠPQaUkdۗ$$Ifl0'#b t9!644 la1$L$7$8$H$IfWD^`La$gd<$$$7$8$H$IfWD^`$a$gd<$dG$VD^a$gdhΡs$L$7$8$H$IfWD^`La$gd<$$$7$8$H$IfWD^`$a$gd<UkdC$$Ifl0'#b t9!644 la1paaaaR$d^a$gdD]$d^a$gdh$d7$8$H$a$gdh$d7$8$H$^a$gdh$d7$8$H$^`a$gdhUkd$$Ifl0'#b t9!644 la1 ߥ!-7Ln¦ŦʦҦקا٧ڧƻƻػƻƻئn`Y h:7hhh:7hhCJH*PJ aJ h:7hhCJPJ aJnH tH h:7hhCJaJnH tH h:7hhCJPJ aJh:7hhCJaJ)h:7hh5CJPJ\aJnHo(tHh:7h!|CJaJ#h:7h!|CJPJaJnHo(tHh:7h!|CJaJo(h:7h!|5CJ\aJo(h:7hD]CJaJo( ٧$d$G$IfWD^`$gd<d$G$IfWD^`gd<$d7$8$H$^a$gdh$d7$8$H$^a$gdhdgdh$d^a$gd!|dgd!|٧ڧ{'Skdw$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd<Skd$$Ifl0#k t9!644 la1ڧ\]^_¨hijk˩̩ͩΩשŶŶŶŶtttŶŶg̛Ŷgh:7hhCJPJ aJh:7hhaJnH tH h:7hhH*aJnH tH h:7hhCJH*aJh:7hhCJH*aJnH tH h:7hhCJaJh:7hhCJaJnH tH h:7hh#h:7hhCJH*PJ aJnH tH h:7hhCJPJ aJnH tH h:7hhCJPJ aJnH tH (^_{Skdۙ$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd<¨jk{'Skd$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd<Skd?$$Ifl0#k t9!644 la1kͩ{Skd$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd<ͩΩש{'Skdϛ$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd<Skdk$$Ifl0#k t9!644 la1!MSkd3$$Ifl0#k t9!644 la1 d$Ifgd<d$G$IfWD^`gd<!KLMNWmnopܪݪުߪ')*@Ostuv«ëīū׫һҫˈҚxh:7hhCJH*aJnH tH "h:7hhh^CJaJnH tH h:7hhCJPJ aJnH tH h:7hhCJH*aJnH tH h:7hhhCJPJ aJ h:7hh#h:7hhCJH*PJ aJnH tH h:7hhCJPJ aJh:7hhCJaJnH tH ,MNWop3Skd$$Ifl0#k t9!644 la1 d$Ifgd<d$G$IfWD^`gd<Skd$$Ifl0#k t9!644 la1ު{c$d$G$IfWD^`$gd<d$G$IfWD^`gd<Skd_$$Ifl0#k t9!644 la1 d$IfVDWD^ `gd<ުߪ)*,Skd'$$Ifl0#k t9!644 la1$d$If^a$gd<d$G$IfWD^`gd<SkdÝ$$Ifl0#k t9!644 la1*@uvī}q d$Ifgd<Skd$$Ifl0#k t9!644 la1Gd$IfWD^`Ggd<d$G$IfWD^`gd<īūث})SkdS$$Ifl0#k t9!644 la1Gd$IfWD^`Ggd<d$G$IfWD^`gd<Skd$$Ifl0#k t9!644 la1],-n{dddddQn7$8$H$VD^`ngdhdG$VD^`gdhSkd$$Ifl0#k t9!644 la1$d$G$IfWD^`$gd<d$G$IfWD^`gd< Z]^`ܬ߬)*+-oîĮSTSԶ׶}mch:7hxq5CJh:7hhCJPJnHo(tHh:7hACJPJnHo(tHh:7hh56CJ\]h:7hhCJ$h:7hh56CJ\]nH tH #h:7hhCJPJaJnHo(tHh:7hhCJH*aJh:7hhCJH*aJnH tH h:7hhCJaJnH tH h:7hhCJaJ#noîĮSTST}~ֶ׶$`7$8$H$VDh^`a$gdxq`7$8$H$VDh^`gdhn7$8$H$VD^`ngdh$`7$8$H$VDh^`a$gdh7$8$H$VD^gdh,Hklзѷط01Z_CDXYoqruzɼʼ./ѽܽYZþľ$%ʸ#h:7h~0#CJPJaJnHo(tH#h:7hxqCJPJaJnHo(tHh:7hxqCJaJh:7hxqCJaJo(h:7hxqCJh:7hxqCJo(h:7hxq5CJo(>зѷpq%&wx|$d7$8$H$^a$gd~0#$^d7$8$H$^^a$gd~0#$d7$8$H$^a$gd~0#$`7$8$H$VDh^`a$gd~0#$`7$8$H$VDh^`a$gdh$ & F7$8$H$a$gdxq$`7$8$H$VDh^`a$gdxq%&4C '(wx23|}HIJ!"PQRS/0Nwxyxnh:7hJv5CJh:7hJvCJaJo(h:7h=wCJPJnHo(tHh:7hJvCJh:7hJvCJo(h:7hJvCJPJnHo(tHh:7hbhCJo(h:7hbhCJh:7h~0#CJPJ aJh:7h~0#5CJh:7h~0#CJaJo(h:7h~0#CJo(h:7h~0#CJ+-.{|IJQRxy$$d7$8$H$^a$gdJv$`7$8$H$VDh^`a$gdJv$`7$8$H$VDh^`a$gdbh$c^d^^a$gd~0#$`7$8$H$VDh^`a$gd~0#%-.RS qr89bctuZ[#$\]67ɽ촤h:7h\~%CJo(h:7h\~%CJPJnHo(tHh:7hypCJh:7hJv5CJo(h:7hJv5CJh:7hJvCJPJnHo(tHh:7h-sCJh:7hJvCJh:7hJvCJo(<$%bc$`7$8$H$VDh^`a$gd~0# $7$8$H$a$gd-s$ & F7$8$H$a$gd-s$`7$8$H$VDh^`a$gd-s$`7$8$H$VDh^`a$gdJv./ ;< Yw$d$Ifa$gd<Vd$IfVD^Vgd<$d^a$gd<d^`gd@)#9TPL HD@<+{^$`7$8$H$VDh^`a$gdyp$`7$8$H$VDh^`a$gdJv  %;<EFf"#o  Yõwwwwwwl`wl`wlwlh:7h<CJaJo(h:7h<CJaJ h:7h<CJPJaJnHtH#h:7h<CJPJaJnHo(tH4h:7hpMSB*CJOJPJQJaJnHo(phtHh:7h@)5CJ\aJh:7h@)5CJ\aJo(4h:7hhB*CJOJPJQJaJnHo(phtHh:7hJvCJo(h:7hJvCJ YZ[\]kG2$Vd$IfVD^Va$gd<Lkd$$If0p#/ | 4 aS d$Ifgd<Vd$IfVD^Vgd<Lkd$$If0p#/ | 4 aSYZ]l+.9Grs)*LMNO谞׌xm\m h:7h<CJPJaJnHtHh:7h<CJaJ&h:7h<>*CJPJaJnH o(tH #h:7h<>*CJPJaJnHtH#h:7h<5CJPJaJnHtH4h:7hO%?B*CJOJPJQJaJnHo(phtHh:7h<CJ]aJ h:7h<CJPJaJnHtHh:7h<CJaJh:7h<>*CJaJ$kGLkdt$$If0p#/ | 4 aSVd$IfVD^Vgd<Lkd$$Ifq0p#/ | 4 aS d$Ifgd<-8Lkdh$$If0p#/ | 4 aS d$Ifgd<Vd$IfVD^Vgd<Lkd$$If0p#/ | 4 aS$d$Ifa$gd<-.rstqM#9TPL HD@<+{^$dWD,`a$gd<$d^a$gd<Lkd$$If0p#/ | 4 aS$d$Ifa$gd<Vd$IfVD^Vgd<()MNOPefgtu$d$&dIfPa$gd<&d$If^`&gd<$\dVDQ^\`a$gd<$\#dVDQ^\`#a$gd<$d$&dIfPa$gd<,&d$If^`&gd<kd\$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd< !")*/0129:;<EFGH[̻؏o```̏h:7h<hewCJaJo(#h:7h<CJPJaJnHo(tHh:7h<hewCJaJh:7h<CJaJo(#h:7h?CJPJ]aJnHtHh:7h<h CJaJ h:7h<CJPJaJnHtHh:7h<CJ]aJ#h:7h<CJPJ]aJnHtHh:7h<CJaJh:7h<CJaJ%,&d$If^`&gd<kdJ$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,&d$If^`&gd<kd2$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,&d$If^`&gd<kd $$If֞ ]9!%3nnnn0T"4 aS"*2:<F$d$Ifa$gd<FG[,hd$IfVDWD^`hgd<kd$$If֞ ]9!%3nnnn0T"4 aS[aipx$d$&dIfPa$gd<,&d$If^`&gd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd< !"#)*=ABHIJ]ܟʑqܟ葹#h:7h<CJPJaJnHo(tHh:7h<hewCJaJh:7h<CJ]aJo(h:7h<CJaJh:7h<hewCJaJo( h:7h<CJPJaJnHtH#h:7h<CJPJ]aJnHtHh:7h<CJ]aJh:7h<CJaJh:7h<CJaJo(),hd$IfVDWD^`hgd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$&dIfPa$gd<,&d$If^`&gd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,hd$IfVDWD^`hgd<kdު$$If֞ ]9!%3nnnn0T"4 aS!$d$Ifa$gd<$d$&dIfPa$gd<!"#,&d$If^`&gd<kdҫ$$If֞ ]9!%3nnnn0T"4 aS#$%&'()$d$Ifa$gd<)*=,ad$If^`agd<kdƬ$$If֞ ]9!%3nnnn0T"4 aS=>?@ABI$d$Ifa$gd<IJ_,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS]^_cdmn|ͿͿͿͨ}iW#h:7h<>*CJPJaJnHtH&h:7h<>*CJPJaJnHo(tH&h:7h<hewCJPJaJnHtHh:7h<CJaJh:7h<CJ]aJh:7h<CJaJh:7h<CJaJo(h:7h<hewCJaJ h:7h<CJPJaJnHtHh:7h<CJ]aJo(&h:7h<CJPJ]aJnHo(tH!_`abcdm$d$Ifa$gd<mn|,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS|}~$d$Ifa$gd<,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$&d4$IfPa$gd<$d$Ifa$gd<,&d$If^`&gd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$&dIfPa$gd<$d$Ifa$gd<,&d$If^`&gd<kd~$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,$\.dVDQ^\`.a$gd<kd$$If֞ ]9!%3nnnn0T"4 aS uABԱ×Åykykyy\yky\kykh:7h<hewCJaJo(h:7h<hewCJaJh:7h<CJaJo(#h:7h?CJPJ]aJnHtHh:7h<h CJaJh:7h<CJ]aJ#h:7h<CJPJ]aJnHtH h:7h<CJPJaJnHtHh:7h<CJaJ&h:7h<>*CJPJaJnH o(tH h:7h<>*CJaJ $%&34Jfghuvw}$d$&dIfPa$gd<&d$If^`&gd<$\dVDQ^\`a$gd<$\.dVDQ^\`.a$gd<}~,&d$If^`&gd<kd|$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,&d$If^`&gd<kdj$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,&d$If^`&gd<kdR$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,&d$If^`&gd<kd@$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<$d$4$Ifa$gd<,hd$IfVDWD^`hgd<kd.$$If֞ ]9!%3nnnn0T"4 aS!)08BD$d$&dIfPa$gd<BCEFMOT]^efmnuv гܧܧܧܧгŧŧŅw܅wh:7h<CJ]aJo(h:7h<hewCJaJ&h:7h<hewCJPJaJnHtHh:7h<CJaJo(#h:7h<CJPJ]aJnHtHh:7h<CJaJh:7h<CJ]aJ h:7h<CJPJaJnHtH#h:7h<CJPJaJnHo(tH'DEF,&d$If^`&gd<kd"$$If֞ ]9!%3nnnn0T"4 aSFGHIJKL$d$Ifa$gd<LMT,hd$IfVDWD^`hgd<kd$$If֞ ]9!%3nnnn0T"4 aST^fnv$d$&dIfPa$gd<,&d$If^`&gd<kd $$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,hd$IfVDWD^`hgd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$4$Ifa$gd<$d$Ifa$gd<$d$&dIfPa$gd<,&d$If^`&gd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd<,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS$d$Ifa$gd< ,ad$If^`agd<kdھ$$If֞ ]9!%3nnnn0T"4 aS (,-67ILVW[\bcdhk~LZghoͿͿͿ͈͜wlwl`Uh:7hc]CJaJh:7hCJaJo(h:7h<CJaJ h:7h<CJPJaJnHtH&h:7h<hewCJPJaJnHtHh:7h<CJ]aJh:7h<CJaJh:7h<CJaJo(h:7h<hewCJaJ h:7h<CJPJaJnHtHh:7h<CJ]aJo(&h:7h<CJPJ]aJnHo(tH! $d$Ifa$gd<(,ad$If^`agd<kdο$$If֞ ]9!%3nnnn0T"4 aS()*+,-6$d$Ifa$gd<67W,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aSWXYZ[\b$d$&dIfPa$gd<$d$Ifa$gd<bcd,&d$If^`&gd<kd$$If֞ ]9!%3nnnn0T"4 aSdefghij$d$Ifa$gd<jk~,ad$If^`agd<kd$$If֞ ]9!%3nnnn0T"4 aS~$d$&dIfPa$gd<$d$Ifa$gd<,$dgd<kd$$If֞ ]9!%3nnnn0T"4 aSor0235FGHI]̮s_SB h:7h-sCJPJaJnHtHh:7h-sCJ]aJ&h:7h-s>*CJPJaJnH o(tH h:7h-s>*CJaJ#h:7h-s>*CJPJaJnHtHh:7h-sCJaJo( h:7h-sCJPJaJnHtH#h:7h-s5CJPJaJnHtHh:7h<CJaJo( h:7h<CJPJaJnHtHh:7h<CJaJh:7hc]CJaJh:7hc]CJaJo(z{23GHI^o$d$&dIfPa$gdjq&d$If^`&gdjqdgd-s$\dVDQ^\`a$gd-s$\#dVDQ^\`#a$gd-sdWDh`gd<$dWDh^`a$gd<$d^a$gd% ]^kl024;<=>DPX\fghnƺغ亨ؓ)h:7h-sh^TCJPJ]aJnHtH#h:7h-sCJPJaJnHo(tHh:7h-sCJaJo(#h:7h-sCJPJ]aJnHtHh:7h-sCJ]aJ h:7h-sCJPJaJnHtHh:7h-sCJaJ:^_l$d$&dIfPa$gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd$$Ifֈ/ wQ$j Hnt0!4 aS0kd$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd$$Ifֈ/ wQ$j Hnt0!4 aS0kd$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq01234<$d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjq<=>??+$d$Ifa$gdjq&d$If^`&gdjqkd|$$Ifֈ/ wQ$j Hnt0!4 aS?@ABCD0kdv$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjqDXYZ[\f$d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjqfghi?+$d$Ifa$gdjq&d$If^`&gdjqkdp$$Ifֈ/ wQ$j Hnt0!4 aSijklmn0kdj$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjqn$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkdd$$Ifֈ/ wQ$j Hnt0!4 aS !"Ŷw\J>2wh:7h-sCJaJo(h:7h-s>*CJaJ#h:7h-s>*CJPJaJnHtH4h:7h-sB*CJOJPJQJaJnHo(phtHh:7h-sCJ]aJh:7h-sCJaJ&h:7h-sh5CJPJaJnHtH&h:7h-sh CJPJaJnHtHh:7h-sh CJ]aJh:7h-sCJaJh:7h-sCJaJo( h:7h-sCJPJaJnHtH#h:7h-sCJPJ]aJnHtH$d$&dIfPa$gdjq$d$Ifa$gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd^$$Ifֈ/ wQ$j Hnt0!4 aS0kdX$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq $d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjq ?&9TPL HD@<+{^gd-skd`$$Ifֈ/ wQ$j Hnt0!4 aS !"78E[wx~$d$&dIfPa$gdjq&d$If^`&gdjqdgd-s$\#dVDQ^\`#a$gd-s "67DEv )15?@AG[bcijwxƺ亨غؓ)h:7h-sh^TCJPJ]aJnHtH#h:7h-sCJPJaJnHo(tHh:7h-sCJaJo(#h:7h-sCJPJ]aJnHtHh:7h-sCJ]aJh:7h-sCJaJ h:7h-sCJPJaJnHtH4~?+$d$Ifa$gdjq&d$If^`&gdjqkdh$$Ifֈ/ wQ$j Hnt0!4 aS0kdb$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkdV$$Ifֈ/ wQ$j Hnt0!4 aS0kdJ$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq $d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkdD$$Ifֈ/ wQ$j Hnt0!4 aS0kd>$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq12345?$d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjq?@AB?+$d$Ifa$gdjq&d$If^`&gdjqkd8$$Ifֈ/ wQ$j Hnt0!4 aSBCDEFG0kd2$$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjqG[cjqx$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd,$$Ifֈ/ wQ$j Hnt0!4 aS$d$&dIfPa$gdjq$d$Ifa$gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd&$$Ifֈ/ wQ$j Hnt0!4 aS *+,Pܽ|kYkYk|k|YkNkNk|kYk|h:7h<CJaJ#h:7h<CJPJaJnHo(tH h:7h<CJPJaJnHtHh:7h<CJaJo(h:7h-sCJaJo(h:7h-sCJaJh:7h-sCJ]aJ#h:7h-sCJPJ]aJnHtHh:7h-sCJaJ&h:7h-sh5CJPJaJnHtH&h:7h-sh CJPJaJnHtHh:7h-sh CJ]aJ0kd $$Ifֈ/ wQ$j Hnt0!4 aS$d$Ifa$gdjq$d$&dIfPa$gdjq$d$Ifa$gdjq&d$If^`&gdjq>?7&$`dVDh^`a$gd<dgd<kd($$Ifֈ/ wQ$j Hnt0!4 aS>? )*NOyy$`dVDh^`a$gd-s$\#dVDQ^\`#a$gd-s$\dVDQ^\`a$gdk$\#dVDQ^\`#a$gdk $da$gdk$d^a$gd<$ & F da$gd<dVD^gd<PZkl|} )*+MO㢎|lZN@/ h:7h-sCJPJaJnHtHh:7h-s>*CJaJo(h:7h-s>*CJaJ#h:7h-s>*CJPJaJnHtHh:7hkCJaJnH o(tH #h:7hk5CJPJaJnHtH&h:7ha5CJPJaJnHo(tHh:7hkCJaJo(#h:7hNCJPJaJnHo(tH h:7hNCJPJaJnHtH#h:7h<CJPJaJnHo(tHh:7h<CJaJo( h:7h<CJPJaJnHtH,KRSYZfho.:;<TUXflvʾܾܾܾܾ瞾ܞ h:7h-sCJPJaJnHtHh:7h-sCJ]aJo(#h:7h-sCJPJaJnHo(tHh:7h-sCJaJo(#h:7h-sCJPJ]aJnHtHh:7h-sCJaJh:7h-sCJ]aJh:7h-sCJaJo(7$d$&dIfPa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd0$$Ifֈ Wrl $ HXs0$" 4 aS 0kd8$$Ifֈ Wrl $ HXs0$" 4 aS$d$Ifa$gdjq !"#$d$Ifa$gdjq&d$If^`&gdjq#$KS?+$d$Ifa$gdjq&d$If^`&gdjqkd:$$Ifֈ Wrl $ HXs0$" 4 aSSZ`hp$d$4$Ifa$gdjq$d$Ifa$gdjqpq?+$d$Ifa$gdjq&d$If^`&gdjqkd<$$Ifֈ Wrl $ HXs0$" 4 aS$d$Ifa$gdjq$d$4$Ifa$gdjq.0?+$d$$Ifa$gdjqd$$If^`gdjqkdD$$Ifֈ Wrl $ HXs0$" 4 aS0247:;0kdL$$Ifֈ lr| $ Ck n0$"4 aS$d$$Ifa$gdjq;$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkdT$$Ifֈ lrl $ Hms0$" 4 aS0kd\$$Ifֈ lrl $ Hms0$" 4 aS$d$Ifa$gdjq:;TUqrsyz誙yg[Kh:7hk>*CJPJaJo(h:7hk>*CJaJ#h:7hk>*CJPJaJnHtH&h:7hk>*CJPJaJnHo(tHh:7h-sCJaJo( h:7h-sCJPJaJnHtH#h:7h-sCJPJaJnHo(tHh:7h-sCJ]aJ#h:7h-sCJPJ]aJnHtHh:7h-sCJ]aJo(h:7h-sCJaJh:7h-sCJaJo($*2:$d$Ifa$gdjq&d$If^`&gdjq:;U?+&d$If^`&gdjqkdd$$Ifֈ lrl $ Hms0$" 4 aSU[_ekq$d$&d4$IfPa$gdjq$d$&dIfPa$gdjqqrs?($>dVDaWD^`>a$gd-skdl$$Ifֈ lrl $ Hms0$" 4 aSsyyyyyyy$d$$&dIfPa$gdTd$$If^`gdT$Hd$VD^^Ha$gdkHd$VD^^Hgdk$\#d$VDQ^\`#a$gdk $d$a$gd-s$[dVDnWD^[`a$gd-s3?BLMNTUXY_`aq89KLopǻةzzzzةl`l`ةةlh:7hkCJ]aJh:7hkCJ]aJo(h:7hkhewCJaJo(h:7hkCJaJo(&h:7hkCJPJ]aJnHo(tH#h:7hkCJPJ]aJnHtHh:7hk>*CJaJ h:7hkCJPJaJnHtHh:7hkCJaJh:7hkCJaJo( h:7hkCJPJaJnHtH" ?+$d$$Ifa$gdTd$$If^`gdTkd$$Ifֈ F % no0V"4 aS #+,0kdv$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT,-./012$d$$Ifa$gdTd$$If^`gdT23LN?+$d$$Ifa$gdTd$$If^`gdTkdd$$Ifֈ F % no0V"4 aSNUWY`a0kdX$$Ifֈ F % no0V"4 aS$d$$Ifa$gdTaqw{$d$$Ifa$gdTd$$If^`gdT?'sd$$IfVDWD^`sgdkkdZ$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT?+$d$$Ifa$gdTd$$If^`gdTkd\$$Ifֈ F % no0V"4 aS#)/890kdV$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT9LT\ago$d$$&dIfPa$gdTd$$If^`gdTopq?4$\#d$VDQ^\`#a$gdk $da$gdkkdX$$Ifֈ F % no0V"4 aSpqr:;des*,-EFIV]gstij~~~~~p~~~ppp~p~h:7h-sCJ]aJo(h:7h-sCJaJo(#h:7h-sCJPJ]aJnHtHh:7h-sCJaJh:7h-sCJ]aJ h:7h-sCJPJaJnHtH%h:7hk5CJ\aJnH o(tH h:7hk>*CJaJ#h:7hk>*CJPJaJnHtHh:7hkCJaJ,239$d$&dIfPa$gdjq&d$If^`&gdjqd$gd-s$`d$VDh^`a$gd-s;d$WD^`;gdk 9:;C?+$d$Ifa$gdjq&d$If^`&gdjqkdZ$$Ifֈ sok $ Hnt0"4 aSCKS[cd0kdT$$Ifֈ sok $ Hnt0"4 aS$d$Ifa$gdjqdefghij$d$Ifa$gdjq&d$If^`&gdjqjk?+$d$Ifa$gdjq&d$If^`&gdjqkdH$$Ifֈ sok $ Hnt0"4 aS0kd<$$Ifֈ sok $ Hnt0"4 aS$d$Ifa$gdjq#+$d$Ifa$gdjq&d$If^`&gdjq+,tx?+$d$Ifa$gdjq&d$If^`&gdjqkd6$$Ifֈ sok $ Hnt0"4 aSx0kd0$$Ifֈ sok $ Hnt0"4 aS$d$Ifa$gdjq$d$Ifa$gdjq&d$If^`&gdjq?+$d$Ifa$gdjq&d$If^`&gdjqkd*$$Ifֈ sok $ Hnt0"4 aS'(AB\]^de~l`l~OCh:7hkCJaJo( h:7hkCJPJaJnHtHh:7hk>*CJaJ#h:7hk>*CJPJaJnHtHh:7hkCJaJnH o(tH #h:7hkCJPJaJnHo(tH h:7hkCJPJaJnHtHh:7hkCJaJo(h:7h-sCJ]aJh:7h-sCJaJo(#h:7h-sCJPJ]aJnHtHh:7h-sCJ]aJo(h:7h-sCJaJ'(0kd$$$Ifֈ sok $ Hnt0"4 aS$d$Ifa$gdjq(BHLPV\$d$&dIfPa$gdjq&d$If^`&gdjq\]^?$$$[d$VDnWD^[`a$gdkkd$$Ifֈ sok $ Hnt0"4 aS$d$$&dIfPa$gdTd$$If^`gdTHd$VD^^Hgdk$~d$VD ^~a$gd$\#d$VDQ^\`#a$gdk$Hd$VD^^Ha$gdk*-789?@CDJKL\st ?@AҾҲҲҲ{{`4h:7homB*CJOJPJQJaJnHo(phtHh:7hkCJ]aJo(h:7hkCJ]aJh:7hkhewCJaJh:7hkhewCJaJo(h:7hkCJaJo(&h:7hkCJPJ]aJnHo(tH#h:7hkCJPJ]aJnHtH h:7hkCJPJaJnHtHh:7hkCJaJ?+$d$$Ifa$gdTd$$If^`gdTkd&$$Ifֈ F % no0V"4 aS0kd$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT$d$$Ifa$gdTd$$If^`gdT79?+$d$$Ifa$gdTd$$If^`gdTkd$$Ifֈ F % no0V"4 aS9@BDKL0kd$$Ifֈ F % no0V"4 aS$d$$Ifa$gdTL\bfims$d$$Ifa$gdTd$$If^`gdTst?'sd$$IfVDWD^`sgdkkd$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT?+$d$$Ifa$gdTd$$If^`gdTkd$$Ifֈ F % no0V"4 aS0kd$$Ifֈ F % no0V"4 aS$d$$Ifa$gdT$(.6?$d$$&dIfPa$gdTd$$If^`gdT?@A?#9TPL HD@<+{^kd$$Ifֈ F % no0V"4 aSAZ[OMkd$$If40#& 9!4 aSf4%$!d$&dIfPa$gdT$d$IfWD^`$gdTXdVD^Xgd6dVDWD^`6gdkVdWD`VgdAZ[u|+,4DEMSU\]clmvwôؤxff#h:7hkCJPJaJnHo(tH*h:7hk>*CJOJQJaJnHo(tH*h:7hk>*CJOJQJaJnH o(tH h:7hk>*CJOJQJaJh:7hkCJOJQJaJ(h:7hkCJOJPJQJaJnHtHh:7hkCJaJh:7hkCJaJo( h:7hkCJPJaJnHtH(whh$d$Ifa$gdT$d$IfWD^`$gdT]kdw$$IfFu#&9!    4 aS%$!d$Ifa$gdT$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS $d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS$,$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS,-5=E$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aSEFMU]}}$d$&dIfPa$gdT d$IfgdT]kd$$IfFu#&9!    4 aS]^_`a$d$Ifa$gdT d$IfgdT]kd$$IfFu#&9!    4 aSabcmw|d$d$&dIfPa$gdT$d$&d4$IfPa$gdT d$IfgdT]kd*$$IfFu#&9!    4 aSwxy%&HIz{|_Od^`gd[#9TPL HD@<+{^$d^a$gdk$d^a$gdk]kd$$IfFu#&9!    4 aS $I!"#-cez{|䭘tfRGh:7h-sCJaJ&h:7h-s5CJPJ\aJnHtHh:7h[5CJ\aJ)h:7h[5CJPJ\aJnHo(tHh:7h[5CJ\aJo()h:7h5CJPJ\aJnHo(tH4h:7hkB*CJOJPJQJaJnHo(phtHh:7hkCJaJnH o(tH h:7hkCJaJo(h:7hkCJaJ h:7hkCJPJaJnHtH|aRR$d$Ifa$gdjq]kd<$$IflF]-#8!    4 la1%$!d$Ifa$gdjqHd$If^H`gdjqdgd-sd^`gd[ 1357<=>abkmoq~øxfxfxfxxfxxxxf#h:7h-sCJPJaJnHo(tHh:7h-sCJaJo( h:7h-sCJPJaJnHtH#h:7h-s>*CJOJPJ QJaJ h:7h-sCJOJPJ QJaJh:7h-sCJaJ*h:7h-s>*CJOJQJaJnHo(tH*h:7h-s>*CJOJQJaJnH o(tH h:7h-s>*CJOJQJaJ(xx'$ d$Ifa$gdjqHd$If^H`gdjq]kd$$IflF]-#8!    4 la1xx'$ d$Ifa$gdjqHd$If^H`gdjq]kd$$IflF]-#8!    4 la1$d$Ifa$gdjqd$IfWDd`gdjq]kd$$IflF]-#8!    4 la117=yy$d$Ifa$gdjq & F=d$1$If^=`gdjq]kd$$IflF]-#8!    4 la1=>bikpp$d$&dIfPa$gdjq & F=d$1$If^=`gdjq]kdd$$IflF]-#8!    4 la1klmno$d$Ifa$gdjq d$Ifgdjq]kd$$IflF]-#8!    4 la1opqx$d$Ifa$gdjq d$Ifgdjq]kdH$$IflF]-#8!    4 la1qq$d$&dIfPa$gdjqd$IfVDWD^`gdjq]kd$$IflF]-#8!    4 la1 !"%')+./:BDHI谡~scM*h:7hq>*CJOJQJaJnH o(tH h:7hq>*CJOJQJaJh:7hqCJaJh:7h[5CJ\aJ)h:7h[5CJPJ\aJnHo(tHh:7h[5CJ\aJo()h:7hq5CJPJ\aJnHo(tH h:7h-sCJPJaJnHtH#h:7h-sCJPJaJnHo(tHh:7h-sCJaJh:7h-sCJaJo($d$Ifa$gdjq d$Ifgdjq]kd,$$IflF]-#8!    4 la1$d$Ifa$gdjq d$Ifgdjq]kd$$IflF]-#8!    4 la1}}$d$&dIfPa$gdjq d$Ifgdjq]kd $$IflF]-#8!    4 la1$d$Ifa$gdjq d$Ifgdjq]kd $$IflF]-#8!    4 la1&}}$d$&dIfPa$gdjq d$Ifgdjq]kd $$IflF]-#8!    4 la1&'()BCDINmYY%$!d$Ifa$gdTHd$If^H`gdT0d^`0gdqd^`gd[]kdf $$IflF]-#8!    4 la1IMNbd  νΫΟΫΟΟ΂ΟsΎΫΎh:7hqCJOJQJaJ *h:7hqCJaJ h:7hqCJPJaJnHtHh:7hqCJaJo(#h:7hqCJPJaJnHo(tH h:7hqCJOJPJ QJaJh:7hqCJaJ*h:7hq>*CJOJQJaJnH o(tH h:7hq>*CJOJQJaJ-NOPX`~~$d$Ifa$gdTHd$If^H`gdT]kd $$IflFp#      4 la1`abcdxx'$ d$Ifa$gdTHd$If^H`gdT]kdD $$IflFp#      4 la1de$d$Ifa$gdT d$IfgdT]kd $$IflFp#      4 la1$d$Ifa$gdT d$IfgdT]kd" $$IflFp#      4 la1}}$d$&dIfPa$gdT d$IfgdT]kd $$IflFp#      4 la1$d$Ifa$gdT d$IfgdT]kd$$IflFp#      4 la1$d$Ifa$gdT d$IfgdT]kdr$$IflFp#      4 la1$d$Ifa$gdT d$IfgdT]kd$$IflFp#      4 la1}}$d$&dIfPa$gdT d$IfgdT]kdV$$IflFp#      4 la1~~#$d$Ifa$gdTHd$If^H`gdT]kd$$IflFp#      4 la1  pp$d$&dIfPa$gdT%!Hd$If^H`gdT]kd:$$IflFp#      4 la1*+xxxxxx$d^a$gdT$d^a$gdq $da$gdq]kd$$IflFp#      4 la1  )*+57MNuw!CEhst*,[)*+z#h:7hTCJPJaJnHo(tH#h:7h% ACJPJaJnHo(tH#h:7hQMCJPJaJnHo(tH h:7hQMCJPJaJnHtH#h:7hqCJPJaJnHo(tHh:7hqCJaJo(h:7hqCJaJnH o(tH h:7hqCJPJaJnHtH/+grݷw_I8 h:7h SCJOJPJ QJaJ*h:7h S>*CJOJQJaJnH o(tH .h:7h S>*CJOJPJQJaJnHo(tH'h:7h SCJOJQJaJnH o(tH h:7h S>*CJOJQJaJh:7h SCJaJ h:7h SCJPJaJnHtH#h:7h SCJPJaJnHo(tH&h:7hThF JCJPJaJnHtH#h:7hTCJPJaJnHo(tH h:7hTCJPJaJnHtHpaa$d$Ifa$gdjq]kd$$IflFp#      4 la1%$!d$Ifa$gdjq d$Ifgdjq$`dVDh^`a$gd S'$ d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1zb$d$&dIfPa$gdjq$d$&d4$IfPa$gdjq d$Ifgdjq_kd$$IfltFp#      4 la1 #&./23_deghijmnoxy (),-.eiknopŒ&h:7h Shi4CJPJaJnHtHh:7h Shi4CJaJo(h:7h SCJaJnH o(tH #h:7h SCJPJaJnHo(tHh:7h SCJaJ h:7h SCJPJaJnHtHh:7h SCJaJo(9#$d$Ifa$gdjq d$Ifgdjq]kdl$$IflFp#      4 la1&,3#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la134_go#$d$Ifa$gdjq d$Ifgdjq]kdP$$IflFp#      4 la1op#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1#$d$Ifa$gdjq d$Ifgdjq]kd4$$IflFp#      4 la1 (.#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1./eko#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1op#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1     ! $ % & O P V W \ ^ b c d e i j                бŢ| h:7hTCJPJaJnHtH(h:7h SCJOJPJQJaJnHtHh:7h SCJOJQJaJ&h:7h ShCJPJaJnHtHh:7h SCJaJ h:7h SCJPJaJnHtH#h:7h SCJPJaJnHo(tHh:7h SCJaJo(.#$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1 ! % ||#$d$Ifa$gdjqPd$IfWD^`Pgdjq]kdn$$IflFp#      4 la1% & \ ^ c #$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1c d    }}#$d$&dIfPa$gdjq d$Ifgdjq]kdR$$IflFp#      4 la1     #$d$Ifa$gdjq d$Ifgdjq]kd$$IflFp#      4 la1     xx$d$&dIfPa$gdjq%!d$Ifgdjq]kd6$$IflFp#      4 la1        qiYd^`gdNdgds$RdVDb^Ra$gdT$dVDbWD^`a$gdTdgdT]kd$$IflFp#      4 la1    % q | } ~        m_D9h:7h:)FCJaJ4h:7hpMSB*CJOJPJQJaJnHo(phtHh:7hN5CJ\aJ)h:7hN5CJPJ\aJnHo(tHh:7hN5CJ\aJo()h:7hq5CJPJ\aJnHo(tHh:7hT5CJ\aJo( h:7hTh<^5CJ\aJ h:7hTCJPJaJnHtHh:7hTCJaJo(#h:7hTCJPJaJnHo(tHh:7hTCJaJ        ?]kd$$IflF$&!    4 la1%$!d$Ifa$gdjqd$IfWD^`gdjqdgdHiG d`gd:)F#9TPL HD@<+{^           1 9 < = A i o t               0 1 7 ? E F G H I c n o    ͽ͖͖x͊x͊xxx͖xx͖x͖x͖x#h:7hHiGCJPJaJnHo(tHh:7hHiGCJaJo( h:7hHiGCJPJaJnHtH*h:7hHiG>*CJOJQJaJnH o(tH h:7hHiG>*CJOJQJaJh:7hHiGCJaJ&h:7hHiG5CJPJ\aJnHtH&h:7h:)F5CJPJ\aJnHtH/        |mm#$d$Ifa$gdjq]kd$$IflF$&!    4 la1$d$Ifa$gdjqd$IfWD^`gdjq  1 9 A zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1A B i o u zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1u v    zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1     qq#$d$&dIfPa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1     zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1  7 ? G qq#$d$&dIfPa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1G H I J K zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1K L c i o zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1o p    zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1               12789<=NUVXfxyz{|=CHJƴݢݖh:7hN]CJaJo(#h:7hACJPJaJnHo(tH#h:7hM$CJPJaJnHo(tHh:7hHiGCJaJh:7hHiGCJaJo(#h:7hHiGCJPJaJnHo(tH h:7hHiGCJPJaJnHtH;     qq#$d$&dIfPa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1     zz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd$$IflF$&!    4 la1  257ll#$d$&dIfPa$gdjqsd$IfVDWD^`sgdjqbkd$$IflF$&!    4 la1g&789:;uu#$d$Ifa$gdjqsd$IfVDWD^`sgdjqbkd$$IflF$&!    4 la1g&;<xyzuu#$d$Ifa$gdjqsd$IfVDWD^`sgdjqbkd$$IflF$&!    4 la1g&z{oo#$d$&dIfPa$gdjq"ld$1$IfVDWD1^"`lgdM$]kd, $$IflF$&!    4 la1#$d$Ifa$gdjq d$Ifgdjq]kd $$IflF$&!    4 la1zzz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd&!$$IflF$&!    4 la1=CInn$sd$IfVDWD^`sa$gdjqsd$IfVDWD^`sgdjq]kd!$$IflF$&!    4 la1IJzzz#$d$Ifa$gdjqsd$IfVDWD^`sgdjq]kd&"$$IflF$&!    4 la1qq#$d$&dIfPa$gdjqsd$IfVDWD^`sgdjq]kd"$$IflF$&!    4 la1䱜xjj\QAh:7h"#V>*CJOJQJaJh:7h"#VCJaJh:7h"#V5CJ\aJh:7h 5CJ\aJ)h:7h 5CJPJ\aJnHo(tHh:7h 5CJ\aJo()h:7hom5CJPJ\aJnHo(tH)h:7h 5CJPJ\aJnHo(tH#h:7hHiGCJPJaJnHo(tHh:7hHiGCJaJo(h:7hHiGCJaJ h:7hHiGCJPJaJnHtHkWW%$!d$Ifa$gdU>}{d$IfWD^{`gdU>}dgd"#Vd^`gd d$gd ]kd,#$$IflF$&!    4 la1'HJKLNQRTijsuv .1abc߱߱߱±߱߱߱{#h:7h]CJPJaJnHo(tH#h:7h\CJPJaJnHo(tH#h:7h"#VCJPJaJnHo(tH h:7h"#VCJPJaJnHtHh:7h"#VCJaJo( h:7h"#VCJOJPJ QJaJh:7h"#VCJaJ*h:7h"#V>*CJOJQJaJnH o(tH 0||$d$Ifa$gdU>}{d$IfWD^{`gdU>}]kd#$$IflF$&!    4 la1vv'$ d$Ifa$gdU>}{d$IfWD^{`gdU>}]kd&$$$IflF$&!    4 la1HIJvv'$ d$Ifa$gdU>}{d$IfWD^{`gdU>}]kd$$$IflF$&!    4 la1JKLssssss$d$&dIfPa$gdU>}Pd$IfWD^`PgdU>}]kd %$$IflF$&!    4 la1 bc|}U~nn___$d^a$gdGd^`gd d$gd]$d^a$gd"#V d^gd"#V]kd%$$IflF$&!    4 la1 cehi{}!,./26Zadouvw STUVY]xyz¶¶¥¶¶¶¶¥¥¥¥¥¥rh:7hj5CJ\aJo(#h:7h]CJPJaJnHo(tH#h:7hGCJPJaJnHo(tH h:7hGCJPJaJnHtHh:7hGCJaJo(h:7hGCJaJh:7h 5CJ\aJ)h:7h 5CJPJ\aJnHo(tHh:7h 5CJ\aJo(+UVyz{g]kd&$$IflFp#      4 la1$d$Ifa$gdU>} d$IfgdU>}dgdjdgd $d$^a$gd] z{  "#%&)*+,/[abjzncWcnh:7hZ\ CJaJo(h:7hZ\ CJaJ,h:7hZ\ CJKHOJPJQJaJnHtHh:7hjCJOJQJaJ#h:7hjCJPJaJnHo(tH h:7hjCJPJaJnHtHh:7hjCJaJo(#h:7hj>*CJPJaJnHtH&h:7hj>*CJPJaJnH o(tH h:7hj>*CJaJh:7hjCJaJ"#$d$Ifa$gdU>} d$IfgdU>}]kd&$$IflFp#      4 la1#$d$Ifa$gdU>} d$IfgdU>}]kd&$$IflFp#      4 la1 uu#$d$&dIfPa$gdU>}d$If^`gdU>}]kd^'$$IflFp#      4 la1#$d$Ifa$gdU>} d$IfgdU>}]kd'$$IflFp#      4 la1"*xx$d$&dIfPa$gdU>}%!d$IfgdU>}]kdB($$IflFp#      4 la1*+,-.$d$Ifa$gdU>}%!d$IfgdU>}]kd($$IflFp#      4 la1./[biww$d$Ifa$gd%!d$IfWD^`gd]kd&)$$IflFp#      4 la1ijzww$d$Ifa$gd%!d$IfWD^`gd]kd)$$IflFp#      4 la1z   "DOPSTV%(*/CFIǻljljljtǩǘ(h:7hjCJOJPJQJaJnHtHh:7hjCJOJQJaJ h:7hjCJPJaJnHtH#h:7hjCJPJaJnHo(tHh:7hjCJaJo(h:7hjCJaJ,h:7hZ\ CJKHOJPJQJaJnHtHh:7hZ\ CJaJo(h:7hZ\ CJaJ-ww$d$Ifa$gd%!d$IfWD^`gd]kd *$$IflFp#      4 la1 uu#$d$&dIfPa$gdU>}d$If^`gdU>}]kd|*$$IflFp#      4 la1    $d$Ifa$gdU>}%!d$IfgdU>}]kd*$$IflFp#      4 la1xx$d$&dIfPa$gdU>}%!d$IfgdU>}]kd`+$$IflFp#      4 la1 !$d$Ifa$gdU>}%!d$IfgdU>}]kd+$$IflFp#      4 la1!"DLTxx$d$&dIfPa$gdU>}%!d$IfgdU>}]kdD,$$IflFp#      4 la1TUVZ[mVV$ d7$8$H$^` a$gdj$ldWD^`la$gdj$ d7$8$H$^` a$gdjdgdj]kd,$$IflFp#      4 la1IKX[gnOR~8\ƺƓ'h:7hjCJOJQJaJnHo(tH$h:7hjCJOJQJaJnHtH&h:7hj>*CJPJaJnH o(tH h:7hj>*CJaJh:7hjCJaJh:7hjCJaJo(#h:7hjCJPJaJnHo(tH h:7hjCJPJaJnHtH2]kd(-$$IflFp#      4 la1$d$Ifa$gdU>} d$IfgdU>}#$d$Ifa$gdU>} d$IfgdU>}]kd-$$IflFp#      4 la1#$d$Ifa$gdU>} d$IfgdU>}]kd.$$IflFp#      4 la1 &,ww#$d$Ifa$gdU>}%!d$IfWD^`gdU>}]kdl.$$IflFp#      4 la1 +,-EKX\]abghpqstwxyz ŐujXjLjLjLh:7hvCJaJo(#h:7hvCJPJaJnHo(tHh:7hvCJaJ4h:7hpMSB*CJOJPJQJaJnHo(phtHh:7hjCJOJQJaJ#h:7hjCJPJaJnHo(tH'h:7hjCJOJQJaJnHo(tHh:7hjCJaJ h:7hjCJPJaJnHtHh:7hjCJaJo($h:7hjCJOJQJaJnHtH,-X\bnn#$d$&dIfPa$gdU>}%!d$IfWD^`gdU>}]kd.$$IflFp#      4 la1bcdef#$d$Ifa$gdU>} d$IfgdU>}]kdP/$$IflFp#      4 la1fghpxxx$d$&dIfPa$gdU>}%!d$IfgdU>}]kd/$$IflFp#      4 la1xyz|}./}nnn^G^$d7$8$H$^`a$gdvd^`gdv$d^a$gdv#9TPL HD@<+{^]kd40$$IflFp#      4 la1{}45  -.0459:;anop˷ˣˣkk'h:7hvCJOJQJaJnHo(tH$h:7hvCJOJQJaJnHtH h:7hvCJPJaJnHtH&h:7hv>*CJPJaJnH o(tH &h:7hv>*CJPJaJnHo(tHh:7hv>*CJaJ#h:7hvCJPJaJnHo(tHh:7hvCJaJo(h:7hvCJaJ*/05:;<DL]kd0$$IflFp#      4 la1$d$Ifa$gdU>} d$IfgdU>}LMNOP#$d$Ifa$gdU>} d$IfgdU>}]kd1$$IflFp#      4 la1PQaho#$d$Ifa$gdU>} d$IfgdU>}]kd~1$$IflFp#      4 la1opww#$d$Ifa$gdU>}%!d$IfWD^`gdU>}]kd1$$IflFp#      4 la1nn#$d$&dIfPa$gdU>}%!d$IfWD^`gdU>}]kd\2$$IflFp#      4 la1   $ 0 1 2 M R S T U V h o p r             !!G"H"`"e"f"n"v""""""׸׸גגג#h:7hvCJPJaJnHo(tH&h:7hv>*CJPJaJnH o(tH h:7hv>*CJaJ$h:7hvCJOJQJaJnHtHh:7hvCJaJ h:7hvCJPJaJnHtHh:7hvCJaJo(9#$d$Ifa$gdU>} d$IfgdU>}]kd2$$IflFp#      4 la1v^$d$&dIfPa$gdU>}#$d$&dIfPa$gdU>}%!d$IfgdU>}_kd@3$$Ifl\Fp#      4 la1o_KPd$If^`PgdU>}d^`gdv$d^`a$gdv$d7$8$H$^a$gdv d^gdv]kd3$$IflFp#      4 la1     ~Pd$If^`PgdU>}]kd(4$$IflFp#      4 la1$d$Ifa$gdU>}     ~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kd4$$IflFp#      4 la1  $ + 1 ~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kd5$$IflFp#      4 la11 2 M S U ~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kdl5$$IflFp#      4 la1U V s y  uu#$d$&dIfPa$gdU>}Pd$If^`PgdU>}]kd5$$IflFp#      4 la1      4]kd6$$IflFp#      4 la1#$d$Ifa$gdU>}]kdP6$$IflFp#      4 la1      !!]R??$d7$8$H$^a$gdv $da$gdv]kd47$$IflFp#      4 la1$d$&dIfPa$gdU>}#$d$&dIfPa$gdU>}Pd$If^`PgdU>}!""A#B#C#H#M#N#K]kd7$$IflFp#      4 la1$d$Ifa$gdU>}Pd$If^`PgdU>}$d^`a$gdv$d^a$gdv$dVD+^a$gdv""A#C#G#H#L#M#d#f#q#w#|#}#~#################1$6$T$U$m$z$$$$$$% %%+%;%C%D%u%y%%%&&ֱֱ֥h:7hvCJ\aJo(h:7hvCJ\aJh:7hvCJaJo( h:7hvCJPJaJnHtH&h:7hv>*CJPJaJnH o(tH h:7hvCJaJh:7hv>*CJaJ#h:7hvCJPJaJnHo(tH6N#O#W#_#`#a#b#c#~oo#$d$Ifa$gdU>}]kd8$$IflFp#      4 la1$d$Ifa$gdU>}Pd$If^`PgdU>}c#d#q#w#}#~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kd~8$$IflFp#      4 la1}#~####~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kd8$$IflFp#      4 la1#####uu#$d$&dIfPa$gdU>}Pd$If^`PgdU>}]kd\9$$IflFp#      4 la1#####~~#$d$Ifa$gdU>}Pd$If^`PgdU>}]kd9$$IflFp#      4 la1#####uu$d$&dIfPa$gdU>}Pd$If^`PgdU>}]kd@:$$IflFp#      4 la1###% %M&N&''{s{{{O#9TPL HD@<+{^dgdv$d7$8$H$^a$gdv$d7$8$H$^a$gdv]kd:$$IflFp#      4 la1& &&%&:&F&I&J&L&N&f&&&&&&&&'''''''3'4'5'9'򴥐mZH#h:7hU>}>*CJPJaJnHtH$h:7hU>}CJOJQJaJnHtH)h:7hU>}5CJPJ\aJnHo(tHh:7h5CJ\aJ)h:7h5CJPJ\aJnHo(tHh:7h5CJ\aJo(4h:7hvB*CJOJPJQJaJnHo(phtHh:7hvCJaJo(h:7hvCJaJh:7hvCJ\aJh:7hvCJ\aJo('3'4'5':'?'@'A'I'Q'n]kd$;$$IflFd#      4 la1$d$Ifa$gdU>} %d$IfgdU>}dgdU>}d^`gd 9':'>'?'@'A'Q'R'S'U'V'e'm'q't'u'v'''''''''ɸɸ{hYIY>hYIh:7hZ\ CJaJh:7hZ\ CJKHPJ aJo(h:7hZ\ CJKHPJ aJ$h:7hZ\ CJOJQJaJnHtH#h:7hU>}CJPJaJnHo(tHh:7hU>}CJaJo('h:7hU>}CJOJQJaJnHo(tHh:7hU>}CJaJ h:7hU>}CJPJaJnHtH$h:7hU>}CJOJQJaJnHtH#h:7hU>}>*CJPJaJnHtH"h:7hU>}>*CJaJnH o(tH Q'R'S'T'U'$d$Ifa$gdU>} %d$IfgdU>}]kd;$$IflFd#      4 la1U'V'e'm'u'$d$Ifa$gdU>}%!d$IfgdU>}]kd<$$IflFd#      4 la1u'v''''#$d$Ifa$gd%!d$Ifgd]kdz<$$IflFd#      4 la1'''''xx#$d$&dIfPa$gd%!d$Ifgd]kd<$$IflFd#      4 la1''''''''''(((( (h(k(o(p(t(u(v((((((((()))0);)<)A)Ǽǰ{{o]]]]#h:7hU>}CJPJaJnHo(tHh:7hU>}>*CJaJ"h:7hU>}>*CJaJnH o(tH #h:7hU>}>*CJPJaJnHtH h:7hU>}CJPJaJnHtHh:7hU>}CJaJo(h:7hU>}CJaJh:7hU>}CJOJQJaJh:7hZ\ CJaJh:7hZ\ CJKHPJ aJo(h:7hZ\ CJKHPJ aJ$'''''$d$Ifa$gdU>} %d$IfgdU>}]kdX=$$IflFd#      4 la1'''''}}$d$&dIfPa$gdU>} %d$IfgdU>}]kd=$$IflFd#      4 la1'''i(j(k(p(u(zkk$d$Ifa$gdU>} d$IfgdU>} d^gdU>}$d^a$gdU>}]kd6>$$IflFd#      4 la1u(v(w((($d$Ifa$gdU>} d$IfgdU>}]kd>$$IflFd#      4 la1(((((#$d$Ifa$gdU>} d$IfgdU>}]kd?$$IflFd#      4 la1(((((#$d$Ifa$gdU>} d$IfgdU>}]kd?$$IflFd#      4 la1(((((#$d$Ifa$gdU>} d$IfgdU>}]kd?$$IflFd#      4 la1(()))#$d$Ifa$gdU>} d$IfgdU>}]kdd@$$IflFd#      4 la1))0)6)<)yy#$d$&dIfPa$gdU>}d$IfgdU>}]kd@$$IflFd#      4 la1<)=)>)?)@)#$d$Ifa$gdU>} d$IfgdU>}]kdHA$$IflFd#      4 la1@)A)B)J)R)}}$d$&dIfPa$gdU>} %d$IfgdU>}]kdA$$IflFd#      4 la1A)B)I)J)N)Q)R)S)T)))***"*%*?*@*A*B*D*Ȣ~p~[I=h:7h0CJ\aJ#h:7h0CJPJaJnHo(tH)h:7hPf5CJPJ\aJnHo(tHh:7h?5CJ\aJ)h:7h?5CJPJ\aJnHo(tHh:7h?5CJ\aJo()h:7hvd5CJPJ\aJnHo(tH h:7hU>}CJPJaJnHtH#h:7hU>}CJPJaJnHo(tHh:7hU>}CJaJh:7hU>}CJaJo(h:7hU>}CJOJQJaJR)S)T)**@*A*++vcS0d^`0gd0$0d^`0a$gd0d^`gd?dgdvd$d7$8$H$^a$gdU>}]kd,B$$IflFd#      4 la1D*E*++++"+#+'+(+)+?+Z+]+d+++++++++++++++ǻǕlj}k}Y}H}H} h:7h0CJPJaJnHtH#h:7h'CJPJaJnHo(tH#h:7h0CJPJaJnHo(tHh:7h0CJaJo(h:7h05CJaJ&h:7h05CJPJaJnHo(tH"h:7h0>*CJaJnH o(tH h:7h0>*CJaJh:7h0CJaJh:7h0CJ\aJo(h:7h0CJ\aJ&h:7h0CJPJ\aJnHo(tH++#+(+)+*+2+:+]kdB$$IflFd#F    4 la$d$Ifa$gd4+ d$Ifgd4+:+;+<+=+>+#$d$Ifa$gd4+ d$Ifgd4+]kd C$$IflFd#F    4 la>+?+Z+[+\+#$d$Ifa$gd4+ d$Ifgd4+]kdvC$$IflFd#F    4 la\+]+d+e+f+#$d$Ifa$gd4+ d$Ifgd4+]kdC$$IflFd#F    4 laf+g+++++qbb#$d$Ifa$gd4+Td$IfVDWD^T`gd0d$IfVDXWDj^`gd0]kdND$$IflFd#F    4 la+++++#$d$Ifa$gd4+d$If^gd4+]kdD$$IflFd#F    4 la+++++#$d$Ifa$gd4+d$IfWDO`gd4+]kd,E$$IflFd#F    4 la+++++++)*+-hq%&\kŹŹsh:7hHiGCJaJo(h:7hHiGCJaJh:7hHiG5CJaJ h:7h0CJPJaJnHtH#h:7h0CJPJaJnHo(tHh:7h05CJaJh:7h05CJaJo(U&h:7h05CJPJaJnHo(tHh:7h0CJaJo(h:7h0CJaJ,+++++{{#$d$Ifa$gd4+d$IfWDd`gd4+oP9]kdE$$IflFd#F    4 la++#$d$Ifa$gd4+ d$Ifgd4+]kdF$$IflFd#F    4 lading company:Hualu Holdings Co., Ltd.:- Interest expenses of loan from ultimate holding company29,150-- Share of underwriting expenses of loan from ulitmate holding company1,500-Fellow subsidiaries: - Sale of water, electricity, steam and waste materials11,97310,667- Sale of bulk pharmaceuticals and chemical products63,14129,057- Purchase of raw materials72,74452,696- Design fee income66116Associate:- Sale of water, electricity and steam377447- Purchase of raw materials1,076276Non-controlling interest shareholders:- Sale of bulk pharmaceuticals and chemical raw materials137,816157,367- Purchase of chemical raw materials-447Notes:On 7 December 1996, the Group was granted the exclusive right to use the trademark Xinhua (Trademark) by SXPGC for its existing and future products in and outside the PRC at an initial annual fee of RMB600,000 increasing at the rate of an extra RMB100,000 per year until the annual fee reaches the cap amount of RMB1,100,000, which shall stay as such until the agreement is terminated. The terms of the agreement shall continue to have effect during the validity period of the Trademark, being 28 February 2013, subject to further renewal of the registration of the Trademark.On 23 March 2012, the Group was entered into the supplemental trademark licence agreement with SXPGC, the annual licence fee to use the Trademark is RMB10,000,000 for the period between 1 April 2012 to 31 December 2014. Other terms of the trademark licence agreement remain unchanged. The Group operates in an economic environment predominated by enterprises directly or indirectly owned or controlled by the PRC government through its numerous authorities, affiliates or other organisations (collectively State-owned Enterprises). During the year ended 31 December 2012, the Group had transactions with State-owned Enterprises including, but not limited to sales of pharmaceutical products and purchases of raw materials. The directors of the Company consider that transactions with other State-owned Enterprises are activities in the ordinary course of business, and that dealings of the Group have not been significantly controlled or owned by the PRC government. The Group has also established pricing policies for products and such pricing policies do not depend on whether or not the customers are State-owned Enterprises. Having due regard to the substance of the relationships, the directors of the Company are of the opinion that none of these transactions is a material related party transaction that requires separate disclosure.(b) As at 31 December 2012, the ultimate holding company provides guarantee to the Group amounted to RMB90,000,000 (2011: RMB230,000,000). (c) Compensation of key management personnelThe remuneration of directors and other members of key management during the year was as follows:20122011RMB000RMB000Short-term benefits3,2982,566Post-employment benefits2552423,5532,808The remuneration of directors and key executives is determined by the remuneration committee having regard to the performance of individuals and market trends.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman22 March 2013, Zibo, PRCAs at the date of this announcement, the board of directors comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Bai HuiliangMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Ren FulongMr. Xu Lie Mr. Zhao Bin PAGE PAGE 1+,-#$d$Ifa$gd4+ d$Ifgd4+]kdF$$IflFd#F    4 la-.hoqzz#$d$Ifa$gd4+d$IfVDnWD^`gd0]kdF$$IflFd#F    4 laqrzz#$d$Ifa$gd4+d$IfVDnWD^`gd0]kdfG$$IflFd#F    4 la#$d$Ifa$gd4+ d$Ifgd4+]kdG$$IflFd#F    4 la#$d$Ifa$gd4+ d$Ifgd4+]kdJH$$IflFd#F    4 la&zzz#$d$Ifa$gd4+d$IfVDWWD^`gd0]kdH$$IflFd#F    4 la&'\cdkzzz#$d$Ifa$gd4+d$IfVDWWD^`gd0]kd.I$$IflFd#F    4 lakl#$d$Ifa$gd4+d$If^gd4+]kdI$$IflFd#F    4 la#$d$Ifa$gd4+d$If^gd4+]kdJ$$IflFd#F    4 la#$d$Ifa$gd4+ d$Ifgd4+]kdJ$$IflFd#F    4 la#$d$Ifa$gd4+ d$Ifgdjq]kdJ$$IflFd#F    4 lazz#$d$Ifa$gdHiGd$IfVDWWD^`gdjq]kdhK$$IflFd#F    4 la DEGPR./1⺮qeSeEeEeEh:7hHiGCJ\aJo(#h:7hHiGCJPJ\aJnHtHh:7hHiGCJ\aJh:7h0CJ\aJo( h:7h0CJPJaJnHtHh:7h0CJaJo(#h:7h05CJPJaJnHtHh:7h05CJaJh:7h0CJaJ h:7hHiGCJPJaJnHtHh:7hHiGCJaJo(h:7hHiGCJaJ#h:7hHiGCJPJaJnHo(tH#$d$Ifa$gd4+d$If^gdjq]kdK$$IflFd#F    4 la#$d$Ifa$gd4+ d$Ifgd4+]kdLL$$IflFd#F    4 la GHI#$d$Ifa$gd4+ d$Ifgd4+]kdL$$IflFd#F    4 laIJzzz#$d$Ifa$gd4+d$IfVDWWD^`gd0]kd0M$$IflFd#F    4 laqq#$d$&dIfPa$gd4+d$IfVDWWD^`gd0]kdM$$IflFd#F    4 la/w\LL$Xd1$^Xa$gdHiG$ & F XHd1$^X`Ha$gdHiG d^gdHiGnd^n`gdHiGdWD`gd0]kdN$$IflFd#F    4 la/2XYvwxsg d$Ifgd4+$d^a$gd0 nd^ngd0;d^`;gd0nWd^n`Wgd0$;d^`;a$gd0$nWd^n`Wa$gd0$ & F XHd1$^X`Ha$gd0$Xd1$^Xa$gd|" 12]^efwx|}൩zhzhz#h:7h iCJPJaJnHo(tH h:7h0CJPJaJnHtHh:7h0CJaJo("h:7h0>*CJaJnH o(tH h:7h0>*CJaJh:7h0CJaJh:7h0CJ\aJo(#h:7h0CJPJ\aJnHtHh:7h0CJ\aJ&h:7h0CJPJ\aJnHo(tH#x} d$Ifgd4+]kdN$$IflF]'#g    4 la$d$Ifa$gd4+#$d$Ifa$gd4+ d$Ifgd4+]kdN$$IflF]'#g    4 la#$d$Ifa$gd4+ d$Ifgd4+]kd^O$$IflF]'#g    4 la}}#$d$&dIfPa$gd4+ d$Ifgd4+]kdO$$IflF]'#g    4 la#$d$Ifa$gd4+ d$Ifgd4+]kd}o(h:70J$mHnHuhU>} hU>}0J$jhU>}0J$Uh6+-jh6+-U+h:7hmCJOJPJQJaJnHo(tHKMNPQSTVW`abmnopqrstuv#$a$##&`#$90P/R :p=y:/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBO> NotesdB*CJaJphO Body textc$>TPL HD@<Td1$7$8$H$^Ta$-B*CJOJQJ_HaJmH nHphsH tHHOH Subhead 1Td^T ;CJaJ~O~ Subhead 2B$'PL HD@<Q^`a$5B*\phDZ@D ~e,g$a$CJOJPJQJaJnHtH<< write $a$CJPJnHtHppChar Char Char Char!d1$CJKHPJaJmHnHtHu.". yblFhe,g"CJaJ6 @26 u#9r G$CJaJ)@A uxP@RP u w%!d1$CJKHOJPJ QJaJtH 0b0 le,g&G$CJaJPOrP Anrede' 1$KHOJPJQJaJtH VV W[CQ W[CQ(d1$CJKHPJaJmHnHtHudOd Default)1$7$8$H$-B*CJOJQJ_HaJmH nHphsH tH  med1HH  Balloon Text+CJOJQJ^JaJ44 cke1,B*OJQJph0`0 HTML 0W@W-6]BeB  HTML P h/$<@&a$5CJ OJPJQJ\^JaJ K y|T0([( 5uP[N~{T1\J"\ oRh2$d8<@&a$"5CJ KHOJPJQJ\^JaJ -2 [e,g43 ` @ 1$3$5$7$8$G$0CJKHOJPJQJ^J_HaJmH nHsH tH6%B6 [ON0W@W4G$ OJQJ^J.?R. ~_g5dVD4^d4/b4 Rh68WD8^`8<2r< Rh 27d8VDWD8^d`8<3< Rh 38d8VDWD8^d`8<4< Rh 49d8VDXWD8^d`8<5< Rh 5:d8VD WD8^d`8,1, RhS ; & F0:0 RhS 2 < & F0;0 RhS 3 = & F0<0 RhS 4 > & F0=0 RhS 5 ? & F4D4 Rhc~@xVD^8E8 Rhc~ 2AHxVD^H8F"8 Rhc~ 3BxVDX^8G28 Rhc~ 4CxVD ^8HB8 Rhc~ 5D4xVD^400R0 Rhyv&{S E & F46b4 Rhyv&{S 2 F & F47r4 Rhyv&{S 3 G & F484 Rhyv&{S 4 H & F 494 Rhyv&{S 5 I & F $$vU_ 1J00vU_ 2KVD^00vU_ 3LHVD^H00vU_ 4MVDX^00vU_ 5NVD ^00vU_ 6O4VD^400vU_ 7P VD^ 00vU_ 8Q| VDx^| 00vU_ 9R VD@^ $2$ TybleW[SRAR Ss Char Char1$CJKHPJ_HaJmH nHsH tH*j12* Vybl;NU5\2Ba2 Us Char Char5\(^r( nf(Qz)W,@, ~{TXdVD4^d,L, egYdVD ^dX$X 6eON0W@W(Zd&+D/G$VDx^d OJQJ^J$ $"}_ 1[0 0"}_ 2\VD^0 0"}_ 3]VD^00"}_ 4^XVDX^X00"}_ 5_ VD ^ 00"}_ 6`VD^00"}_ 7aVD^00"}_ 8bxVDx^x00"}_ 9c@VD@^@6!6 "}_hd5OJQJ\^J8"8 leCJOJPJQJ^JaJ4#4 VhvU_f8VDWD8`8(+r( >\le,ggG$>T> e,gWWhxUDVD]^8Y8 ech~gVi-D M I Oo`hoj8$d%d&d'd-DM NOPQVDWD ^8` OJQJ^J0,0 _evU_kVD^<.< _evU_hlxOJPJQJ^J(B( ckee,gmx4M4 ckeL)ۏnWDd`8C8 ckee,g)ۏoxVD^8N8 ckeL)ۏ 2pWD`00 cke)ۏqWD`2P"2 ckee,g 2 rdx4Q24 ckee,g 3sxCJaJBRBB ckee,g)ۏ 2tdxVD^DSRD ckee,g)ۏ 3uxVD^CJaJ*O@* lʑhv$a$6q6 short_text1CJaJ88 medium_text1CJaJ44 long_text1CJaJvv T Report Text-z$d1$5$7$8$9DH$^a$KHPJ aJmH sH tH JJ T body text{xx1$CJKHaJtH VV TRQk=|d1$WD`CJKHOJPJ QJaJtH  z hps`` sQ*B* ph@ff 4jp Char Char1 Chard1$CJKHOJPJQJaJtH &!& e_4hps atnJ1J %IA^ Char Char3OJPJ QJ_HmH sH tH RAR #IA^ Char Char4$CJKHPJ_HaJmH nHsH tH"W@Q" 3Pp5\VbV JvnUk=d1$VD^CJKHOJPJ QJaJtH JqJ -s Char Char2OJPJ QJ_HmH sH tH NN i Char Char6 CJKHPJ_HmH nHsH tH##F;<WXyz$%BC+,z{XY;#P#K00ܾ@0 K00@t(> K00L@0 K009z9` K00 @0 K0 0 @0`t( K0 0@0! K00t8Jnt( K0607@0J 30K0809\|?0?\DEKELE/G2GGGHHaJbJ2K3KyLzL{M|MMMNNQQXQYQRRSST TUUUU2V3VMWNWWWYYYYYYYYY{Z|Z/[0[p[q[C\D\[\\\\\\\\\\\\!]"]#]$][]b]i]j]]]]]]]]]^^^^5^;^>^?^q^^^^^^^^^^^^^^^^^^^^____=_C_E_F_L_S_U_V_f_g_h_i_________________'`/`7`8`{`~`````````````UbVb_b`bccddddffvfwfff_g`gogpghhiiiiijjjzj{j_l`lllllnnnnAoBoGoLoQoRoSoaomozooooooooopp$p5pFpGp_pppppppppppqqq-q:qHqUqVqoq~qqqqqqqqqqrr#r1r?rMr[r\rxrrrrrrrrrrrrsss+s9s:sssssssssss tt)t7tEtStatbt}ttttttttuu"u#u=uKuYuguuuvuuuuuuuuuu vvv`vnvpv~vvvvvvvvvvvvvvvvvvwww(w-w2w7w?@ABCMWXlmnop ;<CEFRSW[\hiqyz{|}~„Ä $%&'()*?@ABCQRZbclmwۅ܅  -.8BCDEFGH`abcd}~Ɔdžφ׆؆!+,-.rs )*Å͊23Jyz0UVk}~ڑۑ=>l)*2IJSvwɓʓӓ ;Z[x @ATٕb?@ϙЙ$%qϛЛz{RSqrLM./OP/0noųƳʹδ67 +,LM޾߾RS12{|789:;XY./LM#$%234:;<DLT\dlmnopqrstu}~ "*2<FGHIJKLMNOeu'()*+,23456789:;NOPQRSZ[\]^_`abcd #+,-./01234<=>?@ABCS]emuw '.7>?IJKLMNOPQRefghijqr34ST!"#+3;CKLMNOPQRSblt|$%IJKLMWXYZ[\]^_xyz{| $%&'()*+,;EMU]gh !"#$,-./01234MNOPQ[\] '(5Kghnopx=DKQX`a QW\bgmnst !67DZvw}~ekqsw~WXYno|#+34 HJLRTZ[^_ !"/Eabhijrz"*27?HIW`hnr{|234UVW\abckstuvwx| "*+,-./<=>?lsz{;CEFGHIJKRYZ =CGHIJKLMT[\]^_`px?@ab !"#$)./08@ABCDEX_fghijk (./^djk&'OUXY &,345<=[\]bghiqyz{|}~,289$+23agklmnop#*+,-./qyzEOYZ[\lmnsxyz !")*+!" 4<DE~29;<u}JK0127<=>FNOPQRSckstij%&VZ^_`abcipwxy, - p q r w | } ~                             X Y y z                   !"=@DEFGHIX^def#$BIPQRSTUV^fgh ()TZ`a"#48<=^dfghijk0689:;<=STUV"%)*+,-.9:;<cgkl359:;BC\ ]          ! ! !!!!!$!*!0!1!J!N!R!S!T!U!V!W!X!^!d!e!f!""" ""N"\"e"f""""""" ###@#P#a#{#|############################000000000000000000000 0 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 v0 0 0 0 0 00000000 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 000 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 00 00 0 0 0 0 0 v 0 0 0 v 0 0 0  0 0 0  0 0 0  0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0  0 0 0 0 0 0 0 0 0 0 0 000000000000000000)000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0  0 0 0 0 0 0000000000000 %0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 00000000000000000000 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0  00 %0 %0 0 0 0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 %0 0  0 %0 %0 0  0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 00000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 '0'0'0'0'0'00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 '0'00000000  0   0   0 0000000000000  0   0   0   0   0   0   0   0  0 0  0 0  0 0   0   0  0 0   0  0 0   0   0  0 000000 0 0 0000000 0 0  0 0  0 0  0 0  0 0  0 0  0 0 000 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 %0 0  %0 %0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 '0 '0 0  0 0 0  0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #0 #0 0 %0 0 0 0 000000000000 %0 %0 0 0 0 0 0 0 '0 '0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 000000 %0 %0 0  0 0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0  #0 #0 0 0 #0 #0 0  #0 #0#0 0    0  #0 #0#0 0  #0 #0 0 0000 %0 %0 0  0 0 0  '0 '0 0  '0 '0 0  000 000 0 000000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 % 0 0 0 % 0 0 0 % 0 0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 0000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 %0 0 0 0 00000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 % #0 #0 0 % #0 #0 0 0 #0 #0 0 %0 #0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 #0 #0 #0 0 0 #0 0 0 000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 0 0 0 000000000%0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 #0 #0 0 %0 #0 #0 0 %0 0 0 0 %0 0 0 0 0000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 00000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0  #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0#0 0  #0 #0#0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0  #0 #0#0 0  #0 #0 0 00 0000 000000000 0 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 000000000000)0)000000 0)000 0 )00)0)0 0 0 I00@0I00@0I00@0I00@0I00@#0@#0@0@#0@#0@0I000000I0dqrtuv"CD "'/08BLWXjqx  8?FOPQRSTUV 2;DMN{    : ? C D [ l    , - f t  ! " J X f n } ~    $ 5 ; L M _ p ,;=LMNOnoty} NUZchi %&X]bjopu:?DINOiou'+6:;<AF]rs ./CDVal{ (5BCU<ghEF89"U#W#m#n#$$W%X%&&((((W*X*+++<,=,,,/////=E>EKELE\\#]$]i]j]]]]]^^>^?^q^^^^^^^^^^^^^^^^^^^____=_C_E_F_L_S_U_V_f_g_h_i_________________'`/`7`8`{`~```````````hhijQoRooooooop$p5pFpGppppppppppqq-q:qHqUqVq~qqqqqqqqrr1r?rMr[r\rrrrrrrrrrss9s:sssssssss tt7tEtStatbtttttttuu"u#uKuYuguuuvuuuuuuuu vvvnvpvvvvvvvvvvvvww-w2w7w)*IJvwɓʓZ[@A78:;:;lmtu FGNO23:;Z[bc+,34BCIJQRqr!"KLRS$%WX^_$%+,gh,-34OPQ[\no`amn}~~34 Z[hiHI{|UVabstwx*+./>?z{EFIJYZGHKL[\_`./@ADEfgjk./jk&'XY &,34ghyz}~8923klop*+./EOYZxy)*DE;<<=NORSst%&^_bcwx| }                       !"DEHIde#$BIPQTUfg()`a"#<=fgjk89<=UV)*-.;<gkl9:   ! !!!0!1!R!S!V!W!d!e!{#|####000000000000000000000000000000000000000 00000 00000l 0 0 000 v0 0 000 000000000 00 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000 0 0 0 0 0 0000000 000000 0 0 0000 0 0 00 00 @0@0@0@0@0@0 000000000000000000000 000 0 0 0 000 00 0 00000 00 00 0 00 0 0 0 0 0 0 0 0 0 0 00 0000 00 00 0 0 00 0000 00 0 000000 00000000000000000 0 0 0 0 00 00000 00000  0 00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000000000000000000000000000K016K00 K00H13K00K00K00K00 @0K0 0 <@0K0 0<@0K00<@0K00K00<@0K00@0K00<@0K00@0K00<@0K00@2 K00<@2 K00 @0 K0 0@0 K0 0 @ K00@ K0 0@0K01@0K00@0K00@0K00@0 K00@0 K00 K0"0#| K00@0! K0$0%|@0! K00@0K0&0'|@0K00@0 K00@0 K00@0 K0*0+|@0 K00@Ẍ́ K0,0|@Ẍ́ K00K0%0:K0.0:K0%0:K0 0!K040 K000 aqab#bd @0@0@0K01h<K00 K0%0:&l5K00K00K00K00K00K00K00K00K00+@0 K00K00K00K00@0(( K00K00K00K00@0 D K00K00 K00K00 @0 K0 0K0 0 K0 0K0 0 6b2"!!$ K0 0K0 0K0 0K0 0@0 K00K00K00K00@0 K00K00K00K00E6!x K00K00K00@0 K00K00K00A1ZZ| K00K00K00K00bBb2 K00K00@0  K00@0$ K00K00K00K000`99< K00K00K00K00@ K0 0K0 0!K00K00@+tDDD K0"0K0"0#K0 0K0 0!ز۲hp K0$0K0$0%K0"0K0"0# K0&0K0&0'K0$0K0$0%B2 K0(0K0&0K0&0'@80`@> K0*0K0(0K0(0K0(0)@ K0*0+0 K0.0K0.0/K0,0- K000K0001K0.0K0.0/@0  K020K0203K000K0001@0 c K040K040K020K0203@= K060K040K040K0405@0 K080K00K00K00@`0 K00$K00 K00$K00 K00$K00 K00$K00 K00 $K00 K0 0 K00 K0 0K00 K00K00 K00K00 K00K00 K00K00 K00K00 K00K00 K00K00 K00K00 K00K00 K0 0!K00 K0"0#K00 K0$0%K00 K0&0'K00 K0(0)K00 K0*0+K00 K0,0-K00 K0.0/K00 K0001K00 K0203K00 K0405K00 K02`K02K02 K060K00 K0809K00 K0:0;K00 K0<0=K00 K0>0?K00 K0@0AK00 K0B0CK00 K0D0EK00 K0F0G,K00 K0H0I,K00 K0J0K,K00 K0L0M,K00 K0N0O,K00 K0P0Q,K00 K0R0S,K00 K0T0U,K00 K0V0W,K00 K0X0Y,K00 K0Z0[,K00 K0\0],K00 K02dK02K02K0^0 K00 C00;WK00L C00,0?K00L C0@0A,K00L C0B0CdK00L C0D0EK00L C0F0GBK00L C0H0IBK00L C0J0K CK00L C0L0MDCK00L C02oC02C02C0N0K00 K00GJ$x! K00Go0`tu K00G@ K00G0 K00 G@0 K0 0 G@o0 K0 0 K0 0 A6 ! K0 0 A6 ! K00G@040K0D0 K00@0 K00K00 @0 K00 @0 K00 K00K00K00 K0!0"@0J K0#0$@0 K0%0&@0B K0'0(@/0   K0)0*R@09) K0+0K0+0@0K0+0@0 K0001@0HJ K020K020@00K020@00 K0708"a0 K090K090@0K090@0 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K01K00 K02K00 K02K00 K02K00 K02K00 K02 K00 K02K00 K0 2!K00 K0"2#K00 K0$2%K00 K0&2'K00 K0(2)K00 K0*2+K00 K0,2-K00 K0.2/K00 K0021K00 K0223K00 K0425K00 K0627K00 K0829K00 K0:2;K00 K0<2=K00 K0>2?K00 K0@2AK00 K0B2CK00 K0D2EK00 K0F2GK00 K0H2IK00 K0J2KK00 K0L2MK00 K0N2OK00 K0P2QK00 K0R2SK00 K0T2UK00 K0V2WK00 K0X2YK00 K0Z2[K00 K0\2]K00 K0^2_K00 K0`2aK00 K0b2cK00 K0d2eK00 K0f2gK00 K0h2iK00 K0j2kK00 K0l2mK00 K0n2oI00 K03I03I03I0p2I00 K03IK00K03,IK00K03dIK00K03IK00K03ԄIK00K03 IK00K03DIK00K03|IK00K03IK00K03IK00K03$IK00K03\IK00K03IK00K03̆IK00K03IK00K038?K00 K0@8AK00 K00 K0B8CK00 K00 K0D8EK00 K0F8GK00 K0H8IK00 K0J8KK00 K0L8MK00 K0N8OK00 K0P8QK00 K0R8SK00 K0T8UK00 K0V8WK00 K0X8YK00 K0Z8[K00 K05,@0 K05d@0 0 $$$'V ^d   C !#y$X%&&K''!*--/o0#1122234578:WZafmnFo5pRpprsSttvvxz{[~4," [X\Wߓ\1nǙ#ڧY]B o]"PpAI+   czzI"&9''A)D*+1hJv !&'(*+,./01246KY]^_cnt !.:HSUdk{!#,49>DPXZ_kmu :f=j$#k"C BsJ"Qjz9 p)6BJYhnippp$qPqqrrrs4sxss tt,tRttttt v:vvv,{Յ W(̇O߈%dA8ϋM,Vw9r;OZ~ʐϐ0Sܑ 1X]֒U`b]b0:y֖ 5q(`joOm™ǙAsɚߚ1Cmƛ%/`ǜ̜>[t~٧kͩMު*īn$Yk-F[!#)=I_m|}DFLT (6Wbdj~^<?Dfin ~?BG>#Sp0;:Uqs ,2Na9o9Cdj+x(\9Ls?A,E]aw|=ko&N`d3o.o% c       A u    G K o    7;zIJU*.i !T,bfx/LPo  1 U   !N#c#}#####'Q'U'u'''''u((((()<)@)R)+:+>+\+f+++++-q&kI/xKv    "#$%)-35789:;<=>?@ABCDEFGHIJLMNOPQRSTUVWXZ[\`abdefghijklmopqrsuvwxyz{|}~    "#$%&'()*+,-/0123456789;<=>?@ABCDEFGIJKLMNOPQRTVWXYZ[\]^_`abcefghijlmnopqrstuvwxyz|}~     "$%&'()*+-./01235678:;<=?@ABCEFGHIJKLMNOQRSTUVWY[\]^`abcdefghijlnopqrstvwu  '!!t  ,b$l?xK-}*;F@ (  t  c 6A!SHANDON"?B S  ?H0(  r#]t OLE_LINK6 OLE_LINK13 OLE_LINK14 OLE_LINK100 OLE_LINK101 OLE_LINK12 OLE_LINK15_Hlk252804176 OLE_LINK3 OLE_LINK30 OLE_LINK28 OLE_LINK29_Hlk252956248~kK   #   ~1   #cTc$TcTcdTcTcP?T#?T#<*urn:schemas-microsoft-com:office:smarttagschmetcnvV*urn:schemas-microsoft-com:office:smarttags PersonNamehttp://www.microsoft.com 01 3073128305aFalseHasSpaceNegative NumberType SourceValueTCSCTrueUnitName             vJT&&&&)%))))),-M5\566666666::; ;s<|<<<>>??????????????`@i@@@@@@ABBBBBB#C-C.C6C$N1N3N8NPP\\]^CcLcccgg`hfhwh|hkkklmmyyyy@G[aωՉ"MPŖ IOޜ=Jbl!*Τؤ"*3<ռۼ s}EQ \`apDN9E ,6  2<jwT"["""####H#O#T#W#X#`#e#j##########################v###################vij 8VN{ : - f " J Ni&X:'UYY\\[]j]]]]]^^5^?^z^^__=_i_____'`8`{````jj{jBo`oaorr>ssttv`vvvwGxmxxxxxyyyzzzzzzY{z{|-||||}}}}"~3~v~~~~I݀Ձa <Ä܅,*A3Jʓx ATF;Y,c]=aQn!eY4H[ "4?l{;Z=op$k /^k'OY&;]~,9$3ap/qEZ\+E~2<u2t&Vyr   fh)Ta=^0V<c3C f!f""#@#P#a#################################|0b?}8.>~ڟL=R<4-I:H VG>>wC>Z>]>O%?h,?Y?@:R@^@xn@AA% AAH3A6XA{kACBa,Ca1C6DX*D7DinDE4EJE0F:)F`)F8F;FNFG)GHiG>HH7H->HxWHpHhyHaIIXIhJzKK_lV_Qs_`\`b a}aJb_b4Ecd1Yd~`dvdUeR'e/e4eDeHe$`e]4fAf*tfg'g2;gJgzg#h!Kh=Nhbh iMi4iati_|i0jq#j4jHj2l'lm*mAmimz n%ynzn`oaouoO(pApJp4jpyp qqAqi`qjqDrqrmr"sp-sNs{Xshsqs"tKStgtrtuGJuWuvvJvwv=!w=wQw^wDxox%yy.3yZiyy/Az{0{eu{8|?|-}U>}jy} z}E~hl~w~C VX(PiN3PUi[dT~e1|0GPvb1twHz= )DFo)9Nm}?.@7n-stRvz o9qgNN 45dW8hKP/CY_hk} ^0gd ag} CUx:ml!+uG PuI3Jhdh-!;[%hes}aR;` a K ]{^"x$'X&. F7az xq~+`KnU9; q'f*yB+ZcdB#A0?R3eg|]W!k|.=%=CYe-Ay2 ,,0gm~@:*RSM|.Poq2M"5[9h~00Abs' A`dFUVlsb[?4+J08OnJ6Pg|"4GjW 3#BxeHw\`'8$2u} OqRPfh/3  Li<)$6O c#&':~Xa{ kR'D!I Mksz AjV,Bic~,~-%up);.f[r*~P[q (5%n9~A]'-6M\al}T"Th. C!0V+ OR"'[ ispR*1`rd&'"C(pL/'>2UAJW=]=^?ju aY#(?u-R18Iu) LZm ]$:'1`,-?DrO"h%00<bBn*I,3CS]qk@)SSrJYZ]egc]Y (oE &^,u7r:FLO {4.FJpLdV E;z)f;sB\\u6 `V aZkBpU`broAsxyCh|{6Tkm8gIKUkv>_`$vHhN0W}kKp!:(EPob{C"/08BLWXjqx  8?FOP 2;DMN{  : C D [ l    , - f t  ! " J X f n } ~    $ 5 ; L M _ p ,;=LMOnot} NUZchi %&X]bjopu:?DINOiou+:;<AF]rs ./CDVal{ (5BC;"BY|Z/[\\\\\\\!]"]#]$][]b]i]j]]]]]]]]]^^^^5^;^>^?^q^^^^^^^^^^^^^^^^^^^^____=_C_E_F_L_S_U_V_f_g_h_i_________________'`/`7`8`{`~```````````djjAoBoGoLoQoRoSoaomozooooooooopp$p5pFpGp_pppppppppppqqq-q:qHqUqVqoq~qqqqqqqqqrr#r1r?rMr[r\rxrrrrrrrrrrrrsss+s9s:sssssssssss tt)t7tEtStatbt}ttttttttuu"u#u=uKuYuguuuvuuuuuuuuuu vvv`vnvpv~vvvvvvvvvvvvvvvvvvwww(w-w2w7w?@ABCMWXlmnop ;<CEFRSW[\hiqyz{|}~„Ä $%&'()*?@ABCQRZbclmwۅ܅  -.8BCDEFGH`abcd}~Ɔdžφ׆؆!+,)*Å͊23Jz0UVk}~ڑۑ=>l)*2IJSvwɓʓӓ ;Z[x @ATSʹ,M789:;Y./#2:;<DLT\dlmnopqrstu}~ "*2<FGHIJKLMNOeu'()*+,23456789:;NOPQRSZ[\]^_`abc #+,-./01234<=>?@ABCS]emuw '.7>?IJKLMNOPQRefghijqrtS!"#+3;CKLMNOPQRSblt|$%IJKLMWXYZ[\]^_xyz{| $%&'()*+,;EMU]gh !"#$,-./01234MNOPQ[\'5Kgnopx=DKQX`a QW\bgmns !6DZv}~ekqsw~WXYn|#+34 HJLRTZ[ !/Eahijrz"*27?HIW`hnr{|234UVW\abckstuvwx| "*+,-./<=>?lsz{;CEFGHIJKRYZ =CGHIJKLMT[\]^_`px"#$)./08@ABCDEX_fghijk (./^djk&'OUXY &,34[\]bghiqyz{|}~,289$+23agklmnop#*+,-./qyEOYZ\lmnsxyz )* 4<DE~29;<u}0127<=>FNOPQRSckst%&VZ^_`abcipwxp q r w | } ~                                              !"=@DEFGHIX^de#$BIPQRSTUV^fg ()TZ`a"#48<=^dfghijk0689:;<=STUV"%)*+,-.9:;<cgkl359:         ! ! !!!!!$!*!0!1!J!N!R!S!T!U!V!W!X!^!d!e!"f""""#{#|#####!7Q 0!7]0 y_0'q}'wy0i7KtKxy0Z !7i77%!7%!7!7!7!7!7!7[fU_us@??k"?? vvvvM5M7:;<=?@BCMN<^<_|`|aw#@@@ @@@@4@@@@@@H@@@L@@@P@@@T@@@`@@@r@@@v@@@@UnknownMay See??? Lenovo User Johnny TsoiGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚ7&{ @Calibri;[SOSimSunGTimes LT Std[SO3Times] Times-BoldTimes New RomanKM  DFKai-SBPMingLiUU Arial Unicode MSArial?5 .MingLiU0}fԚ[ (DFPFangSongW4-B5PMingLiU;ўSOSimHei?5 z Courier New;& Helvetica5& zaTahoma7&  Verdana;Wingdings F5S+7+7!xxd-#-#2qHX?8|2 2006 ANNUAL RESULTS ANNOUNCEMENTWonderful SkyhggSf\               Oh+'0(8 HT t  $2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky$generated by an Adobe applicationNormal595Microsoft Office Word@I@9@Tb@ȧ&+7՜.+,0 `h Wonderful Skyx-#   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~    Root Entry Fp&"Data LR1Tablec=WordDocumentpSummaryInformation(DocumentSummaryInformation8 CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q